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ABSTRACT  
   Angiogenesis   is   a   highly   regulated   process   orchestrated   by   the  
vascular  endothelial  growth  factor-­A  (VEGF-­A)  system  of   ligands  and  receptors.  
Heparin/heparan  sulfate  (HS)  proteoglycans  and  neuropilin-­1  (NRP-­1)  have  been  
identified  as  co-­receptors  for  VEGF-­A,  yet  the  mechanisms  of  action  have  not  been  
fully   defined.   In   the   present   study,   we   characterized   molecular   interactions  
between  receptors  and  co-­receptors  and  the  two  major  VEGF-­A  isoforms,  using  
surface   plasmon   resonance   (SPR)   and   in   vitro   binding   assays.  We   found   that  
VEGF   dissociated   25-­times   faster   from   its   major   signaling   receptor,   VEGF  
receptor-­2  (VEGFR-­2)  than  from  its  “decoy”  receptor,  VEGF  receptor-­1  (VEGFR-­
1).   We   identified   a   potential   mechanism   for   co-­receptors   to   decrease   the  
dissociation  rate  and  prolong  the  signaling  complex   lifetime.  Using  a  systematic  
approach,   we   obtained   kinetic   parameters   for   each   individual   interaction   in   an  
     ix  
intercomparable   way   to   measure   the   effect   NRP-­1   and   HS   have   on   complex  
stability.  Additionally,  we  demonstrated  that  these  binding  events  influence  VEGF  
activity  within  endothelial  cells.  These  parameters  can  be  used   in  mathematical  
models  to  predict  therapy  outcomes  in  defined  cellular  contexts.  Furthermore,  we  
optimized  a  competition-­based  technique  using  SPR  and  structurally  defined  HS  
oligosaccharides  and  demonstrated  that  it  can  be  used  to  rapidly  measure  affinities  
to  HS-­binding  proteins.  We  used  this  method  to  define  interactions  and  structural  
and  length  requirements  for  heparin/HS  interactions  with  VEGFR-­1,  NRP-­1,  and  
VEGF165,  the  most  relevant  VEGF-­A  isoform,  in  complex  with  VEGFR-­2  and  NRP-­
1.  We  show  that  the  structural  requirements  were  distinct  for  each  interaction.  We  
further   found   that  VEGF165,  VEGFR-­2  and  monomeric  NRP-­1  bound  weakly   to  
heparin   alone,   yet   binding   to   heparin   increased   synergistically  when  presented  
together.  This  enhanced  binding  correlated  with  alterations  in  VEGF  signaling  in  
endothelial   cells.   We   found   that   soluble   NRP-­1   increased   VEGF   binding   and  
activated  phosphorylation  of  VEGFR-­2  and  Erk1/2   in  endothelial  cells,  and   that  
these   effects   required   sulfated   HS.   These   data   suggest   that   the   presence   of  
HS/heparin  and  NRP-­1  may  dictate  the  specific  receptor  type  activated  by  VEGF  
and  ultimately  determine  the  biological  output.  The  ability  of  co-­receptors  to  fine-­
tune   VEGF   responsiveness   suggests   the   possibility   that   VEGF-­mediated  
angiogenesis  can  be  selectively  stimulated  or   inhibited  by   targeting  HS/heparin  
and  NRP-­1.  
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CHAPTER  ONE:  INTRODUCTION  
Vasculogenesis,  angiogenesis  and  vascular  homeostasis  
One  of   the  earliest  processes  during  organogenesis   is   the  formation  of  a  
vascular   system   1.   Vascular   development   and   function   involves   three  
complementary   processes:   vasculogenesis,   angiogenesis,   and   arteriogenesis.  
These  three  processes,  which  involve  migration,  sprouting,  matrix  remodeling  and  
growth  of  endothelial  cells,  are  orchestrated  primarily  by  the  vascular  endothelial  
growth  factor  (VEGF)  system.    
During  vasculogenesis,  angioblasts  differentiate  into  endothelial  cells  and  
form  a  primitive  network;;  angiogenesis  leads  to  the  expansion  of  the  network  by  
sprouting   new   blood   vessels   from   pre-­existing   ones;;   and   lastly,   during  
arteriogenesis,  pericytes  or  vascular  smooth  muscle  cells  cover  blood  vessels  to  
provide   stability   and   control   perfusion   2.   Angiogenesis   continues   to   be   a  
fundamental  process  in  many  physiological  events  in  adult  organisms  (i.e.  wound  
healing,  re-­vascularization  after  injury,  the  ovarian  cycle)  3-­5.    
Growth  of  new  vessels  must  be  tightly  regulated,  and  loss  of  control  over  
this  process  leads  to  a  number  of  pathologic  conditions  in  humans.  Since  blood  
vessels  carry  oxygen  and  nutrients   to   tissues,   tumors  can  hijack   the  process  to  
sustain   growth   and   metastasize   6.   Additionally,   uncontrolled   growth   of   blood  
vessels  in  other  tissues  contributes  to  several  diseases  including:  wet  age-­related  
macular  degeneration,  ulcerative  diseases,  diabetic  retinopathy,  and  rheumatoid  
arthritis,  among  others  6-­9.  On  the  other  hand,   insufficient  angiogenesis   leads  to  
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endothelial   cell   (EC)   dysfunction,   vessel   malformation   or   regression,   and  
insufficient   revascularization,   healing   and   regeneration,   implicated   in   heart   and  
brain  ischemia,  preeclampsia,  hypertension  and  others  3.    
Inhibition  and  enhancement  of  angiogenesis  are  both  targets  for  therapy.  
Current  approaches  aimed  at  reducing  excessive  angiogenesis  by  targeting  VEGF  
have   been   less   successful   than   anticipated   and   directed   therapies   to   re-­
vascularize  ischemic  tissues  remain  an  unmet  need.  A  clear  understanding  of  the  
regulatory  pathways  for  angiogenesis  is  necessary  for  the  development  of  efficient  
therapies  to  treat  related  pathologies.    
VEGF  family  of  growth  factors  
VEGF,   is   a   family   of   growth   factors   including   5   members   expressed   in  
mammals,  VEGF-­A,  also  referred  to  as  vascular  permeability  factor  (VFP),  VEGF-­
B,   VEGF-­C,   VEGF-­D   and   placental   growth   factor   (PlGF).   The   most   studied  
member  is  VEGF-­A  (referred  to  as  VEGF  for  simplicity)  due  to  its  significant  role  
in   vascular   homeostasis.   Deletion   of   a   single   allele   of   VEGF   causes   early  
embryonic  death  due  to  failure  to  develop  blood  vessels  10.  Moreover,  moderate  
overexpression  of  VEGF  also  results  in  lethality  11,  highlighting  the  importance  of  
a  very  tightly  regulated  system.    
Alternative  splicing  of  the  Vegf  gene,  which  contains  9  exons,  produces  five  
different   isoforms   denoted   by   the   amino   acid   (aa)   length   in   humans:   VEGF121,  
VEGF145,   VEGF165,   VEGF189   and   VEGF206   12,   13   (Illustration   1.1).   VEGF165   and  
VEGF121  are  the  most  potent  and  most  abundantly  expressed  isoforms,  varying  in  
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receptor  binding  affinities  and  presence  or  absence  of  heparin/HS  and  neuropilin  
(NRP)   binding   sites14.   The   absence   of   an   extracellular   matrix   (ECM)   binding  
domain   in   VEGF121   renders   it   highly   diffusable,   while   longer   isoforms   have  
intermediate  to  low  diffusibility  and  remain  in  close  proximity  to  the  secreting  cell  
15.  Differences  in  diffusibility  and  VEGF  receptor  (VEGFR)  binding  allow  for  distinct  
biological  activities.    
VEGF  belongs  to  the  family  of  cysteine  knot  growth  factors  together  with  
platelet-­derived  growth  factor  (PDGF).    Monomers  are  assembled  in  an  antiparallel  
orientation  with  8  conserved  cysteines  forming  inter-­  and  intrachain  disulfide  bonds  
16.   VEGF   is   expressed   and   secreted   as   an   approximately   40   kDa   homodimer,  
altough  some  heterodimers  have  been  reported  17.  Binding  sites  are  located  at  the  
end  pole  of  each  monomer  18.  Proteolytic  cleavage  of  VEGF  isoforms  alters  their  
VEGFR   binding   capabilities   in   different   ways,   adding   an   additional   level   of  
regulation  19,  20.    






Illustration  1.1  VEGF  isoforms  derived  from  alternative  splicing  of  the  human  
Vegf-­a  gene.  
Vegf  gene  is  composed  of  9  exons.  Alternative  splicing  generates  isoforms  varying  
in  length  denoted  by  the  amino  acid  number  of  the  mature  protein  (mouse  isoforms  
have  one  less  amino  acid,  therefore  are  named  VEGF120,  VEGF144  and  so  forth).  
Diagram  shows  a  schematic   representation  of   the  arrangement  of  exons   in   the  
most   common   isoforms   (monomers).   Exon   1   encodes   a   26   aa   peptide   signal  
sequence  removed  during  processing  12.  Binding  sites  for  VEGFRs  are  located  in  
exons  2-­5  of  each  monomer,  which  will  be  oriented  to  the  end  poles  of  the  dimer.  
Exons  6-­8  contain  a  55-­residue  sequence  that  represents  a  HS  binding  domain  21  
22  as  well  as  an  NRP-­1  binding  site,  located  on  exon  7  16.    
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VEGFR  Expression  and  Signaling  
VEGF   binds   and   activates   VEGF   receptor   (VEGFR)   tyrosine   kinases  
expressed  in  endothelial  cells  and  other  cell  types  23,  24.  The  VEGFRs  belong  to  
the  same  family  as  PDGF  and  FGF  receptors  and  share  some  common  regulatory  
features  with  most   receptor   tyrosine   kinases   (RTKs)   25.   Ligand  binding   triggers  
receptor  dimerization,  cross-­phosphorylation  and  generation  of  signaling  docking  
sites   inside   the   cell,   and   like   other   RTKs,   VEGFRs   activate   cellular   pathways  
leading  to  common  growth  factor  responses,  such  as  migration,  proliferation  and  
survival  26.    
There  are  3  different  VEGF  receptor  types  with  specific  biological  functions,  
VEGFR-­1   (Flt-­1),   VEGFR-­2   (KDR/Flk-­1)   and   VEGFR-­3   (Flt-­4)   14.   VEGFR-­2   is  
implicated   in   all   processes   related   to   vascular   endothelial   cell   biology   27   while  
VEGFR-­3  is  primarily  involved  in  VEGF  signaling  during  lymphogenesis  28,  hence  
we  consider  it  to  be  outside  of  the  scope  of  these  studies.  Expression  patterns  of  
VEGFR-­1  and  VEGFR-­2  show  differences  both  through  embryonic  development  
and  adulthood.  VEGFR-­2  is  mostly  expressed  in  endothelial  cells  29  and  has  been  
shown   to   be  overexpressed   in   some  cancers   30-­33.  Unlike  VEGFR-­2,  VEGFR-­1  
expression   is   less  restricted  with   it  being  detected   in  macrophages,  monocytes,  
megakaryocytes,   smooth  muscle   cells,   osteoclasts   and   some   tumor   cells   34-­36,  
suggesting  a  more  diversified  function.  Expression  of  both  VEGFR-­1  and  VEGFR-­
2  is  required  for  vascular  development,  since  genetic  targeting  of  either  results  in  
early   embryonic   death   37,   38;;   however,   transgenic   knockout   (KO)  mice   for   each  
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receptor  show  differences   in  vascular  phenotype.  Vegfr-­2-­/-­  mice   fail   to  produce  
hematopoietic   and   endothelial   cells,   while   Vegfr-­1-­/-­   display   endothelial   cell  
overgrowth   and  abnormal   vessel   organization,   suggesting   these   receptors   play  
opposing   roles   during   vasculogenesis   37,   38.   Additional   evidence   suggests   that  
VEGFR-­1   plays   a   negative   role   during   development   of   the   vascular   system.  
VEGFR-­1   phosphorylation   in   response   to   VEGF   has   been   shown   to   be   lower  
compared   to  VEGFR-­2   39,  40.  Moreover,  mice  expressing  a   truncated  VEGFR-­1  
mutant  lacking  its  kinase  domain  (Vegfr-­1  TK-­/-­)  are  viable  and  show  no  vascular  
defects  41,  demonstrating  that  the  kinase  domain  is  expendable  during  for  vascular  
development.  These  findings   led  to   the  proposed  model  where  VEGFR-­2   is   the  
major  mediator   of   angiogenesis  while   VEGFR-­1   acts   as   a   decoy   receptor   that  
“traps”  VEGF  making  it  unavailable  to  bind  and  signal  through  VEGFR-­2.    
The   balance   between   VEGF   binding   to   VEGFR-­1   and   VEGFR-­2   is   an  
important  level  of  control  in  the  regulation  of  pro-­  and  anti-­angiogenic  signals.  The  
events  that  lead  to  a  shift  in  VEGF  binding  from  the  “inactive”  receptor  (VEGFR-­1)  
to  VEGFR-­2  remain  poorly  understood.  The  purpose  of  this  study  is  to  elucidate  
novel  mechanisms   by  which   changes   in   the   cellular  microenvironment   and   the  
availability  of  co-­receptors  catalyze   the  switch   from  “inactive”  or  anti-­angiogenic  
signaling   to   “active”   ligand-­receptor   complex   formation   and   pro-­angiogenic  
signaling.  





Illustration  1.2  VEGFR-­1  and  VEGFR-­2  Structure.  
VEGFRs  share  similar  structures  containing  an  extracellular  domain  organized  in  
7  Ig-­like  domains  (green  for  VEGFR-­1  and  blue  for  VEGFR-­2).  VEGF  binding  sites  
are   located  on  the  extracellular   Ig-­loops  and  are  marked  with  a  different  shade.  
VEGFRs   have   a   single   trans-­membrane   domain   with   two   intracellular   kinase  
domains  spaced  with  a  70-­aa  long  kinase  insert.  The  c-­terminal  domain  contains  
important  phosphorylation  sites  activated  by  VEGF-­binding.       
    
8  
VEGF  receptors  share  similar  structures,  containing  an  approximately  750  
aa-­long  extracellular  portion  organized  in  seven  immunoglobulin  (Ig)-­like  domains,  
a  single  transmembrane  domain,  a  juxtamembrane  domain,  a  split  internal  kinase  
domain  and  a  C-­terminal  tail  (Illustration  1.2).  Mutational  analysis  allowed  for  the  
identification  of  VEGF  binding  sites  on  the  extracellular  domains  of  both  VEGFR-­
1   and   VEGFR-­2.   The   2nd   Ig-­loop   of   VEGFR-­1   is   sufficient   to   bind   VEGF,   with  
additional  residues  in  Ig-­loops  1  and  3  important  for  stabilizing  the  interaction  42,  
and  domains  2  and  3  of  VEGFR-­2  are  required  for  high  affinity  binding  to  VEGF  43  
(Illustration  1.2).  Contacts  between  residues  in  the  7th  Ig-­loop  on  each  monomer  
stabilize  the  receptor  dimer  upon  ligand  binding  44.  Alternative  splicing  of  VEGFR-­
1  produces  a  soluble  isoform  including  Ig-­loops  1-­6  45  
Upon   VEGF   binding   and   receptor   dimerization,   VEGFR-­2  
autophosphorylates   several   intracellular   tyrosine   residues.   Tyrosine   1175  
phosphorylation   located   in   the   C-­terminal   tail   is   required   for   VEGF-­induced  
endothelial  cell  proliferation  and  survival  46.  Phosphorylation  of  Y1175  allows  for  
PLCγ   binding   and   activation   of   the   mitogen-­activated   protein   kinase   (MAPK)  
cascade  to  mediate  proliferation  47  (Illustration  1.3).    On  the  other  hand,  binding  of  
Shb-­Sck  to  p-­Y1175   leads  to  activation  of  PI3K  and  subsequent  AKT  activation  
signaling  endothelial  cell  survival  48.  A  vital  question  that  remains  unanswered  is  
how  cells,  upon  activation  of  VEGFR-­2,  preferentially  select  one  specific  pathway  
over  another.  We  propose   that  coreceptors  and  other  VEGF  binding  molecules  
    
9  
can  alter  the  complex  affinity  and  stabilty,  yielding  differential  activation  signals  that  





Illustration   1.3  VEGF-­induced  VEGFR-­2   dimerization,   autophosphorylation  
and  activation  of  signaling  cascades.  
Schematic   of   two  major   signaling   pathways   activated   by   VEGFR-­2.   Binding   of  
PLCγ  to  phosphorylated  Y1175  activates  Erk1/2  in  the  MAPK  pathway,  leading  to  
gene  expression  and  proliferation.  On  the  other  hand,  binding  of  Shb-­Sck  activates  




In  addition  to  existence  of  different  types  of  signaling  receptors  and  VEGF  
isoforms,   several   co-­receptors   have   been   described   as   essential   for   VEGF  
function,  including  heparan  sulfate  proteoglycans  (HSPGs)  and  NRPs.  VEGF  also  
has  been  found  to  bind  to  the  ECM  protein,  fibronectin  (Fn),  and  this  is  modulated  
by  heparin/HS  49-­51.  Co-­receptors  modulate  VEGF  receptor  activation  by  regulating  
growth   factor   availability   and   altering   the   stability   and   kinetics   of   the   signaling  
complex.  These  molecules  lack  any  known  VEGF-­induced  catalytic  activity.  The  
specific  mechanisms  by  which  co-­receptors  and  ECM  composition   regulate   the  
magnitude  of   the  signal  output  are  still  unclear.  Additionally,   the  mechanism  by  
which  endothelial  cells  switch  from  the  “decoy”  VEGF  signal  through  VEGFR-­1  to  
VEGFR-­2  activation   and  angiogenesis   signaling   are   unknown.  We  hypothesize  
that  cells  use  co-­receptors  and  information  from  the  extracellular  environment  to  
fine-­tune   the   biological   response   to   VEGF   to   meet   the   specific   local   tissue  
demands.  The  presence  of  co-­receptors  as  well  as  modulation  of  VEGF  availability  
by  forming  pre-­complexes  with  ECM  components  might  determine  which  VEGF-­
mediated  biological  response  will  be  predominant.  It  is  essential  to  understand  the  
mechanisms  by  which  cells  control  VEGF  signaling  in  order  to  develop  therapies  
for  aberrant  VEGF  signaling.  Moreover,  developing  accurate  methods  to  study  the  
complex  and  multicomponent  VEGF  system  will  provide  insight  into  the  regulatory  





Neuropilin   (NRP)   is  a   trans-­membrane  glycoprotein   involved   in   inhibitory  
axon  guidance  signaling  during  neural  development  52.  NRP  binds  members  of  the  
plexin  family  and  act  as  a  co-­receptor  for  class  3  semaphorins  53,  54.  There  are  two  
members   of   the  NRP   family,  NRP-­1  and  NRP-­2,  which   share   44%  amino  acid  
homology  53,  55.  Early  transgenic  mouse  models  suggested  that  NRPs  have  a  role  
in   vascular   development.   Specifically,   Nrp-­1-­/-­   mice   die   during   mid-­embryonic  
development  due  to  severe  defects  in  neural  patterning  and  vasculature  56.  Mice  
lacking   NRP-­2   survive   and   do   not   show   gross   vascular   abnormalities   57,  
suggesting  NRP-­1  has  a  more  relevant  role   in   the  vascular  system.  Double  KO  
mice   (Nrp-­1-­/-­,  Nrp-­2-­/-­)   showed  more   severe   vascular   abnormalities   than   either  
single  knockout  (KO),  and  resembled  that  of  Vegf-­a  or  Vegfr-­2  KO  models  58.  On  
the   other   hand,   mice   engineered   to   overexpress  Nrp-­1   showed   excess   blood  
vessel  formation  and  other  vascular  malformations  leading  to  embryonic  death  52.  
Later,   it   was   demonstrated   that   NRP-­1   directly   binds   VEGF   and   enhances  
VEGF165  binding  to  VEGFR-­2  and  VEGF165  chemotactic  and  mitogenic  activity  59.  
Taken  together,  it  is  clear  that  NRP-­1  plays  an  important  role  in  the  VEGF  system  
during  development  and  angiogenesis;;  however,   the  precise  events  that  NRP-­1  







Illustration  1.4  NRP-­1  structure.  
NRP-­1  is  comprised  of  an  extracellular  domain  with  two  CUB  domains  (a1/a2),  two  
coagulation  factor  homology  domains  (b1/b2),  and  one  MAM  domain  (c1).  VEGF  
binding  site  is  located  between  domain  b1  and  b2,  as  well  as  HS  binding  sites.  The  
short  intracellular  domain  of  NRP-­1  contains  a  PDZ  domain  involved  in  synectin  
binding.       
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NRP-­1  is  a  protein  with  a  large  extracellular  domain  (about  840  aa-­long),  a  
single  trans-­membrane  helix  domain  and  a  small  (42  aa-­long)  cytoplasmic  region  
with  no  known  enzymatic  function.  The  extracellular  portion  of  NRP-­1  is  composed  
of   two  CUB  homology  domains   (calcium-­binding  C1r/C1s/sea  urchin  Epidermal  
growth  factor  [Uegf]/  and  Bone  Morphogenetic  Protein  1  [Bmp1]  60)  named  a1/a2,  
followed  by  two  coagulation  factor  V/VIII-­like  discoidin  domains  61,  62,  referred  to  as  
b1/b2,   and   a   MAM   (memprin,   A5   antigen   and   receptor   tyrosine   protein  
phosphatase  m  [ptp-­Mu])  domain,  named  c1  63  (Illustration  1.4).  Crystal  structures  
of  NRP-­1  ectodomains,   in   complex  with  antibodies   that   block  VEGF-­A  binding,  
allowed   for   the   identification   of   a   VEGF   binding   site,   located   between   b1/b1  
domains;;  these  studies  also  revealed  a  set  of  positively  charged  residues  in  b1/b2  
that   are   important   for   heparin/HS   binding   64.   NRP-­1   interacts   with   the   basic  
heparin-­binding  domain  (HBD)  located  on  exon  7  of  VEGF-­A  65.  Domains  a1/a2,  
in  addition  to  b1/b2  are  involved  in  the  recognition  and  binding  to  Sema3A  66.  The  
short   cytoplasmic   region   of  NRP-­1   contains   a  PDZ  binding   domain,  which   has  
been   implicated   in   the   regulation   of   endocytosis   of   VEGFR-­2   67   and   has   been  
shown  to  be  required   for  binding   to  VEGFR-­2  68.  Endothelial  cells  expressing  a  
mutant  NRP-­1  lacking  the  cytoplasmic  region  showed  reduced  VEGF165-­induced  
VEGFR-­2  phosphorylation  of  residue  Y1175  and  Erk1/2  activation  67.  In  vivo,  mice  
expressing  the  truncated  NRP-­1  mutant  show  normal  vascular  development  but  
impaired   adult   arteriogenesis   67,   suggesting   NRP-­1   plays   multiple   specific  
functions  in  the  vascular  system.    
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Heparan  sulfate  proteoglycans  
HS   is   involved   in  numerous   fundamental  processes  during  development,  
maintenance,  and   repair   of   tissues   including   formation  of  morphogen  gradients  
and  growth  factor  signaling  networks  69.  HS  function  is  dependent  on  its  ability  to  
interact  and  modulate  a  wide  variety  of  extracellular  regulatory  proteins.  It  is  not  
surprising  then  that  heparan  sulfate  proteoglycans  (HSPGs)  have  been  shown  to  
interact   with   high   affinity   with   large   number   of   cytokines   and   growth   factors,  
indicative   of   the   important   regulatory   activities   of  HS   70.  HSPGs  are  molecules  
found  on  the  surface  of  cells,  secretory  vesicles  and  the  extracellular  space.  They  
are  characterized  by  having  a  core  protein  with  one  or  more  covalently  attached  
HS  chains.  
HS   is   a   class   of   glycosaminoglycans   (GAGs)   that   consists   of   repeating  
disaccharide   units   of   N-­acetyl-­glucosamine   and   either   glucuronic   (GlcA)   or  
iduronic  acid  (IdoA)  69.  During  biosynthesis,  HS  undergoes  extensive  modification  
including:  de-­acetylation  and  sulfation  of  N-­acetyl-­glucosamines,  catalyzed  by  N-­
deacetylase-­N-­sulfo-­transferases  (Ndst),  epimerization  of  glucuronic  acid  residues  
adjacent  to  N-­sulfo-­glucosamine  to  iduronic  acid,  catalyzed  by  C5  epimerases,  and  
sulfation  on  positions  C2  of  iduronic  acid,  and  C6  and  C3  of  N-­sulfo-­glucosamine  
catalyzed   by   O-­sulfotransferases   70.   The   various   modifications   generate   the  
possibility  of  creating  over  32  different  disaccharides  rendering  HS  as  one  of  the  
most  information-­dense  molecules  found  in  nature  71.    
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Many   of   the   structural   modifications   on   HS   occur   in   patches,   creating  
clusters  of  various  lengths  with  specific  structural  properties.  Clusters  of  N-­sulfated  
regions   (NS  domains)   that  contain  mixtures  of  glucuronic  and   iduronic  acid  are  
alternated  with  unmodified  domains  (NA  domains)  with  high  levels  of  glucuronic  
acid,   interspaced   by   regions   with   alternating   modified   and   unmodified  
disaccharides   (NS/NA   domains)   69.   Typical   sulfated   regions   range   from   4   to   8  
sugars-­long,  and  specific  binding  sites  for  proteins  are  only  small  segments  (3-­10  
disaccharides  out  of  40-­160)  within  HS  chains  69.    
There   are   different   types   of  PGs   classified   by   their   location.  Membrane-­
attached  HSPGs  include  syndecans  1-­4  72  (with  a  trans-­membrane  core  protein)  
and  glypicans  1-­6   73   (glycosylphosphatidylinositol   [GPI]-­linked),  while   perlecans  
and   agrins   are   embedded   in   the   ECM   74.   Certain   enzymes   can   cleave   the  
ectodomain  of  syndecans  and  produce  a  soluble  or  “shed”  HSPGs  with  different  
biological  activities  75.  Heparin  is  a  more  highly  sulfated  form  of  HS  (contains  on  
average  2.7  sulfates  per  disaccharide  unit  while  HS  has  less  than  1),  synthesized  
and  secreted  by  mast  cells.  It  is  the  best-­known  form  of  HS  since  it  is  frequently  
used  in  the  clinic  as  an  anticoagulant.  Additionally,  heparin  is  commonly  used  as  
an  HS  analog  for  studying  protein-­HS  interactions.    
The  sulfation  level  of  HS  varies  depending  on  cell  type,  growth  conditions  
and  in  response  to  certain  stimuli  69.  HS  can  be  further  modified  once  it  reaches  
the  cell  surface  or  ECM.  Extracellular  sulfatases  can  cleave  specific  sulfate  groups  
and   heparanases   cleave   HS   chains   at   specific   sites   generating   shorter  
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polysaccharides  with  various  activities  76,  77.  The  length  and  position  of  NS  domains  
as  well  as  the  locations  of  iduronic  acid  determine  the  specificity  of  binding  sites  
for  proteins.  Rapid  changes  in  HS  in  response  to  certain  stimuli  (i.e.  injury,  hypoxia,  
or   an   increase   in   modifying   enzymes)   can   directly   affect   HS-­protein   binding  
kinetics  and  alter  availability  of  extracellular  growth  factors.  This  ability  renders  HS  
a  sensitive  and  rapid  tool  for  cells  to  use  to  release  pre-­synthesized  growth  factors  
without  the  delay  of  translation  and  secretion.  These  changes  can  also  affect  the  
ability   of   HS   to   act   as   co-­receptors,   and   therefore   steer   a   particular   biological  
response  in  a  specific  direction.    
The   best-­characterized   function   of   HSPGs   is   as   co-­receptors   in   the  
fibroblast  growth  factor-­2  (FGF-­2)  interaction  with  its  cell-­surface  tyrosine  kinase  
receptor   (FGFR).   In   the   FGF   system,   HS   serves   to   approximate   ligand   and  
receptor   at   the   cell   surface   and   stabilize   the   complex   by   interacting   with   both  
proteins  71.  However,  additional  data  indicate  that  the  nature  of  HS  can  dictate  the  
signal  intensity  and  duration  78.  On  the  other  hand,  it  has  been  demonstrated  that  
HSPGs  can  preferentially  distribute  to  lipid  rafts,  capturing  and  enhancing  FGFR  
signaling   79.   ECM   or   soluble   proteoglycans   are   thought   to   be   involved   in  
intercellular   trafficking   and  might   even   play   negative   roles   by   shielding   growth  
factors  from  their  receptors  and  inhibiting  their  activity  78.    
Due   to   the   highly   negative   charge   on   HS   molecules,   most   protein-­HS  
interactions  require  electrostatic  interactions.  However,  there  is  accumulating  data  
on   the   existence   of   highly   specific   or   “unique”   binding   sites   within   HS   chains.  
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Understanding  the  subsequences  that  render  binding  specificity  is  a  crucial  step  
to  develop  potential  HS-­based  growth  factor  activators  or  inhibitors.      
HS  is  able  to  bind  all  but  one  of  the  isoforms  of  VEGF,  and  HSPGs  have  
been  shown  to  be  essential  in  creating  VEGF  gradients  to  support  angiogenesis.  
HS  was  shown  to  enhance  VEGF  binding  to  VEGFRs  80  and  might  interact  directly  
with  the  VEGFRs  81.  One  study  showed  that  genetic  targeting  of  an  HS-­modifying  
enzyme,  HS  6-­O  sulfo-­transferase  2  (HS6ST-­2)  decreased  angiogenesis  during  
vascular   branching   in   zebrafish   82,   further   emphasizing   the   importance   of   HS  
structure  in  the  regulation  of  VEGF.  Modification  of  NRP-­1  by  addition  of  HS  chains  
has  been  reported  as  a  mechanism  to  modulate  VEGFR-­2  83.  After  many  years  of  
extensive   research,   there   are   still   many   unknowns   about   the   specific   role   HS  
structure  changes  have  in  angiogenesis  regulation.  The  complexity  of  the  system  
and   the   number   of   components   involved   has   imposed   severe   limitations   in  
studying   all   levels   of   regulation   that   are   incorporated   by   endothelial   cells   to  
orchestrate  angiogenesis.    
VEGF  and  the  extracellular  matrix  
In   addition   of   HSPGs,   VEGF165   is   also   able   to   interact   with   other  
components  of  the  extracellular  matrix,  including  Fn  51,  84.  VEGF  bound  to  the  ECM  
retains   its   activity   and   is   still   able   to   stimulate   cells   15;;   however   soluble   versus  
matrix-­bound   VEGF   stimulate   cells   in   different   ways.   The   signal   intensity   and  
specific  phosphorylation  pattern  can  be  modulated  by  the  ECM  85.    
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VEGF  binding   to  Fn   is  modulated  by  HS,  by  catalyzing  a  conformational  
change   in  Fn   that   leads   to  exposure  of  a  cryptic  binding  site   for  VEGF   86.  This  
activity  is  dependent  on  the  length  and  sulfation  of  HS,  since  only  heparin  chains  
longer   than  22   saccharides  and  with   6-­O   groups  on  glucosamine  were  able   to  
modify  Fn  87.  Specific  oligosaccharides  can  be  used  to  control  VEGF  availability  to  
form   particular   receptor   complexes,   therefore   to   rationally   manipulate  
angiogenesis.   Understanding   of   the   specific   mechanisms   by   which   the   ECM  
controls   VEGF   activity   is   necessary   for   the   rational   development   of   therapies  
where  aberrant  microenvironments  are  present  in  addition  to  uncontrolled  VEGF  
signaling.    
VEGF  in  disease  
It  is  clear  that  the  VEGF  system  plays  many  roles  in  malignant  diseases  88.  
Overexpression   of   VEGF   and   VEGFRs   is   increased   in   many   tumors   and   it   is  
associated  with  more  aggressive  and  metastatic  capacity   31.  Hence,  VEGF  has  
been  subject  of  intensive  research  as  a  target  for  cancer  treatment.  Additionally,  
VEGF-­blockade   is  used   to   treat  blinding  eye  diseases   that   involve  uncontrolled  
angiogenesis.    Millions  suffering  from  heart  and  brain  ischemia  after  infarction  or  
stroke   could   also   benefit   from   therapies   that   enhance   or   activate   angiogenic  
signaling.      Additionally,   decreased   VEGFR-­2   signaling   due   to   elevated   soluble  
VEGFR-­1   expression   in   the   placenta   during   preeclampsia   could   also   be   an  
indication  for  pro-­angiogenic  treatment  89.    
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Despite   years   of   research,   absence   of   important   information   about   the  
VEGF  system  has  prevented  the  development  of  highly  effective  anti-­angiogenic  
therapies   and   treatments   aimed   at   re-­vascularizing   ischemic   tissues   are  
completely  lacking.    
Anti-­angiogenic  Therapies  
The  introduction  to  the  idea  of  anti-­angiogenic  therapies  to  treat  tumors  was  
first  proposed  by  Judah  Folkman  in  1971,  when  he  and  his  co-­workers  set  out  to  
identify  the  “tumor  angiogenic  factor”  as  a  target  90,  91.  After  33  years,  the  first  anti-­
VEGF  therapy  was  approved  by  the  US  FDA,  a  humanized  monoclonal  anti-­VEGF  
antibody   (bevacizumab   –   Avastin)   that   demonstrated   a   survival   benefit   in  
combination  with  chemotherapy  for  the  treatment  of  metastatic  colorectal  cancer  
92.  Currently,  there  are  over  10  approved  drugs  on  the  market  that  target  VEGF  
and  its  receptors  with  indications  for  diabetic  retinopathy,  wet  age-­related  macular  
degeneration  (AMD)  and  cancer  with  more  in  clinical  trials  93.    
Avastin  antibody  binds  VEGF  and  prevents  it  from  binding  to  its  receptors  
in  endothelial  cells.  Although  based  on  a  solid  rational  hypothesis,  this  approach  
has  encountered  several  setbacks,  providing  modest  survival  benefits  on  the  order  
of  weeks  or  months  or  showing  no  benefit  at  all  in  some  cancers  93.  Understanding  
how  specific  cellular  and  tissue  contexts  affect  VEGF  signaling  and  mechanism  of  
blockade  under  therapeutic  conditions  will  be  crucial  for  the  development  of  more  
efficacious  drugs.  Additionally,  it  is  important  to  retain  VEGF  functions  important  
for  the  homeostasis  of  blood  vessels  in  healthy  tissues.  A  complete  understanding  
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of  all  components  of  the  system  and  possible  biomarkers  is  necessary  to  achieve  
selective   targeting   of   VEGF-­induced   pathways   in   pathological   conditions.   For  
instance,  elevated  levels  of  soluble  VEGFR-­1  prior  to  treatment  were  associated  
with  a  poor  outcome  from  bevacizumab  in  rectal  carcinoma  94.  Similarly,  elevated  
levels  of  NRP-­1  were  associated  with  a  poor  outcome   in  some  clinical   trials   95.  
Understanding  how  the  balance  between  NRP-­1  and  VEGFR-­1  binding  is  shifted  
in  different  microenvironments  could  provide  tools  to  develop  novel  therapies.  
More   recently,  a  different  approach   to  VEGF-­blockade  was  approved   for  
wet  age  related  macular  degeneration  (AMD)  treatment  and  metastatic  colorectal  
cancer  in  combination  with  chemotherapy.  Aflibercept  (Zaltrap  from  Regeneron)  is  
a   fusion  protein   containing   the   second   Ig   domain  of  VEGFR-­1  and   the   third   Ig  
domain  of  VEGFR-­2  fused  to  the  Fc  portion  of  human  IgG1.  Aflibercept  is  able  to  
“trap”  VEGF-­A,  VEGF-­B  and  PlGF  96.  Aflibercept  binds  VEGF  with  an  affinity  of  1  
pM  96,  higher  than  affinities  reported  for  either  VEGFR-­1  or  VEGFR-­2,  as  well  as  
Avastin.  Targeting  other  molecules  in  the  VEGF  system  is  also  being  investigated.  
Ramucirumab   (Cyramza)   is   a   human   monoclonal   antibody   targeted   against  
VEGFR-­2  approved   in   2014   for   use   in   combination  with   chemotherapy   to   treat  
metastatic   non-­small   cell   lung   cancer   (NSCLC)   97.   Additional   clinical   trials   are  
ongoing  for  anti-­PlGF,  anti-­NRP-­1  and  anti-­VEGFR-­1.    
Pro-­angiogenic  therapies  
In  ischemic  tissues,  stimulating  angiogenesis  can  aid  in  revascularizing  and  
restoring   blood   flow.   Some   groups   have   shown   benefits   of   adminitrating  
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recombinant  VEGF  after  stroke  in  mice  98,  but  the  transition  from  animal  models  to  
clinical  trials  has  been  unsuccessful.    
In   this   study,   we   aim   to   define   new   mechanisms   for   the   control   of  
angiogenesis  by  VEGF  binding  to  receptors  on  endothelial  cells.  We  propose  that  
specific  changes  in  the  microenvironment  fine-­tune  the  responses  of  neighboring  
cells   and   maintain   a   balance   in   pro-­   and   anti-­angiogenic   signaling   in   tissue  
homeostasis.   However,   during   pathologies,   changes   in   the   ECM   can   directly  
change  interactions  between  components  of  the  system,  providing  possible  novel  
targets  for  development  of  innovative  treatments.    
We  used  a  surface  plasmon  resonance  (SPR)  tool  to  systematically  analyze  
the  numerous  interactions  between  the  most  relevant  players  in  the  VEGF  system  
involved  in  the  regulation  of  angiogenesis.      
SPR  to  study  molecular  interactions  
SPR  is  an  optical  technique  that  uses  the  evanescent-­wave  phenomenon  
to  detect  molecular  interactions  on  a  surface  in  real  time  and  without  the  need  of  
a   label   99,   100.   In   a   typical   SPR   bioassay,   one   of   the  molecules,   referred   to   as  
“ligand”  is  attached  (covalently  or  non-­covalently)  to  a  gold  surface  (Illustration  1.5)  
with  a  prism  attached  to  the  bottom.  The  binding  partner  or  “analyte,”  is  allowed  to  
flow  over  the  surface  through  a  microfluidics  flow  cell.  Analyte  binding  to  the  ligand  
on   the  surface   results   in  a  change   in   refractive   index,  detected  as  a  change   in  
reflected  light  angle  through  the  prism  101.  The  change  in  refractive  index  is  directly  
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proportional  to  the  change  in  mass  on  the  surface,  providing  a  direct  and  real-­time  
measurement  of  relative  mass  of  material  bound.    
After  the  binding  is  measured  over  a  period  of  time,  the  system  switches  the  
flow  back  to  running  buffer  in  the  absence  of  the  analyte  and  dissociation  of  bound  
material  can  be  measured.  At  the  end  of  the  experiment,  any  remaining  analyte  on  
the   surface   can   be   removed   using   salt,   mildly   acidic   or   basic   solutions   to  
“regenerate”   the   surface   back   to   a   fully   functional   ligand   that   can   be   tested  






Illustration  1.5  SPR  set  up.  
Diagram  of  sensor  chip  with  prism  attached.  Polarized  light  is  directed  through  the  
prism  and  reflected  to  a  detector  on  the  opposite  side.  The  angle  of  the  reflected  
light   changes   proportionally   to  mass   changes   on   the   surface,   due   to   refractive  





Illustration  1.6  Typical  SPR  sensograms.  
Before  t  =  0  s,  buffer  continuously  runs  over  immobilized  molecules.  At  t  =  0  s,  the  
analyte  dissolved  in  running  buffer  is  injected  over  the  sensor  chip.  Binding  of  the  
analyte  to  the  surface  (association)  causes  an  increase  in  refractive  index  of  the  
adjacent  surface  that  is  measured  as  a  resonance  signal  in  arbitrary  response  units  
(RU).   The   rate   of   response   increase   is   called   the   observed   rate,   described   by  
simultaneous   association   and   dissociation   of   the   analyte   until   equilibrium   is  
reached.  Once  equilibrium  is  reached,  the  association  and  dissociation  rates  of  the  
analyte  are  equal  and   the   response  curve   reaches  a  plateau.  At   t  =  200  s,   the  
system  replaces  the  flow  with  running  buffer  and  dissociation  of  bound  analyte  is  
measured  over  time.  Regeneration  of  the  surface  with  high  salt  or  low  pH  is  used  
to  remove  any  remaining  analyte.       
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Almost  all  biological  molecules  rely  on  their  ability  to  reversibly  interact  in  a  
specific  manner  with  other  molecules  to  exert  their  functions.  Understanding  the  
nature  of   these   interactions   is  crucial   for   identifying  potential   targets   to  develop  
new  therapies.  SPR  can  be  used  to  answer  important  questions  about  the  nature  
of   interactions   including,   how   fast   molecules   bind   and   dissociate   from   their  
receptors.  However,  SPR  can  also  be  used  in  a  more  qualitative  manner  to  answer  
questions   about   cooperative   binding,   competition   and   complex   formation  
mechanisms  and  to  identify  subunits  in  complexes  with  multiple  components.      
The  BIO-­RADs  XPR36  is  a  multiplexed  system,  where  6  different  molecules  
can   be   immobilized   in   one   direction   and   the   interaction   with   6   other   partners  
measured   in   the   perpendicular   orientation   (Illustration   1.7).   The   instrument   is  
equipped   with   rotating   microfluidics   cells   that   create   36   separate   interaction  
















Illustration  1.7  BIO-­RAD’s  XPR36  multiplex  system.  
Diagram  of  the  two  possible  orientations  for  lanes  and  channels  on  the  SPR  chip  
for   XPR36.   In   the   vertical   orientation,   up   to   6   ligands   are   immobilized   and   6  
analytes   are   flowed  over   the   surfaces   on   the   horizontal   orientation   creating   36  
unique  interaction  spots.    




The  Langmuir  model  describes  interactions  between  one  analyte  molecule  
and  one  ligand  molecule  (1:1  single  binding  site).  Each  interaction  has  a  specific  
set   of   parameters   or   constants   that   determine   how   fast   the   two   molecules  
associate  and  dissociate.  The  association  rate  is  described  by  the  association  rate  
constant  (ka),   the  concentration  of   the  analyte   in  solution  [A]  and  the  number  of  
free  binding  sites  on  the  surface  of  the  chip  ([B]  =  Rmax  –  Rt)  and  subtracting  the  
simultaneous   dissociation,   defined   by   the   dissociation   rate   (kd)   and   the  
concentration  of  bound  complexes  ([AB]=Rt).  During  the  dissociation  phase,  when  
the  analyte  flow  is  stopped  and  replaced  by  buffer,  the  bound  molecules  begin  to  
dissociate  from  the  surface.  By  measuring  dissociation  over  time  we  can  obtain  
the  kinetic  constant  (kd)  of  the  interaction.  Association  and  dissociation  data  can  
be  fit  to  equations  2  and  3,  respectively  (Materials  and  Methods  section).    
Kinetic   analysis   is   a   powerful   tool   to   understand   the   affinity   and   type   of  
interaction  between  two  molecules.  In  the  case  of  growth  factors,  this  information  
can  provide  insight  into  the  kinetics  of  signaling  processes  in  cells.  For  example,  
how  long  does  a  complex  stay  bound  after  association  under  specific  conditions,  
and  how  co-­receptors  can  aid  or  negatively  influence  an  interaction?      
Competitive  approach  using  SPR  
Analysis   of   SPR   data   to   produce   kinetic   parameters   can   often   prove   to   be  
difficult   in   practice.   Several   assumptions  must   be  made   about   the   system   and  
when   they  are  not  met,  data  can  be  skewed.  For  example,  during  dissociation,  
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rebinding   and   bivalency   effects   can   translate   to   slower   kinetics   compared   to  
intrinsic  dissociation  values.  Several  methods  have  been  developed  to  avoid  false  
assumptions   and   obtain   true   affinities.   Here   we   describe   a   method   to   screen  
heparan   sulfate   oligosaccharides   structural   requirements   for   binding   growth  
factors  and  their  receptors  in  solution.    
First  we  measured  binding  of  the  protein  to  a  surface  containing  immobilized  
heparin.  Then,  we  measured  the  binding  of  the  protein  in  the  presence  of  different  
competitors.   Using   the   decrease   in   binding   observed   we   calculated   the  
concentration  of  free  protein  with  respect  to  competitor  concentration  (Equation  5  
in  Materials  and  Methods  section).  Using  these  values,  we  can  use  equation  6  to  
obtain  affinities  of  competitors  in  solution.  This  tool  is  effective  for  rapidly  screening  
structural  requirements  of  HS  for  binding  to  various  proteins.    
Summary  
   Millions  of  patients  could  benefit  from  the  development  of  new  more  efficient  
tools   to   manipulate   abnormal   angiogenesis   associated   with   various   diseases.  
Angiogenesis   regulation   involves   a   complex   system   of   ligands,   receptors,   co-­
receptors,  and  ECM  components  all  acting  together  to  orchestrate  VEGF  activity  
in  endothelial  cells.  A  comprehensive  understanding  of  the  system  is  crucial  in  the  
search  for  novel  targets  and  approaches  to  activate  or  block  VEGF  signaling.    
Goals  of  research  
The  objective  of  this  project  was  to  delineate  regulatory  mechanisms  of  the  
VEGF  system  that  could  be  used  as  means  to  manipulate  angiogenesis.  We  were  
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interested  in  understanding  how  cells  integrate  inputs  from  their  microenvironment  
to  produce  specific  biological  responses  to  VEGF.  To  achieve  this,  we  proposed  
the  following  aims:  1.  Characterize  binding  kinetics  for  VEGF-­A  isoforms  and  their  
cell   surface   receptors,   co-­receptors   and   extracellular   matrix   binding   sites;;   2.  
Identify   mechanisms   for   co-­receptor   control   of   VEGF   binding   to   cell-­surface  
receptors;;  3.  Define  how  HS  structure  modulates  VEGF  binding  and  activation  of  
signaling   receptors.   The   data   obtained   from   these   studies   will   serve   as   a  
foundation   for   predictive   tools   that   may   contribute   to   the   identification   of   new  




CHAPTER  TWO:  MATERIALS  AND  METHODS  
Materials    
Recombinant  human  VEGF165  (#293-­VE),  VEGFR-­1  and  VEGFR-­2  Fc  chimeras  
(#321-­FL   and   #357-­KD),   recombinant   rat   neuropilin-­1   Fc   chimera   (#566-­N1),  
recombinant   human   and   mouse   neuropilin-­1   (#s   3870-­N1   and   5994-­N1),  
recombinant  human  fibroblast  growth  factor  basic  (FGF-­2  #233-­FB),  recombinant  
human   FGFR-­1   β   (IIIc)   Fc   chimera   (#661-­FR)   and   recombinant   human   active  
heparanase  (#7570-­GH)  were  from  R&D  Systems  (Minneapolis,  MN).  125I-­labeled  
VEGF165  was  prepared  using  a  modified  Bolton-­Hunter  procedure  102.  125I-­Bolton-­
Hunter   reagent   was   obtained   from   PerkinElmer   Life   Sciences   (Boston,   MA).  
ProteOn  XPR36  neutravidin  (NLC)  sensor  chips  were  from  BIO-­RAD  (Hercules,  
CA).   Peroxidase-­AffiniPure   Donkey   Anti-­Human   IgG,   Fc   (gamma)   Fragment  
Specific   antibody   (#709-­035-­098)   was   from   Jackson   Immunoresearch   (West  
Grove,  PA).  TMB  Microwell  Peroxidase  Substrate  System   (50-­77-­00)  was   from  
KPL  (Gaithersburg,  MD).  Streptavidin-­coated  plates  and  protein  A-­coated  plates  
were   from   Pierce   (Rockford,   IL).   Heparin   (12.5   kDa),   heparin-­derived  
oligosaccharides:   tetrasaccharide   (#GT8021,   1.2   kDa),   hexasaccharide  
(#GT8031,   1.8   kDa),   octasaccharide   (#GT8041,   2.4   kDa),   decasaccharide  
(#GT8051,  3  kDa),  heparin  oligosaccharide  I  (#GT8071,  3.5  kDa)  and  II  (#GT8081,  
4.2   kDa),   and   modified   heparins:   fully   de-­O-­sulfated   heparin,   2-­O-­desulfated  
heparin,  6-­O-­desulfated  heparin,  de-­N-­sulfated  heparin  and  N-­acetylated  heparin  
were   from   Neoparin   Inc.   (Alameda,   CA).   VEGFR-­2   (#2478),   Y1175-­
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phosphorylated   VEGFR-­2   (#3770),   anti-­phospho   ERK1/2   (#   9101),   ERK1/2   (#  
4695),  and  anti-­AKT  (#  9272)  antibodies  were  from  Cell  Signaling  Technologies,  
(Danvers,   MA).   Anti-­rabbit   HRP-­linked   secondary   antibody   was   from  
JacksonImmunoResearch   (West   Grove,   PA).   Biotin-­heparin   (#B9806),   bovine  
kidney-­derived  heparan  sulfate  (#H7640),  sodium  chlorate  (#403016)  and  all  other  
chemicals  were  from  Sigma-­Aldrich  (St.  Louis,  MO).    
Fibronectin  (#341635)  and  40  kDa  α-­chymotryptic  fragment  (#F1903)  purified  from  
human   plasma  were   from  Millipore   (Billerica,  MA).   EZ-­link   Sulfo-­NHS-­biotin   kit  
(#21326)   and   Zeba   desalting   2  mL   spin   columns   (#89889)   were   from   Thermo  
Scientific  (Rockford,  IL).  Recombinant  α5β1  integrin  Fc  chimera  was  a  gift  from  Dr.  
Martin  Humphries  103.  
Fibronectin  biotinylation  
Full   length  and   the  hep  2  domain  of   fibronectin   (Fn)  were  biotinylated   following  
manufacturers  directions.  Briefly,  500  μL  of  250  μg/mL  hep  2  domain   fragment  
were  mixed  with  15.6  μL  of  10  mM  sulfo-­NHS-­biotin  (50-­fold  molar  excess)  and  
incubated  for  30  min  at  RT.  For  full  length  Fn,  2.8  μL  of  biotin-­reagent  were  added  
to  500  μL  of  250  μg/mL  solution.  Excess  unreacted  biotin  was  removed  by  running  
solution  through  a  desalting  column.  Our  group  has  previously  demonstrated  that  
heparin  is  able  to  expose  a  VEGF165  binding  site  on  Fn87.  In  order  to  determine  if  
fibronectin   biotinylation   interfered   with   its   ability   to   bind   VEGF   after   heparin  
treatment  we  performed  a  125I-­VEGF165  binding  experiment.  Biotinylated  and  non-­
biotinylated   fibronectin   fragment   (10   μg/mL   in   PBS)   were   coated   to   a   non-­cell  
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culture-­treated   polystyrene   96-­well   plate   (100   μL   per  well)   overnight   at   4°C.   (±  
heparin;;  10  µg/mL).  Additionally,  VEGF  binding  to  biotinylated  Fn  was  tested  on  a  
streptavidin-­coated  plate  (same  conditions  as  hydrophobic  plate  adsorption).  After  
adsorption,  the  Fn  solutions  were  removed  and  wells  were  washed  twice  with  200  
μL  of  PBS.  Wells  were  washed  an  additional  time  with  cold  binding  buffer  (25  mM  
HEPES,  pH  6.5,  150  mM  NaCl,  1  mg/mL  BSA).  Then,  100  μL  of  cold  binding  buffer  
was  added  to  each  well  and  incubated  for  10  min  on  ice  to  prevent  endocytosis.  
Next,  10  µL  of  200  ng/mL  125I-­VEGF165  were  added  per  well  (final  concentration  of  
20  ng/mL)  and  incubated  at  4°C  for  2  h.  Solutions  were  removed  and  wells  were  
washed  three  times  with  binding  buffer.  A  solution  (200  μL)  of  2  M  NaCl,  25  mM  
HEPES,   pH   7.5   was   used   to   extract   bound   VEGF   for   5   min.   Bound   VEGF  
extractions   (in   triplicate)   were   placed   in   tubes   and   counted   in   a   Cobra   Auto-­
Gamma  5005  γ-­counter  (Packard  Instruments,  Meridian,  CT).  We  found  that  there  
was  no  significant  difference  between  the  biotinylated  hep  2  domain  of  Fn  and  the  




Figure  2.1  125I-­VEGF165  binding  to  biotinylated  Fn  fragment.  
VEGF  binding  to  heparin-­treated  and  untreated  Fn  on  a  hydrophobic  plate  (A)  or  
streptavidin  plate  (B)  was  measured.  There  was  no  significant  difference  in  VEGF  
binding  between  biotinylated  and  unmodified  Fn  fragment.       
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Surface  Plasmon  Resonance  
All   interactions  were  characterized  using  the  ProteOn  XPR36  protein  interaction  
array  system  from  BIO-­RAD  at  25°C  in  binding  buffer  (PBS  with  0.05%  Tween  20  
and  0.1%  BSA)  at  a  flow  rate  of  25-­100  μL/min  unless  stated  otherwise.    
Receptor  immobilization  on  GLC  and  GLM  SPR  chips  
Chip  surfaces  were  pre-­conditioned  following  manufacturer’s  instructions.  Briefly,  
three  injections  were  performed  at  30  μL/min  flow  rate  for  60  s  in  both  orientations:  
1   –   0.5%   SDS,   2   –   50   mM   NaOH,   and   3   –   100   mM   HCl.   Immediately   after  
preconditioning  the  chip,  surfaces  were  activated  for  120-­160  s  with  a  mixture  of  
20   mM   EDAC   (N-­(3-­Dimethylaminopropyl)-­N-­ethylcarbodiimide   hydrochloride)  
and  5  mM  sulfo-­NHS   (N-­Hydroxysulfosuccinimide)  at   30  μL/min   (Figure  2.2)   to  
activate  carboxyl  groups.  Using  amino  acid  sequences  of  ligands,  isoelectric  point  
(pI)   values   for   each   recombinant   protein   were   estimated   using   an   online   tool  
(http://web.expasy.org/compute_pi/).   The   pH   of   each   buffer   was   chosen   to   be  
below   the   theoretical   pI   of   each   protein   to   facilitate   attraction   to   the   negative  
surface  of   the  chip.  Receptors  dissolved   in   running  buffer  were   flowed  over   the  
surface  at  the  appropriate  concentrations  and  pH  values  determined  previously.  
After  reaching  the  desired  immobilization  levels,  one  step  of  1  M  ethanolamine  HCl  
at  pH  8.5  at  30  μL/min  for  300  s  was  performed  to  block  any  activated  carboxyl  
groups   left   unreacted   on   the   surface.   Sensograms   recording   the   responses  





Figure  2.2  VEGFR-­1  Fc  chimera  immobilization  on  SPR  chip.  
A)  Surface  was  activated  with  EDAC  –  sNHS  for  160  s  in  the  horizontal  orientation.  
B)   Ligand   was   immobilized   up   to   1600   RU.   C)   Surface   was   deactivated   with  
ethanolamine  for  300  s.         
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Immobilization  of  biotin,  biotin-­heparin  and  biotin-­Fn  on  NLC  SPR  chip  
NLC  chips  were  pre-­conditioned  by  performing  an  injection  of  1  M  NaCl  followed  
by  50  mM  NaOH  injection.  The  injections  were  repeated  once  and  performed  in  
both  orientations  at  a  flow  rate  of  30  μL/min  for  60  s.  Biotin-­heparin  (1-­5  μg/mL)  
was  allowed   to   interact  with   the  NLC  chip   surface   for   180-­300   s   at   25  μL/min,  
reaching  an   immobilization   level  between  80-­120  RUs  per   lane   for  heparin  and  
saturating  the  surface  (Fig  2.3).  Biotin-­fibronectin  (10  μg/mL)  and  biotin-­fibronectin  
fragment  (5  μg/mL)  were  allowed  to  interact  with  two  lanes  each  on  the  NLC  chip  
surface  for  130  s  at  25  μL/min,  reaching  an  immobilization  level  of  approximately  
1600  RUs  per  lane  of  full-­length  Fn  and  580  RUs  of  Fn  fragment.  One  of  two  lanes  
containing  Fn  was  either  treated  with  buffer  or  10  μg/mL  heparin  at  30  μL/min  for  
300s.  Biotin  (0.5-­1  μg/mL)  was  immobilized  to  one  lane,  obtaining  60-­90  RUs  of  




Figure  2.3  Biotin-­heparin  and  biotin  immobilization  on  NLC  chip.  
Biotin-­heparin  (5  μg/mL)  and  biotin  (1  μg/mL)  were  flowed  over  an  NLC  chip  for  
180  s.    Sensograms  show  the  immobilization  level  in  response  units  over  time  of  
biotin-­heparin  (A)  and  biotin  (B)  in  parallel  surfaces  on  an  NLC  chip.       
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Evaluation  of  theoretical  Rmax  
For   each   immobilization   level,   a   theoretical   maximal   response   (Rmax)   was  
calculated  for   the  analytes   to  be  tested  before  performing  kinetic  analyses.  The  
theoretical  Rmax  is  the  estimated  maximal  response  to  be  expected  for  an  analyte  
at  saturating  concentrations  over  a  specific  immobilization  level  of  ligand  (RL).  The  
Rmax  value  is  determined  by  equation  1,  where  MWA  and  MWL  are  the  molecular  
weight  of   the  analyte  and   ligand,   respectively,  and  n   is   the  stoichiometry  of   the  
interaction  (i.e.  1:1  interaction  n=1).    
  
SPR  kinetic  studies  and  sensogram  analysis    
Increasing  concentrations  of  binding  partners  in  running  buffer  were  injected  over  
immobilized  receptors,  heparin  or  Fn  until  equilibrium  was  reached,  then  washed  
to  measure  dissociation.  Injections  of  2  M  NaCl  and  5-­10  mM  NaOH  were  used  to  
regenerate  surfaces  after  each  binding  event.    
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All   sensograms   were   double-­referenced   by   subtracting   buffer   injection   and   a  
surface  containing  immobilized  reference  protein  as  shown  in  illustration  2.1  (BSA  
or  FGFR-­1  Fc  chimera   for   receptor  studies  and  biotin   for  biotinylated  proteins).  
Interspots   were   monitored   as   an   additional   control   of   non-­specific   binding.  
Association  and  dissociation  rate  constants  (ka  and  kd,  respectively)  were  obtained  
by  non-­linear  regression  of  data  to  a  1:1  Langmuir  model  (Equations  2-­4)  using  
OriginLab,  Northampton,  MA.  In  Equation  2,  Rt  represents  the  response  (RU)  at  
time  t,  Rmax  is  the  maximal  response  at  saturating  analyte  concentration  and  [A]  is  
the  ligand  concentration  in  M.  Equilibrium  affinity  constants  (KD)  were  derived  from  
kinetic  parameters   (KD=kd/ka)  or  determined   from  equilibrium  analysis   (Equation  
4).    





Illustration  2.1  Sensogram  referencing.  
One  lane  (blue)  was  used  as  reference  for  non-­specific  binding  to  the  surface.  A  
buffer  injection  (yellow)  in  parallel  to  analyte  injections  was  used  to  correct  for  bulk  






SPR  competition  was  used  to  measure  binding  affinities  of  VEGFR-­1  and  NRP-­1  
with   HS,   chemically   modified   heparins   and   heparin-­derived   oligosaccharides.  
VEGFR-­1  (1  nM)  or  NRP-­1  (5  nM)  Fc  chimeras  were  premixed  with  a   range  of  
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concentrations  of  oligosaccharides  and  chemically  modified  heparins   in  binding  
buffer.  Mixtures  were  incubated  at  room  temperature  (RT)  for  30  minutes  to  allow  
the  protein  to  bind  the  oligosaccharide/modified  heparin  in  solution.  The  mixtures  
were  injected  over  a  biotin-­heparin  chip  surface  at  30  μL/min  for  240  s  to  record  
maximal  response.  Regeneration  steps  were  performed  as  described  above.  Free  
protein  concentration  ([protein]F)  at  each  inhibitor  (i)  concentration  was  calculated  
using  equation   5;;   briefly,   the   ratio   of  maximal   binding   response  of   protein   plus  
inhibitor   (Rmaxi)   to   protein   alone   (Rmax)   times   the   total   protein   concentration  
([protein]T).  Values  were   plotted   against   inhibitor   concentration   and  data   points  
were   fit   to   equation   6   to   obtain   apparent   binding   constants   (KD)   for   each  





Competition  Analysis  of  FGF-­2    
The   competition   method   described   above   was   used   to   test   FGF-­2   binding   to  
oligosaccharide  samples  obtained  from  our  collaborator  Dr.  Joseph  Zaia.  Briefly,  
heparin-­  and  HS-­derived  oligosaccharides  were  obtained  by  partial  digestion  with  
heparin  lyases.  Products  were  separated  by  size  exclusion  chromatography  (SEC)  
and   further   separated   by   high-­resolution   strong   anion   exchange   (SAX)  
chromatography   as   described   previously   105.   Heparin-­   and   HS-­derived  
oligosaccharides  are   referred   to  by   their   degree  of   polymerization   (dp)  and   the  
number  of  saccharide  units.  For  example,  HS  dp8   is  a  HS-­derived  oligo  with  8  
saccharide   units.   FGF-­2   was   incubated   with   increasing   concentrations   of  
oligosaccharide   samples   before   flowing   over   a   surface   containing   immobilized  
heparin.  In  this  instance,  initial  rate  analysis  was  used  to  calculate  the  free  protein  
concentration  as  in  equation  5.  Slope  ratios  from  the  initial  10  s  of  injection  were  
used  in  place  of  maximal  binding  response  (see  chapter  6).  The  following  steps  of  
the  analysis  were  performed  as  described  above.    
Qualitative  SPR  Studies  
Mixtures  of  analytes  in  various  combinations  were  dissolved  in  running  buffer  and  
incubated  for  30-­120  min  before  injecting  over  indicated  surfaces.  Injections  of  2  
M  NaCl  or  10  mM  NaOH  solutions  were  used  to  regenerate  surfaces  after  each  
binding  event.    
ELISA  Binding  Assays  
Biotin-­heparin   (10  μg/mL,  100  μL/well)   in  PBS  was  adsorbed  onto  streptavidin-­
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coated  96-­well  plates  overnight  at  4°C.  Wells  were  washed  with  200  μL  of  binding  
buffer   to   remove  any  unbound  heparin.  Receptor  chimeras   (100  μL/well)  at   the  
indicated  concentrations  in  binding  buffer  were  applied  to  each  well  and  incubated  
for  two  hours  at  4°C.  The  plate  was  rinsed  3  times  with  binding  buffer,  blocked  in  
1.5%  BSA,  0.2%  casein  in  PBS  for  1  h,  and  the  amount  of  bound  receptor  was  
measured  using  an  HRP-­linked  donkey  anti-­human  IgG  (1:5000)  in  blocking  buffer.  
Wells  were  washed  three  times  with  PBS  0.05%  Tween-­20  and  three  times  with  
PBS   before   adding   100   μL   of   peroxidase   substrate   to   determine   the   relative  
amount   of   receptor   bound   at   each   concentration.   Color   development   reactions  
were  stopped  after  5-­10  minutes  with  1  M  sulfuric  acid  and  absorbance  at  450  nm  
(referenced  to  570  nm)  was  measured  using  a  spectrophotometer.  
Radio-­ligand  Binding  Assays  
Receptor  Fc  chimeras  (100  pM,  100  μL/well)  in  binding  buffer  were  adsorbed  onto  
a  Protein-­A-­coated  96-­well  plate  for  1  h  at  RT.  125I-­VEGF165  was  added  to  wells  in  
the   presence   or   absence   of   heparin,   heparin   oligosaccharides,   or   chemically  
modified  heparins  (500  nM  in  100  μL  binding  buffer/well)  and  incubated  for  1  h  at  
room   temperature.   The   plate   was   washed   3   times   and   bound   125I-­VEGF   was  
extracted  using  300μl  of  1  N  NaOH.  Radioactivity  was  quantified  using  a  Cobra  
Auto-­Gamma  5005  counter  (Packard  Instruments,  Meridian,CT).  
Cell  culture  
Bovine  aortic  endothelial  cells  (BAEs)  were  initially  isolated  from  3-­4  week-­old  calf  
aortas  by  collagenase  digestion  106.  Cells  were  maintained  for  up  to  15  passages  
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in  10%  fetal  bovine  serum  (FBS)  in  Dulbecco’s  modified  eagle  medium  (DMEM)  
with  1%  PenStrep  and  L-­glutamine.  Mouse-­VEGFR-­2-­expressing  porcine  aortic  
endothelial   cells   (VEGFR-­2   PAEs)   and   empty   vector   (EV)   PAEs   were   kindly  
provided  by  Dr.  Nader  Rahimi  107,  108.  Cells  were  maintained  in  10%  FBS  in  DMEM  
with  PenStrep  and  L-­glutamine.  All  cell  culture-­related  reagents  were  purchased  
from  Invitrogen/Gibco  (Singapore).  
Extraction  of  extracellular  matrices  from  cultured  endothelial  cells  
Confluent  cell  monolayers  on  24-­well  plates  were  washed  once  with  PBS  (500  
μL).  Cells  were  extracted  using  200  μL  of  20mM  ammonium  hydroxide  and  0.5%  
Triton  X-­100  in  PBS  for  3  min  at  RT,  leaving  the  ECM  associated  with  the  plate.  
Wells  were  washed  three  times  with  PBS  before  measuring  125I-­VEGF165  binding.  
Heparanase  treatment  of  cell  monolayers  and  extracted  ECM  
Confluent  cell  monolayers  on  24-­well  plates  were  washed  once  with  warm  binding  
buffer  (500  μL).  Active  human  heparanase  (100  μg/mL)  dissolved  in  binding  buffer  
was  added  to  wells  and   incubated  for  2  h  at  37°C.  An  additional   treatment  with  
heparin   (10   µg/mL   in   binding   buffer   for   2   h   at   37°C)   was   conducted   in   some  
instances  to  rescue  for  the  absence  of  cell-­derived  HS.  Wells  were  washed  three  
times  with  PBS  before  performing  assays.  
Radio-­ligand  binding  to  endothelial  cells  
VEGFR-­2  and  EV  PAEs  were  seeded  in  24-­well  dishes  (Corning  Inc.,  Corning,  NY)  
in  0.5mL  of  10%  dialyzed  FBS  +/-­  25  mM  chlorate.  Cells  growing  in  the  presence  
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of  chlorate  were  seeded  at  a  higher  density  than  the  control  conditions  to  balance  
for   slower   growth   under   chlorate   conditions   (20,000   and   15,000   cells/well,  
respectively).  Equilibrium  binding  assays  on  confluent  cell  cultures  were  carried  
out  as  described  before  102.  Binding  buffer  consisted  of  25  mM  HEPES  pH  7.3  in  
DMEM   (without   bicarbonate)   containing   0.1%   BSA.   Briefly,   cells   were   washed  
once  with  0.5  mL  of  ice-­cold  binding  buffer  and  0.15  mL  were  added  to  wells  and  
incubated  at  4°C  for  10  min  to  inhibit  endocytosis.  125I-­labeled  VEGF165  (0.26  nM)  
in   the  presence  or  absence  of  soluble  NRP-­1   (sNRP-­1,  5  nM)   in  binding  buffer  
(pre-­incubated  for  2  h  at  RT)  was  added  to  cells  and  allowed  to  bind  for  3  h  at  4  
°C.  Unbound  125I-­VEGF165  was  removed  by  washing  cells  three  times  with  0.5  mL  
cold  binding  buffer.  Bound  125I-­VEGF165  was  extracted  with  0.4  mL  of  1  N  NaOH,  
and  radioactivity  was  counted  in  a  Cobra  Auto-­Gamma  5005  γ-­counter  (Packard  
Instruments,  Meridian,  CT).  
VEGF-­induced  Signaling  
VEGFR-­2-­PAEs   were   seeded   on   35   mm2   dishes   (Corning   Inc.)   in   DMEM  
containing  10%  dialyzed  FBS  with  L-­glutamine  in  the  absence  or  presence  of  25  
mM  sodium  chlorate  (non-­chlorate:  45,000  cells/well;;  chlorate:  60,000  cells/well).  
After   2   days,  media  was   changed   to  DMEM  containing   0.1%  dialyzed  FBS  +/-­  
chlorate  overnight  and  then  treated  with  mixtures  of  VEGF165  and  sNRP-­1  (pre-­
incubated  for  2  h  at  RT)  for  10  min.  For  heparin-­treated  cells,  heparin  (10  µg/mL)  
was  added  directly  into  the  media  for  1  h  at  37°C  before  stimulation.  Cells  were  
lysed  in  extraction  buffer  (1%  Triton-­X  150  mM  NaCl,  1  mM  EDTA,  1  mM  EGTA,  
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0.5%  Nonidet  P-­40,  10  mM  Tris  pH  7.5)  containing  Halt  protease  and  phosphatase  
inhibitor   cocktail   (Life   Technologies   #78440).   Lysates   were   cleared   by  
centrifugation   and   samples   containing   30   μg   of   protein   in   sample   buffer   were  
heated,   resolved   by   8%   SDS-­PAGE   and   transferred   onto   nitrocellulose  
membranes.  Membranes  were  blocked  for  1  h  at  RT  with  5%  milk  in  TBS-­T  (10  
mM  Tris  pH  7.5,  150  mM  NaCl  and  0.1%  Tween-­20),  incubated  overnight  at  4°C  
with  appropriate  primary  antibodies  in  blocking  buffer  and  subsequently  incubated  
with  horse-­radish  peroxidase  (HRP)-­conjugated  secondary  antibodies   for  1  h  at  
RT.   Membranes   were   developed   with   Clarity   ECL   Western   Blotting   Substrate  
reagent   (BIO-­RAD   #170-­5060)   and   imaged   on   a   ChemiDoc   MP   system   (BIO-­
RAD).    Quantification  of  immunoblotting  signals  was  performed  using  Image  Lab  




CHAPTER  THREE:  CHARACTERIZATION  OF  VEGF  BINDING  KINETICS  
INTRODUCTION  
The   potential   for   the   development   of   highly   efficient   therapies   to   target  
VEGF  under  various  cellular  contexts  has  been  limited  by  the  lack  of  information  
on  the  complexities  of  the  system.  Currently  millions  of  patients  could  benefit  from  
the   development   of   targeted   therapies   to   inhibit   or   induce   angiogenesis.  
Mathematical   models   such   as   those   described   by   the   Popel   group   109-­111   are  
powerful  tools  for  predicting  in  vivo  behaviors  of  the  VEGF  system.  These  models  
rely  on  accurate  kinetic  and  affinity  data  to  simulate  cellular  responses  to  changes  
in   normal   and   pathological   conditions.   Even   though   these   approaches   provide  
important   information  when   reviewing   potential   targets   for   therapy,   the   gaps   in  
understanding  of  the  system  as  a  whole  have  limited  their  application  and  reach.  
The  purpose  of  this  study  is  to  identify  new  mechanisms  for  the  regulation  of  VEGF  
at   the  cell  surface  and  extracellular   level,  by   ligand  and  co-­receptor  availability.  
   Additional   information   about   the   microenvironment,   including   receptor  
expression   and   local   ligand   concentrations,   is   required   for   the   application   of  
predictive   tools.  We   set   out   to   systematically   characterize   the  most   significant  
interactions  that  occur  in  the  system  using  an  SPR-­based  approach,  by  describing  
affinities  and  binding  parameters  between  ligands,  receptors  and  co-­receptors.    
Binding   kinetics   and   affinities   can   be   used   to   better   understand   how  
signaling  is  activated.  However,  relying  only  on  equilibrium  affinity  to  describe  a  
molecular   interaction  can  be  misleading  when  comparing   the  effectiveness  and  
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duration   of   the   biological   action   in   vivo.   The   intensity   and   duration   of   signals  
activated  by  receptor-­ligand  interactions  are  directly  related  to  the  complex  lifetime.  
Therefore,  the  dissociation  rate  of  the  complex  is  often  a  more  relevant  parameter  
when  analyzing  how  the  binding  translates  to  a  biological  response.  Determining  
kinetic  parameters  for  each  receptor  and  co-­receptor  to  VEGF  isoforms  will  provide  
insightful   information   that,   combined   with   local   pericellular   environment  
information,  can  be  used  to  predict  biological  responses  to  changes  under  various  
cellular  and  extracellular  contexts.    
  
RESULTS  and  DISCUSSION  
We  used  SPR  and  VEGFR  Fc  chimeras,  which  are  pre-­dimerized   fusion  
proteins  consisting  of  the  extracellular  domains  of  the  VEGFRs  and  the  constant  
Fc  region  of  human  IgG1,  to  systematically  analyze  and  compare  the  interactions  
between  VEGF  and  its  different  receptors  and  co-­receptors.  As  a  reference,  we  
used   bovine   albumin   albumin   (BSA)   or   a   non-­VEGF   binding   receptor   chimera,  
FGFR-­1  Fc,  to  subtract  non-­specific  binding.  VEGFR-­1  Fc,  VEGFR-­2  Fc,  NRP-­1  
Fc,  NRP-­1  monomer  and  FGFR-­1  Fc  were  covalently  immobilized  to  the  surfaces  
of   activated   SPR   chips   by   amine   coupling.   Ligand   immobilization   levels   and  
conditions   were   optimized   to   reduce   non-­specific   binding   and   mass   transport  
effects.   In   order   to   determine   the   best   reference   surface   for   the   analysis,   we  
compared  the  extent  of  VEGF  binding  non-­specifically  to  the  naked  surface  versus  
a   surface   containing   immobilized  FGFR-­1  Fc   chimera   (Figure  3.1).  Each  panel  
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shows  initial  uncorrected  VEGF165  injections  at  5  concentrations  (6.25,  12.5,  25,  
50  and  100  nM)  over  surfaces  with  the  indicated  protein  immobilized  (solid  lines)  
overlaid  with   the   non-­specific   binding   to   the   naked   chip   on   adjacent   interspots  
(dotted  lines).  VEGF165  interacts  strongly  with  the  negatively  charged  unmodified  
surface;;  however,  the  responses  are  flat  and  return  to  baseline  after  the  end  of  the  
injection.  We  concluded  FGFR-­1  Fc  chimera  is  a  more  relevant  reference  since  
the   surface   undergoes   the   same   activation,   immobilization   and   deactivation  
process  of  the  surface  containing  VEGFRs.  The  responses  observed  on  the  FGFR  
surface,  although  lower  than  those  observed  on  the  interspots,  were  also  flat  and  
returned   to  baseline.  The   lower   response  observed  on   the  FGF  surface  can  be  
explained   by   a   reduction   in   the   electrostatic   charges   on   the   surface   after   the  
chemical  modifications  that  occur  during  immobilization.    





Figure  3.1  VEGF165  flowed  over  SPR  surfaces  before  correction.  
VEGFR-­1  Fc  chimera  (A),  VEGFR-­2  Fc  chimera  (B),  NRP-­1  Fc  chimera  (C),  and  
FGFR-­2  Fc  chimera  (D)  were  immobilized  onto  an  SPR  chip.  Recombinant  human  
VEGF165  diluted  at  the  indicated  concentrations  in  running  buffer  was  flowed  over  
the  surfaces  after  stabilization.  Solid  lines  represent  VEGF  binding  to  the  surface  
with  the  indicated  protein  immobilized,  while  dotted  lines  represent  the  response  
observed  on  interspots  adjacent  to  each  surface.      
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One   common  artifact   that   occurs  within   the  SPR  experimental   setting   is  
mass  transport  limitation.  Mass  transport  refers  to  an  interaction  being  limited  by  
the  rate  of  diffusibility.  When  analyzing  data,  it  is  assumed  that  the  transport  rate  
(time  the  analyte  takes  to  reach  the  biosensor  surface)  is  significantly  faster  than  
the   binding   rate,   and   therefore   it   can   be   disregarded.   However,   in   some  
experimental   settings,   this   assumption   is   not  met   and   the   reaction   kinetics   are  
governed  by  the  rate  of  transport  and  not  intrinsic  molecular  binding  kinetics  112.  
Mass  transport  can  skew  data  and  result  in  false  kinetic  constant  determination  or  
in  the  need  for  the  use  of  more  complex  binding  models  that  do  not  necessarily  
describe   true   kinetics   of   the   interaction   113.   Under   appropriate   experimental  
conditions  (fast  flow  rate  and  low  immobilization)  mass  transport  does  not  have  a  
significant  effect  on  binding  kinetics  114.  
To  test  for  the  possibility  of  mass  transport  effects  in  our  system,  we  flowed  
one  VEGF  concentration  over  VEGFR-­1  and  VEGFR-­2  at  different  flow  rates  115  
(Figure  3.2).  By  comparing  the  initial  linear  association  phase,  we  were  able  to  rule  






Table  3.1  Initial  rate  analyses  to  detect  mass  transport.  
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Slopes  of  the  initial  10  s  binding  response  of  a  single  VEGF  concentration  over  a  









     
   VEGFR-­1   VEGFR-­2  
Flow  rate  (μL/min)   Slope  ±  SE   Slope  ±  SE  
100   5.6  ±  0.2   2.5  ±  0.1  
50   5.0  ±  0.2   2.3  ±  0.2  





Figure  3.2  Variations  in  flow  rate  to  detect  mass  transport  effects.  
Symbols  represent  SPR  response  over  the  first  9  s  of  a  VEGF165  injection  at  
different  flow  rates  (25,  50,  100  μL/min)  over  VEGFR-­1  Fc  (A)  and  VEGFR-­2  Fc  
(B)  chimeras.  Red  lines  are  linear  fits  and  slope  values  are  shown  on  table  3.1.    
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VEGF165  binding  kinetics  to  VEGFRs  
After   defining   and   optimizing   the   system,   we   analyzed   VEGF165   and  
VEGF121  binding  to  VEGFRs  and  NRP-­1  Fc  chimeras.  Figure  3.3  shows  increasing  
concentrations  of  VEGF165  binding  to  (A)  VEGFR-­1  and  (C)  VEGFR-­2  Fc  chimeras  
immobilized  by  amine  coupling  to  an  SPR  chip  (black  undulating  lines  represent  
binding   at   concentrations   increasing   from   bottom   to   top).   To   obtain   kinetic  
parameters,   we   performed   global   non-­linear   regression   (red   lines)   of   the  
dissociation   phase   sensograms   to   equation   3   using   OriginLab   (Materials   and  
Methods).  The  dissociation  rate  constant  parameter  was  shared  for  all  data  sets,  
while  equilibrium  binding  response  (Req)  was  kept  local  for  each  concentration.  The  
start   time   of   dissociation   (to)   was   fixed   to   the   time   in   seconds   that   the   system  
switched  the  flow  to  buffer.  For  the  interaction  between  VEGF165  and  VEGFR-­1  Fc  
chimera,  we  observed  a  dissociation  rate  constant  of  5.92  ±  0.07  ×  10-­4  s-­1  (Table  
3.2).  Using  the  dissociation  rate  constant,  we  fit  the  association  phase  curves  to  
equation   2,   with   VEGF165   concentration   values   kept   constant.   The   maximal  
response  at  saturation  (Rmax)  was  shared  for  all  data  sets  since  it  represents  the  
total   number   of   binding   sites   on   the   surface.  We   obtained   an   association   rate  
constant   of   2.91   ±   0.04   ×   106   M-­1   s-­1   (Table   3.3).   Using   the   association   and  
dissociation  rate  constants  we  calculated  the  equilibrium  dissociation  constant  (KD  
=  kd/ka)  of  the  interaction  to  be  196  ±  4  pM.  
We  applied  the  same  process  to  all  SPR  sensograms  analyzed.  When  we  
examined  the  interaction  of  VEGF165  with  the  main  signaling  receptor,  VEGFR-­2,  
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we  observed  a  dissociation  rate  constant  of  1.51  ±  0.07  ×  10-­2  s-­1  approximately  25  
times  faster  than  VEGFR-­1  Fc  chimera.  The  association  rate  constant  was  1.76  ±  
0.04  ×  106  M-­1  s-­1,  comparable  to  VEGFR-­1.  The  calculated  KD  was  8.6  ±  0.5  nM,  
about   40   times   lower   than   that   for   VEGFR-­1,   consistent   with   the   differences  
reported  in  the  literature  between  the  two  receptors  14.    
The  equilibrium  values  obtained  by  the  association  curve  fit  were  plotted  as  
a  function  of  VEGF  concentration  to  perform  equilibrium  analysis.  The  equilibrium  
dissociation  constant  obtained  by  fitting  equilibrium  responses  of  VEGF165  binding  
to  VEGFR-­1  Fc  to  equation  4  (Figure  3.3B)  was  3.7  ±  0.3  nM  (Table  3.10),  higher  
than   the   calculated   KD   from   kinetic   values.   This   discrepancy   could   be   due   to  
limitations  of  the  system  when  measuring  slow  dissociation  rates  116.  On  the  other  
hand,  we  obtained  a  KD  of  18  ±  2  nM  for  VEGF165  binding  to  VEGFR-­2  Fc  chimera,  
consistent   with   our   kinetic   analysis   (Figure   3.3D   -­   Table   3.10).   As   expected,  
VEGF165   bound   VEGFR-­2   Fc   chimera   with   a   lower   affinity   than   to   VEGFR-­1,  
evaluated  by  equilibrium  binding.  




Figure  3.3  Kinetic  analysis  of  VEGF165  binding  to  VEGFR-­1  and  VEGFR-­2  Fc  
chimeras  on  an  SPR  chip.    
VEGFR-­1  and  VEGFR-­2  Fc   chimeras  were   immobilized  onto  an  activated   chip  
surface  until  reaching  728  and  407  RU  of  immobilization  respectively.  Increasing  
concentrations  of  recombinant  human  VEGF165  in  running  buffer  (6.25,  12.5,  25,  
50  and  100  nM)  were  flowed  over  the  surface  and  the  response  was  measured  for  
60s  at  50  μL/min.  Dissociation  was  measured  after  switching  the  flow  to  running  
buffer.  All  sensograms  were  referenced  to  a  surface  containing  immobilized  FGFR-­
1  Fc  and  a  blank  injection  to  correct  for  bulk  shifts.  Association  and  dissociation  
phases  were  analyzed  by  non-­linear  curve  fitting  (red  lines).  Parameters  obtained  
by   fitting  are  shown   in  Tables  3.2  –  3.5.  Req  values  were  plotted  against  VEGF  
concentration   to   implement  equilibrium  analysis  and  results  are  shown   in  Table  
3.10.    
     
    
59  
Table  3.2  Dissociation  phase  analysis  of  VEGF165  from  VEGFR-­1.  
Parameters  obtained  from  global  curve  fitting  (red  lines  Figure  3.3A)  of  dissociation  




  to  (s)  
Fixed  
Req  ±  SE  
(RU)  








113.9  ±  0.1  
5.69  ±  0.07  
x  10  -­4   2.5   0.99  
50   112.5  ±  0.1  
25   107.4  ±  0.1  
12.5   92.1  ±  0.1  
6.25   75.0  ±  0.1  
  
  
Table  3.3  Association  phase  analysis  of  VEGF165  binding  to  VEGFR-­1.  
Parameters   from   fitting   association   phase   data   (red   lines   Figure   3.3A)   and  




  ka  ±  SE  
(M-­1s-­1)  








KD  ±  SE  
(pM)  
1.00  x  10-­7  
2.91  ±  0.04  
x  106   108.7  ±  0.5  
5.92    
x  10  -­4   24.6   0.98   196  ±  4  
5.00  x  10-­8  
2.50  x  10-­8  
1.25  x  10-­8  
6.25  x  10-­9  
  
  
Table  3.4  Dissociation  phase  analysis  of  VEGF165  from  VEGFR-­2.    
Parameters  obtained  from  global  curve  fitting  (red  lines  Figure  3.3C)  of  dissociation  




  to  (s)  
Fixed  
Req  ±  SE  
(RU)  
Rmin  ±  SE  
(RU)  








10.2  ±  0.3   24.6  ±  0.2  
1.51  ±  0.07  
x  10  -­2   3.29   0.97  
50   8.8  ±  0.3   21.9  ±  0.1  
25   6.4  ±  0.3   18.1  ±  0.1  
12.5   3.3  ±  0.3   12.7  ±  0.1  





Table  3.5  Association  phase  analysis  of  VEGF165  binding  to  VEGFR-­2.  
Parameters   from   fitting   association   phase   data   (red   lines   Figure   3.3C)   and  




  ka  ±  SE  
(M-­1s-­1)  
Rmax  ±  SE  
(RU)  






KD  ±  SE  
(nM)  
1.00  x  10-­7  
1.76  ±  0.04  
x  106   34.9  ±  0.3  
1.51    
x  10  -­2   1.76   0.96  
8.6  ±  
0.5  
5.00  x  10-­8  
2.50  x  10-­8  
1.25  x  10-­8  
6.25  x  10-­9  
  
  
VEGF  binding  kinetics  to  NRP-­1:  dimeric  and  monomeric    
We  then  analyzed  the  kinetics  of  VEGF165  binding  to  NRP-­1  Fc  chimera  and  
a   monomeric   NRP-­1   protein   (Figure   3.4).   NRP-­1   Fc   chimera   contains   the  
extracellular  domains  (a1,  a2,  b1,  b2  and  c  –  Illustration  1.4)  of  the  rat  sequence  
(shares  approximately  93%  homology  with  the  human  sequence)  fused  to  the  Fc  
region   of   human   IgG1.   Hence,   the   protein   is   expressed   as   a   dimer   through  
formation  of  disulfide  bonds  between  the  Fc  domains  of  each  construct.  On  the  
other  hand,  sNRP-­1  is  a  construct  containing  only  the  extracellular  domains  of  the  
mouse  sequence  (also  shares  ~93%  homology  with  human  NRP-­1)  expressed  as  
a   monomer.   Both   constructs   contain   residues   important   for   dimerization   and  
oligomerization  located  on  the  c1  domain  117.  
VEGF165  bound  NRP-­1  Fc  chimera  with  a  kd  of  9.0  ±  0.4  ×10-­2  s-­1  and  a  ka  
of  3.6  ±  0.2  ×  106  M-­1  s-­1  (Table  3.6).  The  calculated  affinity  (KD)  was  25  ±  2  nM.  
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VEGF165   binding   to   NRP-­1   monomer   showed   very   similar   kinetics,   with   an  
association  rate  constant  of  2.64  ±  0.08  ×  106  M-­1  s-­1  and  a  kd  of  6.5  ±  0.2  ×10-­2  s-­
1  and  a  calculated  KD  of  25  ±  1  nM  from  kinetic  parameters.  Equilibrium  analysis  
of  both  interactions  resulted  in  a  KD  of  22  ±  7  nM  for  the  Fc  chimera  and  28  ±  4  nM  
for  the  monomeric  form  of  NRP-­1  (Table  3.10).  It  is  interesting  that  we  found  such  
small  variation   in  VEGF165  binding  kinetics  between   the  dimeric  NRP-­1  and   the  
monomer.   It   is  possible   that   immobilization  of  NRP-­1   to   the  surface  of   the  chip  
places   each   NRP-­1  monomer   in   close   proximity   to   another,   and   the   observed  
kinetics  resemble  binding  to  the  “pre-­dimerized”  NRP-­1.    
Using  Rmax  values  and  immobilization  levels  for  each  surface,  we  calculated  
the  percentage  of  protein  on  the  surface  that  was  available  for  binding  VEGF  using  
equation  1.  The  surface  of  VEGFR-­1  Fc  was  86%  active  while  surfaces  containing  
VEGFR-­2  Fc  chimera,  NRP-­1  Fc  chimera  or  NRP-­1  were  closer   to  50%  (Table  
3.11).    




Figure  3.4  Kinetic  analysis  of  VEGF165  binding  to  NRP-­1.    
NRP-­1  Fc  chimera  (A  and  B)  or  NRP-­1  monomer  (C  and  D)  were  immobilized  onto  
an  SPR  chip  reaching  295  and  166  RU  of  immobilization,  respectively.  VEGF165  
(6.25,  12.5,  25,  50  and  100  nM)  binding  responses  were  measured  for  60  s  at  0  
μL/min.  Association  and  dissociation  phases  were  analyzed  by  non-­linear  curve  
fitting   after   correction   (red   lines).   Parameters   obtained   by   fitting   are   shown   on  
Tables  3.6  –  3.10.      
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Table  3.6  Dissociation  phase  analysis  of  VEGF165  from  NRP-­1  Fc  chimera.    
Parameters  obtained  from  global  curve  fitting  (red  lines  Figure  3.4A)  of  dissociation  




  to  (s)  
Fixed  
Req  ±  SE  
(RU)  
Rmin  ±  SE  
(RU)  








13.9  ±  0.7   2.3  ±  0.1  
9.0  ±  0.4  
x  10  -­2   1.75   0.66  
50   14.2  ±  0.7   2.2  ±  0.1  
25   8.8  ±  0.6   1.7  ±  0.1  
12.5   6.1  ±  0.6   1.8  ±  0.1  
6.25   4.3  ±  0.6   1.7  ±  0.1  
  
  
Table   3.7   Association   phase   analysis   of   VEGF165   binding   to   NRP-­1   Fc  
chimera.  
Parameters  from  global  fitting  of  association  phase  data  to  equation  2  (red  lines  




  ka  ±  SE  
(M-­1s-­1)  
Rmax  ±  SE  
(RU)  






KD  ±  SE    
(nM)  
1.00  x  10-­7  
3.6  ±  0.2  
x  106   21.8  ±  0.4   9.0  x  10  
-­2   2.27   0.92   25  ±  2  
5.00  x  10-­8  
2.50  x  10-­8  
1.25  x  10-­8  
6.25  x  10-­9  
  
  
Table  3.8  Dissociation  phase  analysis  of  VEGF165  from  NRP-­1  monomer.    
Parameters  obtained  from  global  curve  fitting  (red  lines  Figure  3.4C)  of  dissociation  




  to  (s)  
Fixed  
Req  ±  SE  
(RU)  
Rmin  ±  SE  
(RU)  








22.3  ±  0.6   4.1  ±  0.1  
6.5  ±  0.2  
x  10-­2   1.89   0.80  
50   18.8  ±  0.5   2.0  ±  0.1  
25   13.1  ±  0.5   2.9  ±  0.1  
12.5   8.4  ±  0.5   2.6  ±  0.1  
6.25   6.2  ±  0.5   2.5  ±  0.1  
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Table  3.9  Association  phase  analysis  of  VEGF165  binding  to  NRP-­1  monomer.  
Parameters  from  global  fitting  of  association  phase  data  to  equation  2  (red  lines  




  ka  ±  SE  
(M-­1s-­1)  
Rmax  ±  SE  
(RU)  




KD  ±  SE    
(nM)  
1.00  x  10-­7  
2.64  ±  0.08    
x  106   31.4  ±  0.4   6.5  x  10
-­2   2.38   25  ±  1  
5.00  x  10-­8  
2.50  x  10-­8  
1.25  x  10-­8  
6.25  x  10-­9  
  
Table  3.10  VEGF165  binding  affinities  to  immobilized  VEGFRs  and  NRP-­1.  
Equilibrium  curve  fit  results  (red  lines  in  Figures  3.3B  3.3D,  3.4B  and  3.4D)  for  the  
indicated  receptors  binding  to  VEGF165  (Equation  4).  
  
   KD  ±  SE  (nM)  
Rmax  ±  SE  
(RU)  
Red.  
Χ2   Adj.  R
2  
VEGFR-­1  Fc  Chimera   3.7  ±  0.3   120  ±  2   4.2   0.98  
VEGFR-­2  Fc  Chimera   18  ±  2   41  ±  1   281   0.99  
NRP-­1  Fc  Chimera   22  ±  7   18  ±  2   3.21   0.93  
NRP-­1  monomer   28  ±  4   28  ±  2   2.09   0.99  
  
Table  3.11  Theoretical  Rmax  binding  response  of  VEGF165.  
Theoretical  maximal  responses  were  calculated  using  equation  1  and  compared  
to  maximal  binding  response  observed  on  chips.  
  





Rmax  from    
Equilibrium  Fit  (RU)  
Percent    
Active  
VEGFR-­1  Fc   200   728.9   140   109   86  
VEGFR-­2  Fc   220   407.1   71.1   35   58  
NRP-­1  Fc   238   295.0   47.6   22   38  




VEGF121  binding  kinetics  to  VEGFRs  
VEGF121  analysis   revealed   fewer  differences  between  binding  kinetics   to  
VEGFR-­1  and  VEGFR-­2  Fc   chimeras,   compared   to  VEGF165.  VEGFR-­1  bound  
VEGF121  with  a  dissociation  rate  constant  of  8.8  ±  0.2  ×  10-­3  s-­1,  15-­times  faster  
than  VEGF165   and  with   a   similar   association   rate   of   1.43   ±   0.03   ×   106  M-­1   s-­1,  
resulting   in   a  KD   of   6.2   ±   0.2   nM   (Table   3.12   and   3.13).   Equilibrium   analysis  
resulted  in  an  affinity  of  7.2  ±  0.6  nM  (Table  3.17)  consistent  with  the  calculated  
affinity  from  kinetic  parameters.  VEGF121  binding  to  VEGFR-­2  showed  a  kd  of  3.0  
±  0.2  ×10-­3  s-­1  and  a  ka  of  5.47  ±  0.01  ×  106  M-­1  s-­1  with  a  KD  of  5.5  ±  0.3  nM  (Tables  
3.14  and  3.15).  The  equilibrium  analysis  yielded  a  slightly  lower  affinity  (KD  =  17  ±  
6  nM  Table  3.16).    
The  ability  of  NRP-­1  to  bind  VEGF121  has  been  debated.  Given  that  NRP-­1  
binds  the  HBD  of  VEGF  located  on  exon  7,  it  has  been  assumed  to  be  unable  to  
interact   with   shorter   VEGF   isoforms.   However,   some   groups   have   reported  
VEGF121   interaction  with  NRP-­1   118,   119.  We   observed   no   detectable   binding   of  
VEGF121  to  NRP-­1  Fc  chimera  (Figure  3.6)  or  monomer  (not  shown).  
  




Figure  3.5  Kinetic  analysis  of  VEGF121  binding  to  VEGFR-­1  and  VEGFR-­2  Fc  
chimera  on  a  SPR  chip.    
Increasing  concentrations  (6.25,  12.5,  25,  50  and  100  nM)  of  recombinant  human  
VEGF121  in  running  buffer  were  flowed  over  the  surfaces  containing  VEGFR-­1  and  
VEGFR-­2   Fc   chimeras   (1610   and   1450   RU   immobilized   respectively)   and  
response  was  measured  for  180  s  at  30  μL/min.  Dissociation  was  measured  after  
switching   the   flow   to   running   buffer.   Association   and   dissociation   phases  were  
analyzed  by  non-­linear  curve  fitting  (red  lines).  Results  of  the  curve  fit  are  shown  
in  Table  3.12  –  3.16.  
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Table  3.12  Dissociation  phase  analysis  of  VEGF121  from  VEGFR-­1.    
Parameters  obtained  from  global  curve  fitting  (red  lines  Figure  3.5A)  of  dissociation  




  to  (s)  
Fixed  
Req  ±  SE  
(RU)  








30.1  ±  0.4  
8.8  ±  0.2  
x  10  -­3   6.12   0.86  
50   26.2  ±  0.4  
25   22.8  ±  0.4  
12.5   19.0  ±  0.4  
6.25   15.6  ±  0.4  
  
  
Table  3.13  Association  phase  analysis  of  VEGF121  binding  to  VEGFR-­1.    
Parameters  from  global  fitting  of  association  phase  data  to  equation  2  (red  lines  





  ka  ±  SE  
(M-­1s-­1)  
Rmax  ±  SE  
(RU)  






KD  ±  SE    
(nM)  




42.6  ±  0.2   8.8    x  10  -­3   11.1   0.90  
6.2  ±  
0.2  
5.00  x  10-­8  
2.50  x  10-­8  
1.25  x  10-­8  
6.25  x  10-­9  
  
  
Table  3.14  Dissociation  phase  analysis  of  VEGF121  from  VEGFR-­2.    
Parameters  obtained  from  global  curve  fitting  (red  lines  Figure  3.5C)  of  dissociation  




  to  (s)  
Fixed  
Req  ±  SE  
(RU)  








19.6  ±  0.5  
3.0  ±  0.2  
x  10  -­3   5.63   0.89  
50   14.6  ±  0.4  
25   11.0  ±  0.4  
12.5   7.5  ±  0.4  




Table  3.15  Association  phase  analysis  of  VEGF121  binding  to  VEGFR-­2.    
Parameters  from  global  fitting  of  association  phase  data  to  equation  2  (red  lines  




ka  ±  SE  
  (M-­1s-­1)  
Rmax  ±  SE  
(RU)  






KD  ±  SE  
(nM)  
1.00  x  10-­7  





x  10  -­3   16.3   0.86   5.5  ±  0.3  
5.00  x  10-­8  
2.50  x  10-­8  
1.25  x  10-­8  
6.25  x  10-­9  
  
  
Table  3.16  VEGF121  binding  affinities  to  immobilized  VEGFRs.    
Equilibrium   curve   fit   results   (red   lines   in   Figures   3.5B   3.5D)   for   the   indicated  
receptors  binding  to  VEGF121  (Equation  4).  
  
     KD  ±  SE  
(nM)  
  Rmax  ±  SE  
(RU)  
Red.  
Χ2   Adj.  R
2  
VEGFR-­1  Fc  Chimera   7.2  ±  0.6   39.5  ±  0.8   3.38   0.99  
VEGFR-­2  Fc  Chimera   17  ±  6   42  ±  5   37.8   0.89  
  
  
Table  3.17  Theoretical  Rmax  binding  response  of  VEGF121.  
Theoretical  maximal  responses  were  calculated  using  equation  1  and  compared  
to  maximal  binding  response  observed  on  chips.  
  





Rmax  from    
Association  Fit  (RU)  
Percent    
Active  
VEGFR-­1  Fc   200   1610   225   43   19  
VEGFR-­2  Fc   220   1450   185   39   21  
  





Figure  3.6  VEGF121  binding  to  NRP-­1  Fc  chimera  immobilized  on  SPR  chip.  
NRP-­1  Fc  chimera  was  covalently  attached  to  an  activated  SPR  sensor  chip  by  
amine   coupling   until   1460   RU   of   immobilization   were   reached.   Increasing  
concentrations  (6.25,  12.5,  25,  50  and  100  nM)  of  recombinant  human  VEGF121  in  
running  buffer  were  flowed  over  the  surface  and  response  was  measured  for  180  
s   at   30   μL/min.  We   observed   no   significant   binding   to   NRP-­1   Fc   under   these  
conditions.    





Figure  3.7  Iso-­affinity  plot.  
(A)  Kinetic  and  equilibrium  rate  constants  derived  from  binding  data.  (B)  Rate  map  
summarizing   binding   affinity   and   kinetics.   Dashed   lines   indicate   different  
combinations  of  ka  and  kd  that  result  in  the  same  KD.  Data  point  colors  in  the  graph  
correspond  to  the  interaction  indicated  in  the  Table  above.    
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VEGF165  affinities   for  VEGFR-­1  reported   in   the   literature  are   inconsistent  
and  range  between  1  and  30  pM  24,  39,  40,  120,  121,  and  between  50  pM  and  1  nM  23,  
27,  40,  43,  120,  121  for  VEGFR-­2.  Additionally,  nearly  all  published  studies  fail  to  report  
binding   kinetics.   Here,   we   provide   additional   data   on   the   interactions   between  
VEGF  and  the  different  receptors  and  co-­receptors  all  measured  under  one  set  of  
consistent   conditions.   The   kinetic   parameters   and   calculated   affinities   from   all  
analyses  are  summarized  on  Figure  3.7.    
We  found  that  the  affinity  of  VEGFR-­1  for  VEGF165  was  lower  than  reported  
values.   The   discrepancies   we   observed   could   be   explained   by   the   different  
experimental  settings.  For  example,  most  measurements  reported  in  the  literature  
were  performed  on   intact  cell  surfaces  where  components  of   the  ECM  and  cell  
surface  HSPGs  known  to  bind  and  alter  VEGF  binding,  are  present.  It  is  surprising  
that  the  affinities  observed  in  this  study  using  pre-­dimerized  forms  of  the  receptor  
are   lower  than  those  measured  on   intact  cells,  since,   in   the  plasma  membrane,  
receptor   dimerization   has   been   shown   to   be   the   rate   limiting   step   122.  
Understanding  how  the  kinetics  of  ligand-­receptor  binding  and  activation  translate  
to  biological  output  is  an  area  of  great  interest.  The  data  presented  here  begin  to  
compile  relevant   information  about  the  nature  of  VEGF-­receptor  complexes  and  
how  the  different  isoforms  and  receptors  expressed  display  variations  in  complex  
lifetime,  ultimately  relating  to  their  biological  function.    
The  differences   in   affinities   for  VEGF165   observed  with  VEGFR-­1   versus  
VEGFR-­2   are   largely   due   to   the   difference   in   dissociation   rate   constants.   This  
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finding  has  profound  significance  when  considering  the   intact  biological  system.  
The  observation  that  VEGFR-­1  displays  low  intrinsic  kinase  activity  in  endothelial  
cells,  and  that  deletion  of  Vegfr-­1  in  mouse  embryos  results  in  embryonic  lethality  
due   to   endothelial   cell   overgrowth,   led   to   the   proposal   of   a   negative   role   for  
VEGFR-­1   in   regulating  VEGF   activity   123.   The   hypothesis   that,   in  most   cellular  
contexts,  VEGFR-­1  functions  as  a  decoy  receptor  is  supported  by  the  observation  
of  a  slower  VEGF165  dissociation  rate  compared  to  VEGFR-­2.  It   is  possible  that  
under   certain   stimuli   (i.e.   changes   in   ECM   composition   and   co-­receptor  
availability),  the  interaction  of  VEGF165  with  VEGFR-­2  may  be  stabilized  (slower  
off  rate)  such  that  it  becomes  the  predominant  complex  in  comparison  to  VEGF165-­
VEGFR-­1.   This   would   require   that   co-­receptors   function   to   decrease   the  
dissociation  rate  of  the  ligand  from  the  complex.  Thus,  modulation  of  co-­receptor  
levels  or  pericellular  location  could  act  as  a  switch  to  shift  cells  from  a  VEGF  non  
responsive  to  responsive  state.    
An  additional  “optimal  dwell”  model  could  be  relevant  in  the  VEGF  system.  
Ligand-­induced   receptor  activation  might   require  an  optimal   interaction   time   for  
activation,  and  those  ligands  that  dissociate  too  fast  or  remain  bound  too  long  may  
result  in  reduced  activity.  This  has  been  demonstrated  in  other  receptor  systems  
124,  and  could  serve  as  possible  mechanism  for  VEGFR-­1  to  “trap”  VEGF165  and  
decrease  VEGFR-­2  mediated  angiogenesis  signaling.  On  the  other  hand,  VEGF121  
binds   indiscriminately  to  both  receptors,  and  does  not  bind  NRP-­1  directly.  This  
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observation  correlates  to  the  observed  decreased  biological  activity  compared  to  
VEGF165,  since  VEGF121  activity  is  not  influenced  by  the  presence  of  co-­receptors.    
NRP-­1   is   expressed   in   some   cancer   cell   lines,   including   PC3,   prostate  
cancer  cell  line,  and  MD-­MB-­231,  a  breast  cancer  line  125.  PC3  cells  bind  VEGF165  
with  an  apparent  KD  of   0.28  nM   59.   The   reported  affinity  was  measured  on   cell  
surfaces,  disregarding  the  influence  of  HSPGs.  We  determined  a  KD  of  25  nM  for  
the  interaction  between  NRP-­1  and  VEGF165.  Understanding  how  NRP-­1  regulates  
VEGF   in  disease  systems  will  be   important  when  determining  best   therapies   to  
treat  aberrant  or  deficient  angiogenesis.  Here  we  have  determined  the  kinetics  of  
VEGF  binding  to  NRP-­1,  in  both  dimeric  and  monomeric  forms  in  the  absence  of  
HSPGs.  This  will  allow  for  the  quantification  of  the  contribution  that  different  co-­
receptors   have   on   VEGF   binding   to   VEGFRs   and   better   understand   how   they  




CHAPTER  FOUR:  MECHANISMS  OF  CO-­RECEPTOR  CONTROL  
This  section  has  been  adapted  from  the  work  published  in:  Teran,  M.  and  Nugent,  
M.  A.  (2015).  "Synergistic  Binding  of  Vascular  Endothelial  Growth  Factor-­A  and  its  
Receptors   to   Heparin   Selectively   Modulates   Complex   Affinity."   Journal   of  
Biological  Chemistry.  
INTRODUCTION  
Angiogenesis   is   a   fundamental   process   by   which   new   blood   vessels   are  
formed  from  pre-­existing  ones  4,  5.  Formation  and  growth  of  new  vessels  is  tightly  
regulated,   and   loss   of   control   over   this   process   contributes   to   a   number   of  
pathologic   conditions   6-­9.   In   some   instances   the   angiogenic   signal   is   deficient,  
leading   to   endothelial   cell   dysfunction,   vessel   malformation   or   regression,   and  
insufficient  revascularization,  healing  and  regeneration  3.  In  other  cases,  excessive  
angiogenesis  facilitates  tumor  growth  and  metastasis  and  leads  to  loss  of  sight  in  
diabetic   retinopathy   and  wet   age-­related  macular   degeneration   8.   Inducing   and  
inhibiting  angiogenesis  is  of  great  clinical  interest  as  a  means  to  stimulate  tissue  
repair  (e.g.  after  myocardial  infarction,  stroke,  diabetic  ulcers,  etc.)  and  to  inhibit  
tumor  growth  and  vision  loss  126.  However,  the  lack  of  a  detailed  understanding  of  
all   the   factors   that  control   the  balance  of   the  angiogenic  signal  has  significantly  
limited   the   potential   for   designing   efficient   therapies   for   directing   angiogenesis.  
Defining   the   various   molecular   interactions   between   the   major   angiogenic  
regulatory   factors  will  provide   insight   toward   the  development  of  approaches   to  
control  and  direct  angiogenesis.    
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VEGF-­A  is  the  major  regulator  of  angiogenesis  in  normal  and  disease  states  
and  is  critical  for  the  maintenance  of  vessel  homeostasis  in  adult  organisms  127.  
Alternative  splicing  of  the  VEGF-­A  gene  generates  several  isoforms  varying  in  their  
ability  to  bind  VEGF  receptors,  heparan  sulfate  proteoglycans  (HSPGs)  and  NRP-­
1   128-­130.   VEGF165,   the   predominant   isoform   in   humans,   exerts   its   angiogenic  
effects   by   binding   and   activating   two   cell-­surface   receptor   tyrosine   kinases,  
VEGFR-­1  and  VEGFR-­2,  expressed  in  vascular  endothelial  cells  131.  HSPGs  and  
NRP-­1  are  required  for  efficient  VEGF  signaling  59,  80;;  nevertheless,   the  specific  
mechanistic  roles  that  these  co-­receptors  play  remain  unclear.    
HS  is  a  linear  sulfated  glycosaminoglycan  consisting  of  repeating  disaccharide  
units  containing  N-­acetyl  glucosamine  and  glucuronic  acid  that  can  be  extensively  
modified.  Variations   in   length  and  structure,   including  sulfation  of  O-­groups,  de-­
acetylation  and  sulfation  of  N-­groups  of  glucosamine  residues,  and  epimerization  
of  glucuronic  acid  to  iduronic  acid,  make  HS  a  highly  information-­dense  molecule  
132,   133.   This   variability   in   structure   allows   for   the   presence   of   multiple   protein  
binding   sites   within   HS   71.   Heparin,   commonly   used   as   a   substitute   for   HS   in  
experimental  model  systems,  is  a  more  abundantly  sulfated,  mast  cell-­derived  form  
of  HS  134.  HSPGs,  which  consist  of  one  or  more  HS  chains  covalently  attached  to  
a  core  protein,  are  ubiquitously  present  in  the  cell  surface  and  ECM  of  almost  all  
mammalian   cells   and   have   been   implicated   in   controlling   the   distribution   and  
availability  of  ligands;;  more  interestingly,  HS  is  also  involved  in  the  regulation  of  
several   other   aspects   of   receptor-­ligand   interaction,   including   complex   stability,  
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internalization  and  degradation  135.  The  most  well  defined  example  of  growth  factor  
regulation  by  HSPGs   is   the  FGF-­2/HS/FGFR-­1  system,  where  HSPGs   facilitate  
ligand-­receptor  binding  and  activation  136,  137.    
Neuropilins  were  first   identified  as  transmembrane  glycoproteins   involved  in  
axonal   guidance   138,   139.   Subsequently,   NRP-­1   was   established   as   a   VEGF165  
binding  protein  140,  and  was  proposed  as  a  co-­receptor  for  the  VEGFR-­2-­VEGF165  
signaling   axis.   NRP1-­/-­  mice   die   in   utero   and   display   gross   cardiovascular   and  
neuronal   abnormalities,   demonstrating   that   NRP-­1   is   required   for   vascular  
development.  Mice  expressing  a  VEGF  isoform  unable  to  bind  NRP-­1  die  before  
postnatal  day  14  due  to  bleeding  in  multiple  organs  or  cardiac  failure  141-­144,  further  
reinforcing  the  notion  that  NRP-­1-­VEGF165  interactions  are  essential  for  vascular  
development.   Additionally,   recent   reports   suggest   that   expression   of   these   co-­
receptors  on  adjacent  cells  (trans)  as  opposed  to  cis  (same  cell)  with  respect  to  
VEGFR-­2  on  endothelial  cells  leads  to  significant  changes  in  signal  transduction  
upon  VEGF165  binding  145,  146.    
HS/heparin  has  been  proposed  to  regulate  VEGF  biological  activity  not  only  
by  binding  VEGF165  directly  147,  but  also  by  interacting  with  receptors  and  NRP-­1  
148-­151.   However,   the   data   demonstrating   direct   interaction   between   VEGF  
receptors  and  HS/heparin  have  yet  to  be  produced  or  remain  incomplete.  In  this  
study,   we   identified   new   potential   mechanisms   for   the   regulation   of   the  
VEGF/VEGFR  system  by  HS  and  NRP-­1.  We  used  a  combination  of  SPR  and  
other  in  vitro  binding  assays  to  study  molecular  interactions  between  the  various  
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components  of  the  VEGF  system.  Our  findings  indicate  that  VEGFR-­1  and  NRP-­1  
bind  heparin  directly,  while  VEGFR-­2  does  not.  Additionally,  we  demonstrated  that  
heparin  has  no  significant  effect  on  VEGF165  binding  to  VEGFR-­1,  despite  its  direct  
interaction  with  receptor  and  VEGF165  152.  Alternatively,  heparin  enhances  VEGF165  
binding  to  the  VEGFR-­2  and  appears  to  be  required  for  VEGF165  binding  to  NRP-­
1.  Analysis  of  the  size  and  structural  requirements  for  HS  interactions  with  VEGFR-­
1  and  NRP-­1,  as  well  as  the  requirements  for  the  enhanced  VEGF165  binding  to  
NRP-­1   and   VEGFR-­2   suggest   that   the   presence   and   structure   of   HS   may  
ultimately  define  the  specific   type  of  VEGF-­VEGFR  complexes  that   form  on  the  
cell  surface,  ultimately  controlling  VEGF  activity.  Understanding  how  specific  co-­
receptors  are  involved  in  enhancing  and  attenuating  VEGF165  signaling  will  provide  
useful   insight   for   the   development   of   new   therapies   that   aim   to   manipulate  
angiogenesis  to  facilitate  tissue  repair  and  prevent  disease.    
RESULTS  and  DISCUSSION  
VEGFR-­1  and  NRP-­1,  but  not  VEGFR-­2,  interact  directly  with  heparin  
Previous   studies   indicate   that   VEGF   receptors   directly   interact   with  
HS/heparin  molecules  to  modulate  VEGF  function  149-­151,  153;;  however,  information  
about   the   direct   binding   events   and   mechanisms   of   regulation   remain   to   be  
determined.  The  binding  kinetics  between  heparin  and  VEGF  receptors  as  well  as  
the   co-­receptor   NRP-­1   were   evaluated   using   SPR   with   heparin-­immobilized  
sensor  chips.  SPR  response  curves  at  increasing  concentrations  (black  and  grey  
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lines)  of  VEGFR-­1,  VEGFR-­2  and  NRP-­1  Fc  chimeras  are  shown  in  Figure  4.1A,  
B  and  C,  respectively.  Curve  fittings  to  a  1:1  Langmuir  binding  model  are  shown  
as   red   lines   and   resulting   kinetic   parameters   are   summarized   in   Table   4.1.  
VEGFR-­1  showed  a  5-­fold  higher  affinity  (KD  obtained  from  the  ratio  of   the  rate  
constants   kd/ka)   for   heparin   than   did   NRP-­1   (KD   values   of   11   and   50   nM,   for  
VEGFR-­1  and  NRP-­1  respectively).   Interestingly,  we  observed  no  binding  when  
VEGFR-­2   was   injected   over   immobilized   heparin.   These   results   suggest   that  
heparin-­like   molecules   might   act   by   selectively   interacting   with   cell   surface  
receptors  in  the  absence  of  ligand.    
Dissociation  of  VEGFR-­1  and  NRP-­1  Fc  chimeras  from  the  heparin   layer  
was  found  to  be  too  slow  to  be  reliably  measured  using  conventional  SPR  kinetic  
experimental  methods.  Hence,  we  decided  to  measure  binding  of  VEGFR-­1  and  
NRP-­1  to  heparin  in  solution  using  a  competition  approach  154.  VEGFR-­1  (Figure  
4.2A)  and  NRP-­1  (Figure  4.2B)  were  pre-­mixed  with  increasing  concentrations  of  
heparin  as  a  competitor  before  flowing  the  mixture  over  immobilized  heparin  at  a  
slow   flow   rate   to   favor   mass   transport.   Receptors   in   complex   with   heparin   in  
solution  are  unable  to  associate  with  the  heparin  immobilized  on  the  chip  surface  
resulting   in   a   decrease   in   SPR   response.   Free   protein   concentration   at   each  
competitor  concentration  was  calculated  using  the  maximal  SPR  response  (Rmax)  
in   equation   5   (Materials   and   Methods)   and   plotted   against   competitor  
concentration  (Figure  4.2A  and  B).  The  calculated  free  protein  data  points  were  fit  
to  Equation  6  (red  line)  to  determine  apparent  affinity  (KD)  values  for  VEGFR-­1  and  
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NRP-­1  binding  to  heparin  (Figure  4.2A  and  B,  and  Tables  4.2  and  4.3).  The  use  of  
this  approach  has  been  found  to  yield  a  more  reliable  and  straightforward  analysis  
of  complex  interactions  154.    
Additionally,  we  analyzed  the  kinetics  of  the  interaction  between  VEGF165  
and  heparin  on  the  SPR  chip  surface.  Figure  4.3  shows  the  binding  sensograms  
obtained  by  flowing  increasing  concentrations  of  VEGF165  over  the  biotin-­heparin  
surface.  We  found  the  interaction  to  have  an  affinity  of  60  ±  2  nM  calculated  from  
kinetic   parameters   (Table   4.1).   The   data   presented   here   can   be   used   for   the  
development  of  predictive  models.    
HSPGs   have   been   proposed   to   regulate   VEGF165   signaling   through  
VEGFR-­2  80,  153,  155  but  a  mechanism  for   this  observation  has  not  been  defined.  
Contrary   to   previous   reports   suggesting   that   VEGFR-­2   interacts   directly   with  
HSPGs   149,   153,   we   did   not   observe   VEGFR-­2   binding   to   immobilized   heparin  
(Figure   4.1C).   To   ensure   that   this   observation   was   not   an   artifact   of   our   SPR  
system,  we   immobilized   heparin   onto   streptavidin-­coated   plates   and  measured  
binding  of  all  three  receptor  Fc  chimeras  by  an  ELISA.  We  found  that  under  these  
conditions,  VEGFR-­1  and  NRP-­1  showed  significant  binding,  while  VEGFR-­2  did  
not   (Figure  4.1D).  Together   these   results  suggest   that  HS/heparin  can   regulate  




Figure  4.1  VEGFR-­1  and  neuropilin-­1  interact  directly  with  heparin.  
SPR  sensograms  of  (A)  VEGFR-­1  Fc  chimera  (0.31  nM  –  5  nM;;  lower  to  upper  
curves),  (B)  NRP-­1  or  (C)  VEGFR-­2  Fc  chimeras  (3.1  nM  –  25  nM;;  lower  to  upper  
curves)  binding  to  biotin-­heparin  immobilized  on  an  NLC  sensor  chip.  Dissociation  
was  measured  after  flow  was  replaced  by  buffer  (only  360  s  of  1200  s  are  shown).  
Binding   data   is   shown   as   black   and   grey   lines  while   global   curve   fits   to   a   1:1  
Langmuir  interaction  model  are  shown  in  red.  The  kinetic  parameters  obtained  for  
each  interaction  are  listed  in  Table  4.1.  Sensograms  shown  are  representative  of  
5  individual  surfaces  on  the  chip  and  each  experiment  was  performed  three  times.  
(D)  Binding  of  receptor  Fc  chimeras  to  biotin-­heparin  coated  on  streptavidin  plates  
was  measured  using  an  ELISA  detecting  the  Fc  fragment  of  the  chimeras.  p  values  
were  determined  by  a   two-­tailed  Student’s   t   test.   *   indicates  a  p  of  0.02  vs.  no  





Figure   4.2   Competition   analyses   of   VEGFR-­1   Fc   chimera   and   NRP-­1   Fc  
chimera  binding  to  heparin  in  solution.  
VEGFR-­1  (1  nM)  or  NRP-­1  (5  nM)  were  mixed  with  increasing  concentrations  of  
heparin   (competitor)   and   allowed   to   incubate   for   30  min   at   RT.  Mixtures   were  
flowed   over   a   heparin-­coated   SPR   chip   and   maximal   binding   responses   were  
recorded.   Free   protein   concentration   (free   [Fc   chimera]   nM)   at   each   inhibitor  
concentration  (squares)  was  calculated  using  equation  6,  plotted  against  inhibitor  
concentration   and   fit   to   equation   5   (red   line).   Apparent   affinity   (KD)   values   for  
VEGFR-­1  and  NRP-­1  binding  to  heparin  obtained  using  the  competition  analysis  
are  shown  in  Tables  4.2  and  4.3,  respectively.  




Figure  4.3  VEGF165  binding  to  heparin.  
SPR   sensogram   (black   lines)   responses   with   increasing   concentrations   of  
VEGF165   (6.25   nM   –   100   nM;;   lower   to   upper   curves)   binding   to   biotin-­heparin  
immobilized  on  an  NLC  sensor  chip.  Dissociation  was  measured  after   flow  was  
replaced  by  buffer  (only  140  s  of  1200  s  are  shown).  Red  lines  are  global  curve  fits  
to  a  1:1  Langmuir  interaction  model.  The  kinetic  parameters  obtained  by  fitting  are  
shown   on   Table   4.1.   The   insert   shows   additional   equilibrium   analysis   (fit   to  
equation  4)  of  the  steady-­state  responses.  The  fit  resulted  in  an  affinity  of  60  ±  20  
nM,  consistent  with  the  calculated  affinity  from  kinetic  parameters  (Reduced  Χ2  =  
21  and  Adj  R2  =  0.97).  
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Table  4.1  Binding  kinetics  of  VEGFR-­1  and  NRP-­1  Fc  chimera  interaction  with  
heparin  by  SPR.  
Values   obtained   from   non-­linear   regression   of   SPR   data   from   Fig.   1A   and   B  
(simulated  data   in  red).  ka  is   the  association  rate  constant,  kd  is   the  dissociation  
rate  and  KD  is  the  affinity  constant  calculated  from  rate  constants  (kd/ka).  Standard  
errors   (SE)   were   calculated   from   5   independent   association   and   dissociation  
datasets  and  combined  for  the  calculation  of  the  KD.  
  
   ka  ±  SE  (M-­1s-­1)   kd  ±  SE  (s-­1)   KD  ±  SE  (nM)  
VEGFR-­1   3.8  ±  0.9    ×  105  
4  ±  2    
×  10-­3   11  ±  6  
NRP-­1   1.88  ±  0.3    ×  105  
10  ±  2  
×  10-­3   50  ±  10  
VEGF165  
2.74  ±  0.08  
×  106  
1.63  ±  0.04  
×  10-­1   60  ±  2  
  
Structural  and  size  requirements  for  HS  binding  to  VEGFR-­1  and  NRP-­1  
Since   VEGFR-­1   and   NRP-­1   directly   interact   with   heparin,   we   explored   the  
possibility   that   there  are  distinctions   in   the   size  and   structural   requirements   for  
heparin  to  bind  to  each  receptor.  To  delineate  the  minimum  heparin  chain  length  
required   for  binding   to  VEGFR-­1  and  NRP-­1,  we  screened  a  series  of  heparin-­
derived  oligosaccharides  using  the  competition  method.  VEGFR-­1  and  NRP-­1  Fc  
chimeras  were   pre-­incubated  with   the   indicated   oligosaccharides   for   30  min   to  
allow  them  to  bind   in  solution,  and   then  mixtures  were   flowed  over   immobilized  
heparin.  In  Figure  4.4,  binding  of  receptor  to  various  oligosaccharides  in  solution  
is  shown  as  a  percentage  of  the  maximal  SPR  response  observed  in  the  absence  
of   oligosaccharide.   Heparin   derived   oligosaccharides   ranging   from   4  
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(tetrasaccharide)   to  approximately  14  saccharide  units   (oligosaccharide   II)  were  
tested   for   binding   VEGFR-­1   and   NRP-­1.   Competition   of   VEGFR-­1   binding   to  
heparin  was  observed  exclusively  in  the  presence  of  oligosaccharides  with  10  or  
more  saccharide  units.  In  the  case  of  NRP-­1,  only  moderate  binding  was  observed  
with  an  oligosaccharide  of  14  saccharide  units,  indicating  that  NRP-­1  has  a  more  
stringent  requirement  for  longer  heparin  chains  compared  to  VEGFR-­1.    
Table   4.2   Binding   affinities   of   VEGFR-­1   Fc   chimera   for   heparin,   HS,  
oligosaccharides  and  N-­desulfated  heparin.      
Apparent  affinity  constants  (KD)  for  VEGFR-­1  Fc  chimera  binding  to  heparin,  HS  
and   a   series   of   oligosaccharides   determined   by   non-­linear   regression   of  
competition  data  fit  to  equation  5  (Figure  4.2  and  4.5  red  line).  SE,  reduced  chi-­
squared  and  adjusted  R2  were  used  to  test  for  goodness  of  fit.  Oligo  I  and  II  are  
heparin   oligosaccharide   I   (11-­12   saccharides-­long,   3500   Da)   and   II   (~14  
saccharide  units  4200  Da).  N-­DS,  N-­desulfated  heparin.    
  
     KD  ±  SE  (nM)   Reduced  Χ2   Adj  R2  
Heparin   1.40  ±  0.09   6.2  ×  10-­4   0.995  
Heparan  sulfate   24  ±  2   6.93   0.986  
Oligo  I   390  ±  80   2.5  ×  10-­2   0.791  
Oligo  II   110  ±  20   1.4  ×  10-­2   0.875  





Figure   4.4   Size   and   structural   requirements   for   VEGFR-­1   and   NRP-­1  
interaction  with  HS  chains.  
Heparin  oligosaccharides  of  various  lengths  were  screened  for  the  ability  to  bind  
VEGFR-­1   (A)   and   NRP-­1   (B)   Fc   chimeras   using   the   competition   approach.  
Oligosaccharides  or  modified  heparins  at  a  single  concentration   (500  nM)  were  
incubated  with  the  indicated  proteins  in  solution  for  30  min  at  RT  before  measuring  
binding  of  the  protein  to  immobilized  heparin  on  an  SPR  chip.  Using  the  maximal  
binding  response  in  the  absence  of  competitor,  free  protein  concentrations  in  the  
presence  of  the  indicated  oligosaccharide  were  calculated  and  presented  as  the  
percentages  of  total  protein  bound  in  solution.  High  percentage  represents  a  high  
level  of  binding  between   the  soluble  oligosaccharide  and  protein   (i.e.,   the  SPR  
signal   representing   protein   binding   to   the   heparin-­chip   was   reduced).   Bars  
represent   mean   ratios   ±   SD   of   5   separate   surfaces   on   the   SPR   chip   and  
experiments  were   repeated   two   times   independently.  Oligo   I  and   II  are  heparin  
oligosaccharide  I  (11-­12  saccharides-­long  3500  Da)  and  II  (~14  saccharide  units  
4200  Da).  A  series  of  chemically  modified  heparins  were  also  analyzed  for  binding  
to  VEGFR-­1  (C)  or  NRP-­1  (D)  using  the  competition  method  described  above.    




Figure  4.5  Competition  analyses  of  VEGFR-­1  and  NRP-­1  binding  to  heparan  
sulfate  and  heparin  oligosaccharide  II.    
The  indicated  receptor  Fc  chimera  was  incubated  with  increasing  concentrations  
of   HS   (A   and   B)   or   heparin   oligosaccharide   II   (C   and   D)   for   30   min   before  
measuring  binding  to  heparin   immobilized  on  an  SPR  sensor  chip.  Free  protein  
concentration   at   each   inhibitor   concentration   was   calculated,   plotted   against  
inhibitor  concentration  (mean  of  5  independent  surfaces  ±  SD)  and  fit  to  equation  
5   (red   lines).   Apparent   affinity   (KD)   values   obtained   from   non-­linear   regression  
analysis  are  shown  in  Tables  4.2  and  4.3.    
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We   next   investigated   the   sulfation   requirements   for   heparin   binding   to  
VEGFR-­1  and  NRP-­1.  Fully  de-­O-­sulfated  heparin  is  a  derivative  in  which  all  O-­
sulfate  esters  have  been  chemically  removed  from  heparin  without  changing  the  
backbone   structure.   In   2-­O-­desulfated   and   6-­O-­desulfated   heparin,   only   the  O-­
sulfate  groups  on  C-­2  of  uronic  acid  and  C-­6  of  glucosamine,  respectively,  have  
been  removed.  Most  of  the  other  sulfate  groups  remain  intact.  Heparin  lacking  all  
O-­sulfate  groups  showed  reduced  competition  for  VEGFR-­1  binding  to  heparin  and  
no   competition   for   NRP-­1   binding   (Figure   4.4C   and   D).   Binding   of   heparin   to  
VEGFR-­1  and  NRP-­1  is  more  dependent  on  the  sulfation  of  C-­6  on  glucosamine  
than  on  the  C-­2  position  of  uronic  acid,  since  the  2-­O-­desulfated  heparin  was  still  
able  to  compete  for  binding  almost  as  well  as  heparin.  On  the  other  hand,  a  heparin  
derivative   lacking  N-­sulfate   groups   on   glucosamine   residues   was   able   to   bind  
VEGFR-­1   but   showed   significantly   reduced   ability   to   bind   NRP-­1.   Apparent  
affinities  (KD)  were  calculated  by  fitting  SPR  binding  inhibition  data  (Figure  4.5)  at  
increasing  concentrations  of  competitor  to  equation  5  (red  lines)  for  VEGFR-­1  and  
NRP-­1  binding  to  heparan  sulfate  (Figure  4.5A  and  B)  and  heparin  oligosaccharide  
II   (Fig.   4.5C   and   D),   and   values   are   shown   in   Tables   4.2   and   3.   The   distinct  
structural  requirements  for  heparin  to  bind  to  VEGFR-­1  versus  NRP-­1  suggest  that  
variations  in  HS  fine  structure  could  function  to  selectively  regulate  VEGF  binding  




Table   4.3   Binding   affinities   of   NRP-­1   Fc   chimera   for   heparin,   HS   and  
oligosaccharide  II.  
Apparent  affinity  constants  (KD)  for  NRP-­1  Fc  chimera  binding  to  heparin,  HS  and  
oligosaccharide   II  were  obtained   from  non-­linear   regression  of  competition  data  
(Figures   4.2   and   4.5   red   lines).   Standard   error   (SE),   reduced   chi-­squared   and  
adjusted   R2   were   obtained   from   fit.   Oligo   II   is   heparin   oligosaccharide   II   (~14  
saccharide  units).  
  
   KD  ±  SE  (nM)     Reduced    Χ2   Adj  R
2  
Heparin   2.8  ±  0.8   117   0.999  
Heparan  sulfate   170  ±  14   0.0442   0.985  
Oligo  II   760  ±  40   17.2   0.999  
  
  
VEGF165  bridges  the  interaction  between  VEGFR-­2  and  heparin  
The   presence   of   HSPGs   is   required   for   effective   VEGF165   binding   and  
signaling  to  endothelial  cell  surfaces  80,  148,  153;;  however,  the  specific  mechanisms  
by  which  HS  molecules  assist  in  VEGF165  signaling  remain  unknown.  Interpretation  
of  results  with  intact  cells  has  proven  challenging  due  to  the  number  of  components  
involved  in  the  system  and  the  wide  range  of  potential  interactions.  Consequently,  
we  focused  on  measuring  the  influence  of  heparin  on  the  interactions  of  VEGF165  
with  each  major   cell   surface  binding  partner,  VEGFR-­1,  VEGFR-­2  or  NRP-­1   in  
isolation.  First,  we  investigated  if  VEGF165  could  promote  receptor  interactions  with  
heparin.  Figure  4.6  shows  the  response  elicited  by  flowing  the  indicated  receptor  
Fc  chimera  (blue  line),  VEGF165  (red  line),  or  a  pre-­equilibrated  equimolar  mix  of  
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the  two  (green  line),  over  immobilized  heparin.  We  did  not  detect  a  major  change  
in  VEGFR-­1  binding  to  heparin  in  the  presence  of  VEGF165.  A  similar  result  was  
observed  with  NRP-­1  (Figure  4.6C).  In  contrast,  when  VEGFR-­2  was  allowed  to  
interact   with   VEGF165   in   solution,   the   mixture   showed   significantly   increased  
binding  (Figure  4.6B)  above  the  sum  of   that  observed  with  either  protein  alone.  
This  result  agrees  with  previous  reports  showing  that  VEGF165  promotes  VEGFR-­
2  binding  to  heparin  156,  and  suggests  that  the  VEGF165–VEGFR-­2  complex  may  
contain  a  synergistic  heparin  binding  domain  that  is  not  present  in  either  protein  
alone.  To  determine  the  extent  to  which  the  increase  observed  could  be  attributed  
to  VEGFR-­2,  we  used  a  binding  plate  assay  to  measure  the  amount  of  receptor  
bound  to  heparin  in  the  presence  (green  bars)  or  absence  (blue  bars)  of  VEGF165.  
We   first   allowed   the   VEGF165   to   bind   to   the   heparin-­coated   plate   under   static  
conditions  for  a  prolonged  time  and  then  measured  receptor  binding.  We  found  a  
significant  increase  in  the  binding  of  VEGFR-­2  to  the  heparin-­coated  plate  in  the  
presence   of  VEGF165   (Figure   4.6D).   Interestingly,   this   effect  was   not   seen  with  
VEGF121,  an  isoform  that  is  unable  to  bind  heparin  or  NRP-­1  (Figure  4.7).    




Figure  4.6  VEGF165  facilitates  the  interaction  between  VEGFR-­2  and  heparin.  
VEGFR-­1  (A),  VEGFR-­2  (B)  or  NRP-­1  (C)  Fc  chimeras  were  pre-­incubated  with  
(green  line)  or  without  (blue  line)  VEGF165  at  equimolar  concentration  (25  nM)  for  
30  min  at  RT  and  then  injected  over  a  surface  containing  immobilized  heparin  on  
an  SPR  chip.  Red  line  represents  VEGF165  interaction  with  heparin  in  the  absence  
of   receptors.   (D)  VEGF165   (25  nM)  or  buffer  was  allowed   to   interact  with  biotin-­
heparin  coated  on  a  streptavidin  surface  for  1  h.  Unbound  VEGF165  was  removed  
and  receptor  Fc  chimeras  (10  nM)  were  added  and  allowed  to   incubate  for  3  h.  
Bound  Fc  chimeras  was  measured  by  ELISA.  p  values  were  determined  by  a  two-­
tailed   Student’s   t   test.   Asterisk   indicates   a   p   value   of   0.01   vs.   no   VEGF165.  
Experiment  was  repeated  five  times  independently.    




Figure  4.7  VEGF121  is  unable  to  bridge  the  interaction  between  VEGFR-­2  and  
heparin.  
(A)  VEGFR-­2  Fc  chimera  and  VEGF165  or  VEGF121  were  pre-­incubated  alone  or  
mixed   at   25   nM   for   2   h   at  RT   before   being   injected   over   a   surface   containing  
immobilized  heparin  on  an  SPR  chip.  VEGFR-­2  Fc  chimera  alone  (R-­2  /  light  blue),  
VEGF165  alone  (V165  /  red),  VEGF165  alone  (V165  /  orange),  VEGFR2-­R  Fc  chimera  
with  VEGF165  (V165  +  R-­2  /  green),  and  VEGFR2-­R  Fc  chimera  with  VEGF121  (V121  
+  R-­2  /  dark  blue).  (B)  Maximal  response  (RU)  for  each  condition  is  represented  in  
the  bar  graph  as  mean  ±  SD  of  5  separate  surfaces  on  the  SPR  chip.  Experiment  
was  repeated  two  times  independently.    
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Heparin  selectively  increases  VEGF165  binding  to  VEGFR-­2  and  NRP-­1  
To   gain   insight   into   the   roles   that   HSPGs   play   in   the   VEGF   system,  
specifically   the   role  heparin  plays   in   the   regulation  of  VEGF165   interactions  with  
each  receptor  type,  we  immobilized  receptor  Fc  chimeras  onto  Protein  A-­coated  
plates  and  measured  125I-­VEGF165  binding  in  the  presence  or  absence  of  heparin  
(Figure  4.8).  Heparin  had  no  statistically  significant  effect  on  VEGF165  binding  to  
VEGFR-­1,  but  increased  VEGF165  binding  to  VEGFR-­2.    Interestingly,  binding  of  
VEGF165  to  NRP-­1  appeared  to  require  the  presence  of  heparin  (Figure  4.8C),  as  
there  was  no  significant  binding  of  VEGF165  to  NRP-­1  in  the  absence  of  heparin.  
The  structural  requirements  for  heparin  to  bind  to  NRP-­1  are  distinct  from  
those  for  binding  VEGF165  determined  in  previous  studies  104,  152.  Thus,  we  were  
interested  in  determining  the  size  and  structural   features  required  for  heparin  to  
enhance  VEGF165   binding   to  VEGFR-­2  and  NRP-­1.   It   has  been   shown   that  N-­
desulfated   and   6-­O-­desulfated   heparin   derivatives   are   unable   to   bind   VEGF165  
whereas  the  absence  of  2-­O-­sulfate  groups  does  not  appear  to  affect  binding  152,  
and   the   minimum   size   of   oligosaccharide   chain   able   to   bind   VEGF165   is   an  
octasaccharide   104.   To   determine   the   structural   requirements   for   heparin   to  
enhance  VEGF165  binding   to  VEGFR-­2  and  NRP-­1,  we  measured   125I-­VEGF165  
binding  to  immobilized  Fc  chimera  receptors  on  a  plate  in  the  presence  of  a  series  
of   heparin   oligosaccharides   and   modified   heparins.   Only   heparin   was   able   to  
enhance  125I-­VEGF165  binding   to  VEGFR-­2  (Figure  4.9A  and  B)  suggesting   that  
relatively  long  chains  with  both  N-­  and  O-­sulfation  are  required  for  this  effect.    
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On   the   other   hand,   VEGF165   binding   to   NRP-­1   was   enhanced   by  
oligosaccharides   that  are  a  minimum  of  14  saccharide  units-­long  (Figure  4.8C),  
which  agrees  with   the  size   requirement   for  heparin  binding   to  NRP-­1.  We  also  
found  that  removal  of  N-­  or  O-­sulfate  groups  reduced,  but  did  not  eliminate,  the  
ability  to  enhance  VEGF165  binding  compared  to  unmodified  heparin  (Figure  4.9D).  
Interestingly,  heparin  lacking  only  sulfate  groups  on  the  2-­O  position  was  as  active  
as  heparin  at  enhancing  binding  to  NRP-­1,  while  6-­O-­desulfated  heparin  showed  
an  effect  more  comparable  to  fully  de-­O  sulfated  heparin.  The  data  indicate  that  
sulfate  groups  at  the  2-­O  position  are  dispensable  for  the  heparin  effect  on  VEGF-­
NRP-­1   interaction.   Taken   together,   these   results   suggest   that   changes   in   the  
composition  of  HS  chains  on  cell  surfaces  might  differentially  affect   interactions  
between  VEGF  and  its  receptors,  ultimately  modulating  cellular  responses.  





Figure  4.8  Heparin  selectively   increases  VEGF165  binding   to  VEGFR-­2  and  
NRP-­1.  
VEGFR-­1   (A),  VEGFR-­2   (B)  or  NRP-­1   (C)  Fc   chimeras  were   immobilized  onto  
Protein  A-­coated  plates  and  125I-­VEGF165  binding  was  quantified  in  the  presence  
or  absence  of  heparin  (10  μg/mL).  Panel  D  shows  VEGF  binding  at  20  ng/mL  +/-­  
heparin.  p  values  were  determined  by  a  Student’s   t   test.  Asterisk   indicates  a  p  
value  of  0.01  vs.  no  heparin  added.  Each  data  point  represents  the  average  of  3  ±  
SD.  Experiment  was  repeated  three  times.  




Figure   4.9   Size   and   structural   requirements   for   heparin-­induced  
enhancement  of  VEGF165  binding  to  VEGFR-­2  and  NRP-­1.  
125I-­VEGF165   binding   to   immobilized   VEGFR-­2   or   NRP-­1   Fc   chimeras   was  
measured  in  the  presence  of  heparin  oligosaccharides  (A  and  C)  and  chemically  
modified  heparins  (B  and  D).  Bars  represent   the  mean  ratio  of   femtomoles  125I-­
VEGF165  bound  in  the  presence  of  heparin  oligosaccharides  or  modified  heparins  
to  VEGF  alone  ±  SD.  
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VEGFR-­2,  VEGF165  and  NRP-­1  synergize  to  bind  heparin  as  a  complex  
To   better   understand   how   the   various   components   of   the  VEGF   system  
might  act  together  to  regulate  VEGF165  binding,  we  tested  a  series  of  combinations  
including  a  soluble  monomeric  form  of  NRP-­1  (sNRP-­1),  VEGFR-­2  and  VEGF165  
for   their  ability   to  bind  heparin  using  SPR.  We  observed   intriguing  synergy   that  
suggests   that   these   various   components   interact   to   form   a   stable   high   order  
molecular   complex.   Specifically,   when   VEGF165,   VEGFR-­2   and   sNRP-­1   were  
allowed  to  interact  in  solution  prior  to  being  exposed  to  the  heparin-­linked  sensor  
chip,   the  mixture  showed  a  response  greater   than   the  additive  effects  of  all   the  
single  components  as  well  as  any  of  the  two  component  mixtures  (Figure  4.10).  
Under   these   conditions,   none   of   the   individual   components   showed   significant  
binding   to  heparin.   In  particular,  sNPR-­1,  unlike   the  dimeric   form,  did  not  show  
significant  binding  to  heparin  alone  but  did  show  binding  when  pre-­incubated  with  
VEGF165   or   VEGFR-­2.      We   suspect   that   under   these   conditions   sNRP-­1  
dimerization   is   facilitated  by   the  dimeric  VEGF165  and  VEGFR-­2.  This  would  be  
consistent  with  previous  studies  that  indicate  that  dimerization  of  NRP-­1  is  a  critical  
element  of  the  mechanism  by  which  NRP-­1  modulates  VEGF  157.    
It  is  difficult  to  quantitatively  analyze  the  binding  profiles  from  these  mixing  
reactions  since  the  relative  quantity  of  complexes  formed  in  solution  is  unknown;;  
however,   visual   inspection   of   the   dissociation   profiles   suggests   interesting  
differences   in   the   stability   of   the   various   complexes.   For   instance,   VEGF165  
interaction  with  heparin  (Figure  4.10  light  blue  line  and  bar  graph)  appears  very  
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unstable,   showing   fast   dissociation;;   however,   when   in   complex   with   VEGFR-­2  
(orange),  dissociation  was  much  slower.  On  the  other  hand,  a  complex  containing  
sNRP-­1   and   VEGF165   (green),   dissociated   more   rapidly   than   VEGF-­VEGFR-­2  
complexes  suggesting  that  the  specific  nature  of  the  heparin-­complexes  that  form  
are  dependent  on  the  particular  molecular  components  present.  Interestingly,  the  
binding   response  elicited  by  mixtures  of  sNRP-­1  and  VEGFR-­2  (red)  showed  a  
profile  that  was  distinct  from  all  other  curves,  with  a  relatively  reduced  association  
rate,  and  with  almost  no  dissociation.  Thus,   the   formation  of  each  higher  order  
complex   appears   to   have   its   own   particular   kinetic   properties   suggesting   a  
potential  sequence  of  events  that  might  occur  as  VEGF  interacts  with  its  various  
binding   sites   on   a   cell.   However,   it   is   important   to   recognize   that   the   cell-­free  
binding  experiments  are  not  able  to  capture  all  aspects  of  the  complexity  of  these  
events,  as  they  would  occur  on  the  surface  of  a  cell.    




Figure   4.10   VEGFR-­2,   VEGF165   and  NRP-­1   synergize   to   bind   heparin   as   a  
complex.  
(A)  VEGFR-­2  Fc  chimera,  sNRP-­1,  and  VEGF165,  were  pre-­incubated  alone  or  in  
various  equimolar  (25  nM)  combinations  for  2  h  at  RT  before  being  injected  over  a  
surface   containing   immobilized  heparin  on  an  SPR  chip.  VEGFR-­2  Fc   chimera  
alone  (yellow),  sNRP-­1  alone  (purple),  VEGF165  alone  (light  blue),  VEGFR-­2  Fc  
chimera  with  sNRP-­1  (red),  VEGFR2-­R  Fc  chimera  with  VEGF165  (orange),  sNRP-­
1  with  VEGF165  (green),  and  VEGFR-­2  Fc  chimera  with  sNRP-­1  and  VEGF165  (dark  
blue).  The  purple  and  yellow  lines  overlap  somewhat.  (B)  Maximal  response  (RU)  
for  each  condition   is  represented   in   the  bar  graph  as  mean  ±  SD  of  5  separate  
surfaces  on  the  SPR  chip.  Experiment  was  repeated  two  times  independently.    




Figure   4.11   sNRP-­1   enhances   VEGF165   binding   and   signaling   in   VEGFR-­2  
expressing  PAEs  and  it  requires  sulfation  of  HS  chains.  
(A)  125I-­VEGF165  binding  to  chlorate-­treated  PAE  cell  surfaces  in  the  presence  or  
absence   of   sNRP-­1.   Cells   were   grown   in   the   presence   or   absence   of   25  mM  
sodium   chlorate   for   2   days.   Wells   were   washed   and   125I-­VEGF165   binding   +/-­  
sNRP-­1  was  measured  after  incubating  for  3  h  at  4  °C.  (B)  Confluent  cells  were  
treated  with  VEGF165  +/-­  sNRP-­1  for  10  min.  Protein  was  collected  and  analyzed  
by  western  blot.  Membranes  were  incubated  with  the  indicated  primary  antibodies  
followed   by   HRP-­linked   secondary   antibodies.   Blots   show   enhanced   VEGF165-­
induced  VEGFR-­2  (Y1175)  and  Erk1/2  phosphorylation  in  the  presence  of  soluble  
NRP-­1  and  this  effect  is  lost  when  cells  are  grown  in  media  containing  chlorate.  
Bar  graphs  show  quantification  of  the  ratio  of  phospho-­VEGFR-­2  (pVEGFR-­2)  to  
total  VEGFR-­2  (VEGFR-­2)  and  of  the  ratio  of  phospho-­ERK  (pERK)  to  total  ERK  
(ERK)   relative   to   untreated   for   each   chlorate-­treated   and   non-­chlorate-­treated  
(mean  ±  s.e.m.,  n=3  or  4).    
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NRP-­1  enhances  VEGF165  binding  and  activation  of  VEGFR-­2  and  Erk1/2  in  
endothelial  cells  
To  test  the  biological  implications  of  the  binding  synergy  observed  between  
co-­receptors  in  vitro,  we  used  porcine  aortic  endothelial  cells  (PAEs).  These  cells  
do  not  express  endogenous  VEGFR-­2  or  NRP-­1.  We  used  cells  that  have  been  
engineered  to  express  full  length  VEGFR-­2  or  empty  vector  (EV)  107,  108.  We  found  
that  soluble  NRP-­1  significantly  enhanced  the  binding  of  125I-­VEGF165  to  VEGFR-­
2-­expressing  PAE  cell  surfaces  and  to  a  lesser  degree  to  empty  vector  (EV)  PAEs  
(Figure  4.10A).  NRP-­1  was  not  able  to  enhance  binding  to  PAE  cells  pretreated  
with  sodium  chlorate,  a  potent   inhibitor  of  proteoglycan  sulfation,   indicating   that  
this   effect  was   dependent   on   the   presence   of  HS.  Moreover,  VEGF  binding   to  
VEGFR-­2   expressing   PAEs   in   the   absence   of   NRP-­1   was   also   significantly  
reduced  by  chlorate.  These  results  are  consistent  with  the  in  vitro  binding  studies  
showing   that  maximal  VEGF  binding   is   achieved   in   the  presence  of  VEGFR-­2,  
NRP-­1,   and  HS.   To   determine   if   the   alterations   in   VEGF   binding   translated   to  
changes  in  VEGF-­mediated  activity,  we  evaluated  VEGF-­stimulation  of  VEGFR-­2  
and  Erk1/2  phosphorylation.  Consistent  with   the  effect  on  binding,  we  observed  
that  the  addition  of  NRP-­1  enhanced  VEGFR-­2  phosphorylation,  and  to  a  lesser  
extent   Erk1/2   phosphorylation.   Interestingly,   the   ability   of   VEGF   to   stimulate  
VEGFR-­2  and  Erk1/2  phosphorylation,  and  for  NRP-­1  to  influence  these  signaling  
events,  was  abolished  in  cells  treated  with  chlorate  (Figure  4.11B).  The  addition  of  
exogenous  heparin  was  able  to  partially  rescue  the  VEGF  response  in  chlorate-­
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treated  cells,  but  not  the  NRP-­1  effect  (Figure  4.12).    
The  results  obtained  from  chlorate  treatments  provide  initial  clues  about  the  
role  HS  plays  in  regulating  NRP-­1  function  within  the  VEGFR-­2-­VEGF165  signaling  
axis.   However,   chlorate   treatment   is   a   potent   chemical   inhibitor   that   alters   all  
biological   sulfation   reactions   thus   the   results   could   include   not   HS-­related  
activities.  Therefore,  we  wanted  to  test  a  more  specific  and  biologically  relevant  
method  to  remove  of  HS  from  cell  surfaces.  We  treated  cells  with  active  human  
heparanase  (HSPE)   for  2h,  and  then  tested  VEGF  binding   in   the  presence  and  
absence  of  sNPR-­1,  as  well  as  the  ability  of  exogenous  heparin  to  rescue  the  lost  
HS   functionality   (Figure   4.13).   HSPE-­treatment   of   VEGFR-­2   PAEs   decreased  
VEGF  binding  and   impeded  sNRP-­1’s  ability   to  enhance  VEGF  binding   (Figure  
4.13).  These  data  support  a  model  where  soluble  NRP-­1  enhancement  of  VEGF  
interaction  with  VEGFR-­2  is  dependent  on  cellular  HS.  The  addition  of  heparin  also  
increased   VEGF   binding   to   cells,   but   had   no   additional   enhancement   in   the  
presence  of  sNRP-­1.  In  HSPE-­treated  cells,  binding  of  VEGF  to  heparin-­treated  
cells  was  decreased   in   the  presence  of  sNRP-­1  compared  to  heparin-­treatment  
alone.  These  data  suggest  that  heparin  and  sNRP-­1  share  common  mechanisms  
and   more   experiments   are   required   to   understand   the   step-­wise   mechanisms  
necessary  for  maximal  VEGF  binding  and  activity.  
HSPE  is  upregulated  in  many  cancers  and  has  been  correlated  with  poor  
outcomes   due   to   high   metastatic   capabilities   76.   HSPE   cleaves   HS   chains   at  
specific  sites  producing  various  oligosaccharides  158.  In  this  study,  we  treated  cells  
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with   HSPE   and   washed   off   all   resulting   HS-­derived   products   to   study   VEGF  
binding  to  cells  with  decreased  HS  content.  It  would  be  important  to  test  the  roles  
of  HSPE  products  in  respect  to  sNRP-­1,  as  these  soluble  fragments  of  HS  might  
directly  participate  in  modulating  the  VEGF  system.    
We  have  demonstrated   that   the   synergistic   binding  of  VEGF,  VEGFR-­2,  
NRP-­1,  and  heparin/HS  observed  in  vitro  correlates  with  enhanced  endothelial  cell  
responsiveness  to  VEGF165.  Specifically,  that  ability  of  NRP-­1  to  influence  VEGF  
activity   requires   sulfated   HS   chains.   This   evidence   further   demonstrates   the  
biological   significance   of   understanding   the   complex  multimeric   binding   events  
within   the   VEGF   system   (Illustration   4.1).   Any   attempt   to   rationally  manipulate  
VEGF  activity  will  require  an  appreciation  of  these  synergistic  binding  interactions.  





Figure  4.12  The  addition  of  exogenous  heparin  partially  rescued  the  VEGF165-­
induced  VEGFR-­2  phosphorylation  but  not  the  NRP-­1  effect.    
Cells  grown  for  2  days  in  the  presence  or  absence  of  25mM  chlorate  were  treated  
with  10  µg/mL  heparin  or  buffer  for  2  h  at  37°C  before  stimulation  with  VEGF165  +/-­  
sNRP-­1  (10  ng/mL  VEGF  and  5  nM  sNRP-­1)  for  10  min.  Protein  was  collected  and  
analyzed  by  western  blot.  Blots  show  total  and  phosphorylated  (at  Y1175)  levels  
of   VEGFR-­2.   Cells   grown   in   chlorate   show   decreased   VEGF165-­induced  
phosphorylation.  Pre-­treatment  with  heparin  rescues  receptor  phosphorylation  but  
not  the  sNPR-­1  enhancement  effect.      
  





Figure  4.13  Heparanase  treatment  decreased  VEGF165  binding  to  VEGFR-­2  
PAEs  and  impeded  sNRP-­1  enhancement  of  VEGF  binding.    
VEGFR-­2-­expressing   PAEs   were   treated   with   100   µg/mL   recombinant   active  
heparanase  for  2  h  at  37°C  to  remove  HS  chains.  Wells  were  washed  with  buffer  
to   removed   HS   products   before   treating   with   10   µg/mL   heparin   or   buffer.  
Radiolabeled  VEGF165   (10   ng/mL)   +/-­   sNRP-­1   (5nM)   binding  was  measured.   *  
indicates  p<  0.01  and  **  indicates  p  <  0.001  




Illustration   4.1   Synergistic   binding   model   for   the   VEGFR-­2/VEGF165/NRP-­
1/heparin  complex.  
(A)   Representation   of   the   different   interacting   partners   and   their   hypothesized  
complex  stability.  R2  is  VEGFR-­2,  mN1  is  monomeric  NRP-­1,  V  is  VEGF165,  and  
H  is  heparin.  Arrow  size  correlates  to  maximal  heparin  binding  response  observed  
in  Fig.  4.10.  Block  or  small  arrow  represents  no  binding  or  very  low  affinity  binding  
between  components.  Large  arrows  symbolize  strong  interaction  or  high  complex  
stability  between  components.  (B)  Model  for  complex  formation  between  VEGF165,  




CHAPTER  FIVE:  HEPARIN-­REGULATED  FIBRONECTIN  CONFORMATION  IN  
VEGF  ACTIVITY  
INTRODUCTION  
The   ECM   is   a   dynamic   structure   that   represents   the   link   to   the   outside  
environment   of   cells   159.  During  angiogenesis,   endothelial   cells   breakdown  and  
remodel  the  ECM  in  order  to  proliferate  and  migrate  in  response  to  growth  factor  
stimulation  4.  Fibronectin  (Fn)   is  one  key  ECM  protein   involved   in  cell  adhesion  
and   is   deposited   by   endothelial   cells   during   angiogenesis   160.   Fn   consists   of  
repeating  units  of  type  I,  type  II  and  type  III  domains  that  assemble  into  a  complex  
structure   with   numerous   binding   sites   for   cell   adhesion   and   protein-­protein  
interactions,  including  binding  to  growth  factors  and  cytokines  161.  One  function  of  
Fn  is  to  anchor  cells  to  the  ECM  by  binding  the  heterodimeric  transmembrane  cell  
adhesion  receptors,  integrins  162.  Fn  binds  primarily  α5β1  integrin  through  the  RGD  
motif  located  on  FnIII  repeat  10  162.  Fn-­null  mice  and  mice  expressing  an  Fn  mutant  
lacking   the   Arginine-­Glycine-­Aspartate   (RGD)   binding   site   display   vascular  
abnormalities  and  die  in  utero  163,  164,  demonstrating  the  importance  of  Fn  and  Fn-­
integrin   interactions   in   vascular   development.   Thus,   it   is   not   surprising   that  
therapies  aimed  at  disrupting  Fn-­integrin  interactions  are  being  investigated  in  the  
clinic  as  antiangiogenic  therapies  165.    
Fn  can  also  bind  heparin  and  HS  through  the  hep  2  domain  located  on  type  
III   repeats   12   to   14.   Our   laboratory   demonstrated   that   heparin   binding   to   Fn  
induces  a  conformational  change  exposing  a  cryptic  VEGF  binding  site,  even  after  
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heparin  removal  by  washing  86.  It  is  possible  that  Fn  plays  a  role  in  linking  VEGF  
signaling   to   integrin-­mediated  cell  adhesion  during  migration  and  could  also  be  
involved  in  the  regulation  of  receptor-­ligand  complex  endocytosis.  In  this  study,  we  
aim  to  understand  the  specific  physical  interactions  between  Fn,  α5β1  integrin,  and  
components  of  the  VEGF  system.    
  
RESULTS  and  DISCUSSION  
To   study   the   specificity   of   fibronectin   and   the   role   it   plays   in   the   VEGF  
system,  we  biotinylated  and  immobilized  a  proteolytic  Fn  fragment  containing  the  
hep   2   domain   to   a   neutravidin-­coated   SPR   chip   surface.   First,   we   measured  
heparin   binding   at   increasing   concentrations.   Heparin   bound   to   immobilized  
fibronectin  eliciting  a  response  of  30  RUs;;  however,  binding  did  not  show  a  dose-­
dependency  and  did  not  return  to  baseline  over  the  course  of  dissociation  (Figure  
5.1A).  After  regenerating  the  surface  with  a  2  M  NaCl  solution  (Figure  5.1B),  we  
analyzed   the   ability   of   heparin   to   change   the   conformation   of   Fn   and  allow   for  
VEGF165   binding.   After   a   heparin   injection,   Fn   was   able   to   bind   VEGF165   a  
significantly  greater  degree  than  the  untreated  Fn  surface  (Figure  5.2C  and  D).    
Given  our  findings  that  HSPGs  can  bind  not  only  VEGF  but  also  the  cell-­
surface   receptors,  we   investigated  whether  heparin  and  non-­heparin-­treated  Fn  
could  also  interact  with  VEGFR-­1,  VEGFR-­2  and  NRP-­1  Fc  chimeras.  Fn  was  able  
to  bind  VEGFR-­1  and  NRP-­1  Fc  chimeras  only  after  heparin  treatment  (Figure  5.3  
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blue  and  green  solid  lines).  VEGFR-­2  showed  no  detectable  binding  to  treated  or  
untreated  Fn  fragment  (red  lines).    
Treatment  of  ECMs  deposited  by  endothelial  cells  with  heparin  increases  
VEGF165  binding  (Figure  5.4).  sNRP-­1  also  enhanced  VEGF  binding  to  the  ECM,  
and  removal  of  endogenous  HS  with  heparanase  disrupted  the  additive  effect  seen  
in   the   presence   of   both   heparin   and   sNRP-­1.   This   observation   suggests   that  
heparin   and   sNRP-­1   compete   for   binding   to   the   ECM   in   the   absence   of  
endogenous  HS.   It   is   important   to   further   investigate   the   binding   requirements  
under  the  different  ECM  contexts  to  understand  how  VEGF  interactions  with  Fn,  
NRP-­1  and  HSPGs  ultimately  regulate  VEGF  signaling.    





Figure  5.1  Heparin  binding  to  Fn  hep  2  domain  on  SPR  chip.    
Biotinylated  Fn  hep  2  domain  was  immobilized  at  1900  RU  on  a  neutravidin  SPR  
sensor  chip.  Increasing  concentrations  of  heparin  in  running  buffer  were  flowed  
over  the  surface  and  response  was  measured  for  60  s  at  50  μL/min  (A).  Surface  
was  regenerated  to  baseline  with  a  2  M  NaCl  injection  at  100  μL/min  for  18  s  (B).    




Figure  5.2  Heparin-­treatment  of  Fn  fragment  allows  for  VEGF165  binding.  
Biotinylated  Fn  hep  2  domain  was  immobilized  on  to  two  lanes  of  an  SPR  sensor  
chip.  One  of  the  lanes  was  treated  with  running  buffer  (A)  and  one  with  10  μg/mL  
heparin   in   running   buffer   (B),   sensograms   are   shown   without   any   correction.  
VEGF165  binding  at  4  concentrations   in   running  buffer  was  measured  over  both  
surfaces,  untreated  (C)  showed  little  or  no  VEGF165  binding  to  Fn  hep  2  domain.  





Figure  5.3  NRP-­1  and  VEGFR-­1  bind  heparin-­treated  hep  2  domain.    
VEGFR-­1,  VEGFR-­2  or  NRP-­1  Fc  chimera  (12.5  nM)  were  flowed  over  heparin  
(10   μg/mL   injection   for   60   s   at   100   μL/min)   and   non-­heparin-­treated   Fn   hep   2  
domain  for  60  s  at  100  μL/min.  





Figure  5.4  VEGF  binding  to  deposited  ECM  extracted  from  PAEs.  
Cells  were  grown  in  24  well  plates  for  2  days.  Wells  were  washed  and  cells  were  
extracted   with   20   mM   ammonium   hydroxide   0.5%   Triton   X-­100.   ECMs   were  
treated  with  buffer  or  HSPE  (100  μg/mL)  for  2h.  Wells  were  washed  with  buffer  to  
removed   HS   products   before   treating   with   10   µg/mL   heparin   or   buffer.  
Radiolabeled   VEGF165   +/-­   sNRP-­1   binding   was   measured.   Bars   represent   the  
means  of  3  separate  experiments  ±  SD.    
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The  importance  of  integrins  during  vascular  development  and  angiogenesis  
is  demonstrated  in  transgenic  models  166;;  α5-­null  mice  die  early  during  embryonic  
development   and   show  significant   vascular   defects.  Moreover,   endothelial   α5β1  
integrin   mediates   cell   adhesion   during   branching   167.   Some   reports   show   that  
matrix-­bound   VEGF   induces   VEGFR-­2   interaction   with   β1   subunit   and   prolong  
VEGFR-­2  signaling  85.  There  is  still  significant  information  missing  on  the  specific  
complex  formation  mechanisms  and  how  they  regulate  VEGF  activity.  To  better  
understand  the  specific  physical  interactions  of  the  components  involved,  we  were  
interested   in   evaluating   Fn   interactions   with   integrin   and   VEGF   upon   heparin-­
induced  conformational  change.  We   first  analyzed   the   interaction  between  α5β1  
integrin,  to  immobilized  full-­length  Fn  in  our  system.  Figure  5.5  shows  increasing  
concentrations  of  α5β1  integrin  Fc  chimera  flowed  over  biotin-­Fn-­coated  surfaces.  
α5β1  integrin  bound  Fn  with  an  affinity  of  450  ±  40  nM.    
It  is  possible  that  the  ECM  and  integrins  modulate  VEGF  internalization  by  
forming  complexes  with   ligand-­bound  VEGFR-­2   168.  Alignment  of  VEGFR-­2   (by  
binding  VEGF  on  Fn)  and  integrins  on  Fn  might  provide  a  mechanism  for  these  
receptors   to   interact.  Based  on   this  hypothesis,  we   tested   if  VEGFR-­2-­VEGF165  
complexes  can  bind  to  heparin-­treated  or  untreated  Fn.  We  found  that  VEGF165  
binds   heparin-­treated   Fn   and   the   hep   2   domain   of   Fn   (Figure   5.6A   and   B),  
consistent   with   our   findings   described   above   and   previous   studies   from   our  
laboratory   86.  Similarly,  we  observed  no  VEGFR-­2  binding   to  heparin-­treated  or  
untreated  Fn.  Injections  of  VEGF165  and  VEGFR-­2  pre-­incubated  mixtures  showed  
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a  response  higher  than  VEGF  alone  on  heparin-­treated  surfaces,  indicating  that  
VEGF-­VEGFR-­2  complexes  can  bind  heparin-­treated  Fn  and  the  hep  2  domain  of  
Fn.  Additionally,  we  demonstrate  that  the  structural  changes  catalyzed  by  heparin  
do  not   influence  α5β1   integrin  binding   to   full-­length  Fn   (Figure  5.6C).  Lastly,  we  
tested  if  binding  of  VEGF-­VEGFR-­2  complexes  interfered  with  α5β1  integrin  binding  
or  if  all  components  could  bind  Fn  simultaneously.  We  observed  no  change  in  α5β1  
integrin  binding  to  non-­heparin  treated  Fn  in  the  presence  of  VEGF-­VEGFR-­2.  On  
the  other  hand,  binding  to  heparin-­treated  surfaces  displayed  an  additive  binding  
response  without   any  apparent   synergy   (Figure  5.6  C  and  D  green   solid   lines)  
suggesting   that   VEGF-­VEGFR-­2   complexes   and   integrins   can   bind   Fn  
simultaneously  to  independent  sites  on  Fn.  These  results  support  a  model  where  
Fn-­bound  VEGF165  is  able  to  bind  VEGFR-­2  and  integrins,  thus  providing  a  direct  
link   for   these   receptors   to   interact.   More   experiments   are   required   to   better  
understand   how   this   complex   translates   to   altered   VEGF   endocytosis   and/or  
signaling.   However,   these   results   provide   a   possible   mechanism   for   the  
coordination  of  multiple  components   linking  VEGF  signaling  with   the  ECM,  and  
integrins.    





Figure  5.5  α5β1  integrin  binding  to  full-­length  Fn.  
Increasing  concentrations  of  α5β1  integrin  (200,  400  and  800  nM)  were  flowed  over  
immobilized  fibronectin.  Curves  were  fit  to  association  and  dissociation  equations  
and  parameters  are  summarized  in  Tables  5.1-­3.    
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Kinetic  analysis  α5β1  Integrin  binding  to  Fn  
Table  5.1  Dissociation  Phase  Analysis  of  α5β1  binding  to  Fn.  
Parameters  obtained  from  global  curve  fit  of  data  presented  on  Figure  5.5  (starting  






Req  ±  SE  
(RU)  
Rmin  ±  SE  
(RU)  








163.9  ±  0.9   9.1  ±  0.2  
2.96  ±  0.02  
x  10  -­2   7.29   0.98  400   86.1  ±  0.8   3.0  ±  0.2  
200   6.8  ±  0.7   0.4  ±  0.2  
  
  
Table  5.2  Association  Phase  Analysis  of  α5β1  binding  to  Fn.  
Parameters   obtained   from   fitting   data   (from   start   of   injection   until   start   of  












Χ2   Adj.  R
2  
8.00  x  10-­7  
7.2  ±  0.6  
x  10  4   270  ±  20  
2.96  
x  10  -­2   10.3   0.997  4.00  x  10
-­7  
2.00  x  10-­7  
  
  
Table  5.3  Calculated  Affinity.  
Affinity   constant   obtained   from   kinetic   parameters   obtained   in   association   and  
dissociation  phase  analyses  (KD  =  kd  /  ka).  
  
KD  ±  SE  (nM)  





Figure  5.6  Fn  interactions  with  VEGF,  VEGFR-­2  and  Integrin.    
Human   Fn   or   heparin-­binding   fragment   (hep   2   domain)   were   biotinylated   and  
immobilized  onto  a  neutravidin-­coated  SPR  chip.  One  surface  was  treated  with  10  
μg/mL   heparin   (solid   lines)   and   one   was   left   untreated   (dotted   lines)   before  
injecting  the  analytes  over  the  surface.  VEGF,  VEGFR-­2  or  pre-­incubated  mixture  
of  both  was  injected  over  full  length  Fn  (A)  and  hep  2  domain  (B).  VEGFR-­2  and  
VEGF  combinations  in  the  presence  of  α5β1  integrin  were  tested  for  binding  to  full  
length  Fn  (C)  and  hep  2  domain  (D).  
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CHAPTER  SIX:  DEFINING  HS  STRUCTURAL  REQUIREMENTS  FOR  
BINDING  FGF-­2  
INTRODUCTION  
FGF-­2  is  potent  growth  factor  that  stimulates  many  cell   types  resulting  in  
biological   responses   that   include   proliferation,   migration   and   differentiation   169.  
Much  like  VEGF,  FGF-­2  binds  and  activates  cell  surface  tyrosine  kinase  receptors  
to  trigger  a  signaling  cascade  26.  The  involvement  of  HSPGs  in  the  FGF-­2:FGFR  
system  is  the  epitome  of  the  classical  co-­receptor  function  of  HS  169.  Both  FGF-­2  
and  FGFRs  bind  heparin  and  many  studies  have  demonstrated  that  cells  require  
HS  to  respond  to  FGF-­2  170.  Since  then,  the  role  of  HS/heparin  in  the  FGF  system  
has  become  one  of  the  most  studied  in  the  field.    
HSPGs   function   by   binding   both   the   FGF-­receptor   and   ligand   and  
approximating   the   components   of   the   complex   to   form   a   competent   ternary  
complex  171.  Our  laboratory  has  demonstrated  that  HSPGs  with  multiple  HS  chains  
accumulate   in   cholesterol-­rich   lipid   raft   domains   in   the   membrane,   aiding   in  
receptor   clustering   and   ligand   presentation   79.   Additionally,   HS   stabilizes   the  
signaling   complex   allowing   for   effective   receptor   transphosphorylation   172,   173.  
Currently,  FGF  is  an  active  target  for  the  development  of  therapies  for  treatment  
of  some  cancer  types,  renal  disease,  and  tissue  repair,  among  others  174.  
Studies  regarding  the  structural   requirements   for  HS  to  bind  FGF-­2  have  
shed   some   light   on   the   specificity   of   the   HS-­protein   interactions   71.   A  
pentasaccharide  with  N-­sulfated  glucosamine  residues  and  at  least  one  iduronic  
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acid   sulfated   at   2-­O   position   is   the  minimal   unit   that   can   bind   FGF-­2,   with   no  
requirement  for  6-­O  sulfation  175.  Additional  data  further  demonstrated  specificity  
in   sulfation   requirements   for   the   formation   of   competent   ligand-­receptor.   For  
example,  even  though  6-­O  sulfation  is  not  required  for  FGF-­2  binding,  it  is  required  
for  binding  FGFR  and  mitogenic  signaling  176.  The  minimal  oligosaccharide  length  
able  to  facilitate  FGF-­2  –  receptor  binding  is  12-­units  long,  with  sulfates  in  the  6-­O  
position  in  addition  to  2-­O  and  N-­sulfation  177.    
Using   information   about   ligand-­receptor-­HS   ternary   complex   formation  
requirements  and  biological  functionality,  structurally  defined  oligosaccharides  can  
be   designed   to   enhance   or   inhibit   FGF-­2   activity.   For   instance,   short   6-­O  
desulfated   oligos   have   been   shown   to   inhibit   FGF-­2   binding   to   its   receptor   by  
competing   for   binding  and  blocking   the  ability   of   native  heparin   to  promote   the  
mitogenic   activity   of   FGF-­2   177.   The   development   of   rapid   tools   to   test   for  HS-­
protein   interactions   is  a  crucial   step   in   the  development  of  novel   therapies   that  
involve  manipulation  of  growth  factor  activity  in  vivo.  Here  we  describe  a  method  
for  affinity  analysis  of  structurally  defined  heparin/HS  oligosaccharides  binding  to  
FGF-­2.   This   method   can   be   applied   to   other   proteins,   such   as   cytokines   and  
receptors,  as  we  have  previously  described  in  VEGF  system  (Chapter  4).      
RESULTS  and  DISCUSSION  
Oligosaccharide  samples  were  obtained  from  our  collaborator  Dr.  Joseph  
Zaia.  Briefly,  generation  of  oligosaccharides  was  achieved  by  partial  digestion  of  
porcine   intestinal  mucosa  heparin  by  heparin   lyase   I  and  bovine  kidney-­derived  
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HS  was   digested  with   a  mixture   of   heparin   lyases   as   described   previously   178.  
Products   were   fractionated   by   length   and   further   separated   by   charge   and  
structural  properties.  In  the  present  study,  various  oligosaccharides  obtained  using  
this  method  were  tested  for  binding  to  FGF-­2.  By  coupling  the  affinity  analysis  with  
structural   data   obtained   by  mass   spectrometry,   insightful   information   about   the  
specific  structures  required  for  high  affinity  binding  can  be  rapidly  obtained  179.    
To   analyze   the   interactions   between   oligosaccharides   and   FGF-­2,   we  
immobilized  biotin-­heparin  to  a  neutravidin-­coated  SPR  chip  achieving  130  RU  of  
immobilization.  Figure  6.1A  shows  the  response  observed  by  flowing  increasing  
concentrations  of  FGF-­2  over  heparin  at  30  μl/min  for  240s.  Due  to  the  slow  flow  
rate,   the   binding   deviated   from   a   one   to   one  model,   and   kinetic   data   was   not  
obtained.  Slow  flow  rates  are  advantageous  to  competition  analysis,  but  can  hinder  
kinetic  studies  by  the  introduction  of  artifacts  such  as  mass  transfer,  rebinding  and  
avidity   effects.   However,   we   were   able   to   perform   equilibrium   analysis   using  
response   values   at   steady-­state   (Req).   Figure   6.1B   shows   data   points   from   4  
independent  surfaces  on  the  chip.  Each  data  set  was  independently  fit  to  equation  
4  and  average  affinity  (KD)  ±  standard  deviation  resulting  from  fit  is  shown  in  Table  
6.1.  Goodness  of  each  fit  was  measured  by  reduced  Χ2  (values  were  between  3.7  
to  8.0)  and  adjusted  R2  (between  0.98  and  0.99)  for  each  surface.  We  observed  
FGF-­2   bound   heparin  with   an   affinity   of   24   ±   0.4   nM,   consistent  with   reported  
values  of  FGF-­2  binding  to  the  ECM  with  affinities  ranging  from  1-­10  nM  180.  The  
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analysis  of  the  four  independent  surfaces  demonstrates  the  reproducibility  of  the  
data  and  provides  additional  accuracy.    
Next,  we  performed  a  competition  study  to  define  affinities  between  FGF-­2  
and  each  oligosaccharide  sample  obtained  from  our  collaborator.  Briefly,  FGF-­2  
(10  nM)  was  pre-­incubated  with  increasing  concentrations  of  each  oligosaccharide  
for  1  h  at  RT  before  flowing  over  the  heparin  surface.  Using  the  first  10  s  of  the  
binding  response,  we  performed  initial  rate  analysis.  During  the  initial  phase,  the  
response   is   linear  and  proportional   to   the  concentration  of   free  FGF-­2  because  
dissociation  is  negligible  (concentration  of  bound  complexes  [AB]  is  low)  181.  Using  
the  slope  ratios  we  calculated  [FGF-­2]f  (FGF-­2  that  was  not  bound  to  competitor  in  
solution  and  was  “free”  to  bind  heparin  on  the  surface)  as  a  fraction  of  total  FGF-­2  
at   each  oligosaccharide   competitor   concentration.   Figure   6.3   shows  decreased  
FGF-­2  surface  binding  with  increasing  concentrations  of  competitor  (heparin  dp6,  
a   6   disaccharide-­long   heparin   fragment).   Finally,   to   obtain   affinities   for   FGF-­2  
binding   to   oligosaccharides,   we   plotted   [FGF-­2]f   as   a   function   of   competitor  
concentration,  and  fit  the  data  to  equation  6.  Results  obtained  from  fits  are  shown  
on  Table  6.2.    
We  found  that  heparin  dp6  and  dp8  bind  FGF-­2  with  high  affinity  (Table  6.2).  
As   expected,   the   affinities   between   FGF-­2   and   heparin-­   or   HS-­derived  
oligosaccharides  obtained  are   lower   than   the  affinity   for  unfractionated  heparin.  
The  longer  oligosaccharides  (dp8)  derived  from  heparin  and  HS  have  significantly  
higher  affinities   than   the  shorter   fragments,  39  ±  3  nM  versus  230  ±  20  nM   for  
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heparin-­derived   and   46   ±   2   versus   600   ±   71   nM   for   HS   –derived   fragments.  
Additionally,   HS-­derived   fragments   have   lower   affinity   when   compared   to   the  
heparin  equivalents.  This  is  expected  due  to  the  high  level  of  sulfation  observed  in  
heparin  182.  
We   have   demonstrated   this   method   for   rapidly   analyzing   HS-­protein  
interaction  affinities  is  a  powerful  tool  to  identify  protein-­HS  binding  specificity  that  
may  potentially  help   in  developing  HS-­based   therapies   to  block  or  enhance   the  
activity  of  growth  factors  and  cell  surface  receptors.    




Figure  6.1  FGF-­2  binding  to  heparin  on  SPR  chip  
(A)   Increasing   concentrations   of   FGF-­2   in   running   buffer   were   flowed   over   a  
surface  containing  biotin-­heparin  at  30  μl/min   for  240s.   (B)  Equilibrium  analysis  
was   performed   using   bound   maximal   responses   at   steady-­state   for   each  
concentration   on   FGF-­2.   Four   separate   surfaces   were   assayed   and   average  
affinities  ±  standard  deviations  are  shown  in  Table  7.1.    






Figure   6.2   FGF-­2   binding   to   heparin   on   SPR   chip   in   the   presence   of  
increasing  concentrations  of  heparin-­derived  dp6  competitor.  
FGF-­2  (10  nM)  was  pre-­incubated  with  increasing  concentrations  of  heparin  dp6  
as  a  competitor.  The  sensograms  show  decreased  FGF-­2  binding  response  due  
to  a  reduction  in  concentration  of  free  FGF-­2  in  solution.  





Figure   6.3   Competition   analysis   of   FGF-­2   binding   to   heparin-­derived  
oligosaccharides.  
Initial   rate   analysis   of   FGF-­2   binding   to   heparin   in   the   presence   of   increasing  
concentrations   of   heparin-­derived   dp6   (A)   and   dp8   (C).   Calculated   free   FGF-­2  
concentration  as  a  function  of  heparin-­derived  competitor  concentration  (B  and  C)  
was  fit  to  equation  6  to  obtain  affinity  values  shown  in  Table  6.2.    





Figure   6.4   Competition   analysis   of   FGF-­2   binding   to   HS-­derived  
oligosaccharides.  
Initial   rate   analysis   of   FGF-­2   binding   to   heparin   in   the   presence   of   increasing  
concentrations   of   HS-­derived   dp6   (A)   and   HS   dp8   (C).   Calculated   free   FGF-­2  
concentration  as  a  function  of  HS-­derived  competitor  concentration  (B  and  C)  was  
fit  to  equation  6  to  obtain  affinity  values  shown  in  Table  6.2.    





Figure   6.5   Competition   analysis   of   FGF-­2   binding   to   HS-­derived  
oligosaccharides.  
Initial   rate   analysis   of   FGF-­2   binding   to   heparin   in   the   presence   of   increasing  
concentrations   of   HS   B6-­23   fraction   product   (A).   Calculated   free   FGF-­2  
concentration  as  a  function  of  competitor  concentration  (B)  was  fit  to  equation  6  to  
obtain  affinity  values  shown  in  Table  6.2.    
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Table  6.1  Equilibrium  analysis  of  FGF-­2  binding  to  heparin.  
Equilibrium  curve  fit  results  (red  lines  in  Figure  6.1B)  for  the  FGF-­2  binding  to  5  
separate  surfaces  on  the  heparin-­coated  chip  (Equation  4).  
  
  
   KD  ±  SD  (nM)  







Heparin   24  ±  0.4   140  ±  3   3.7  –  8.0   0.98  –  0.99  
    
Table   6.2   FGF-­2   affinities   for   various   heparin-­   and   HS-­derived   fragments  
obtained  by  non-­linear  regression  analysis  by  terms  of  equation  6.  
Apparent   affinity   constants   (KD)   for   FGF-­2   binding   to   heparin-­   and   HS-­derived  
oligosaccharides  were   obtained   from   non-­linear   regression   of   competition   data  
(Figures  6.3-­6.5  red  lines).  Standard  error  (SE),  reduced  chi-­squared  and  adjusted  
R2  were  obtained  from  fit.    
  
   KD  ±  SE  (nM)  
[FGF]t  –  Fixed  
(nM)   Reduced  Χ
2   Adj.  R2  
Heparin  dp6   230  ±  20   10   0.16   0.97  
Heparin  dp8   39  ±  3   10   4.8   0.98  
HS  dp6   600  ±  71   10   0.17   0.95  
HS  dp8   46  ±  2   10   0.035   0.99  




CHAPTER  SEVEN:  GENERAL  DISCUSSION  
Excessive   blood   vessel   growth   in   the   retina   can   lead   to   blindness   and  
tumors  exploit  vessels  to  grow  and  metastasize  3.  On  the  other  hand,  insufficient  
vessel   growth   or   maintenance   in   some   tissues   can   lead   to   stroke,   myocardial  
infarction,  ulcerative  disorders  and  neurodegeneration  5.  A  highly  complex  system  
is  required  for  proper  vascular  development  and  tissue  homeostasis.  However,  this  
complexity  has  made  it  extremely  difficult  to  develop  highly  efficient  therapies  to  
manipulate  angiogenesis,  even  after  many  years  of  research.    
The  most  successful  use  of  anti-­angiogenic  drugs  is  for  treatment  of  the  wet  
form  of  age-­related  macular  degeneration  (AMD),  where  a  VEGF-­specific  antibody  
is  injected  directly  into  the  eye  to  reduce  or  stop  neovascularization  of  the  retina.  
In  less  successful  cases,  like  treatment  of  various  types  of  cancers,  an  anti-­VEGF  
antibody   is   injected   intravenously,   either   alone   or   in   combination   with  
chemotherapy,  to  block  vessel  recruitment  into  growing  tumors  and  hence  inhibit  
tumor  growth  and  prevent  metastasis  183.  Although  the  conceptual  basis  for  these  
therapies  is  reasonable,  the  results  have  not  been  as  successful  as  anticipated.  
Additionally,   therapies  aimed  at   revascularization  of   ischemic   tissues  remain  an  
unmet  need.  More  effective  anti-­  and  pro-­angiogenic  therapies  will   likely  require  
the  use  of  a  combination  approach  that  targets  multiple  components  of  the  VEGF  
system.  To  achieve  this  end,  a  more  detailed  understanding  of  how  the  various  
components  of  the  VEGF  system  interact  to  provide  such  sophisticated  control  of  
angiogenesis  is  needed.    
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There   are   still   many   factors   in   the   VEGF   system   that   remain   poorly  
understood   as  well   as   a   vast   number   of   contradicting   results   presented   in   the  
literature,  further  emphasizing  our  lack  of  understanding.  In  this  study,  we  applied  
a  systematic  approach  to  investigate  interactions  between  various  components  of  
the  VEGF  system.  Some  aspects  of  these  interactions  have  been  described  in  the  
past   14,  while  many  had  yet   to  be  determined.  We  obtained  kinetic  data  on   the  
interactions  that  are  most  relevant  to  the  angiogenic  signal,  and  further  analyzed  
how  additional  components  influence  the  properties  of  the  signaling  complex.  This  
information  provides  a  basis  for  the  development  of  predictive  tools  to  test  novel  
therapies  with  higher  efficacies.  Additionally,  based  on  our  findings,  we  propose  
combinations  of   components   that   could  be  used  as   therapies   to  obtain  desired  
responses.   These   are   hypothetical   combinations   that   would   require   additional  
validation  as  treatments.    
VEGFRs  –  VEGF  
The  two  main  VEGF  receptors  expressed  in  endothelial  cells  are  VEGFR-­1  
and  VEGFR-­2,  which  share  similar  structures  but  different  affinities  for  VEGF165  14.  
They   also   have   different   signaling   properties,   VEGFR-­2   being   responsible   for  
activating   the   specific   signaling   cascades   in   endothelial   cells   that   lead   to  
angiogenesis   48.   On   the   other   hand,   the   role   of   VEGFR-­1   in   regulation   of  
angiogenesis   remains   controversial.   VEGFR-­1-­/-­   mice   show   early   embryonic  
lethality  due  to  endothelial-­cell  overgrowth  184  and,  unlike  VEGFR-­2,  VEGFR-­1  is  
more  widely  expressed  in  tissues  apart  from  the  endothelium,  suggesting  a  more  
    
131  
diversified  function  123.  VEGFR-­1  has  a  low  intrinsic  kinase  activity  in  response  to  
VEGF165,  and  mice  that  express  a  truncated  form  of  VEGFR-­1  lacking  the  entire  
intracellular   kinase   domain   develop   without  major   vascular   defects   185.   Hence,  
VEGFR-­1  has  been  considered  to  play  a  negative  role  in  VEGF-­induced  signaling.  
The   differential   functions   of   VEGFR-­1   and   VEGFR-­2   are   crucial   for   vascular  
homeostasis;;   however,   how   these   receptors   coordinate   to   regulate   receptor  
activation  remains  poorly  understood.  Our  observation  that  VEGF165  dissociates  
from  VEGFR-­1  25-­times  slower  than  from  VEGFR-­2  supports  the  decoy  receptor  
model  for  VEGFR-­1  and  provides  a  potential  mechanism  for  additional  regulation  
by  co-­receptors.  We  propose  that,  under  specific  cellular  contexts,  co-­receptors  
decrease   the  dissociation   rate  of  VEGF165   from  VEGFR-­2,  hence   increasing   its  
apparent   affinity   and   allowing   VEGF165   to   preferentially   bind   VEGFR-­2   over  
VEGFR-­1.   Co-­receptors   provide   additional   regulation   of   VEGF-­VEGFR  
interactions  leading  to  complex  control  of  angiogenesis.  
Another  VEGF   isoform,  VEGF121,   lacks   the  ability   to  be   regulated  by  co-­
receptors.  Mice  expressing  only  the  VEGF120  isoform  (the  murine  version  of  human  
VEGF121)   display   defects   in   myocardial   angiogenesis,   and   defects   in   vascular  
growth  and  patterning  141,  142,  suggesting  the  roles  are  not  redundant  with  those  of  
VEGF165.  We   observed   that   VEGF121   binds   VEGFR-­1   and  VEGFR-­2  with   very  
similar  kinetics,  suggesting  VEGF121  is  less  sensitive  to  regulation  by  co-­receptors.  
Additionally,  this  finding  implies  that  the  residues  responsible  for  differential  VEGF  
binding  to  VEGFR-­1  and  VEGFR-­2  are  located  on  exons  6  and  7,  which  are  absent  
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in  isoform  VEGF121.  Site-­directed  mutagenesis  could  provide  more  information  of  
the  specific  residues  that  enhance  binding  affinity  to  VEGFR-­1  and  not  VEGFR-­2.  
A  VEGF  mutant  with  decreased  affinity  for  VEGFR-­1  could  render  it  more  efficient  
at  activating  VEGFR-­2-­mediated  signaling  as  a  means  to  induce  revascularization  
of  ischemic  tissues.  
Dimerization  has  been  shown  to  be  the  rate-­limiting  step  for  other  receptor  
tyrosine  kinases,  such  as  within  the  EGF  system  122.  It  was  interesting  to  find  that  
the  chimeric  system  showed  lower  affinities  than  those  reported  in  the  literature.  
This   could   be   due   the   differences   in   experimental   settings,   since   most  
observations  reported  were  performed  on  cell  surfaces,  disregarding  the  influence  
that   co-­receptors   have   on   the   apparent   affinities.   Here   we   have   isolated   each  
interaction  and  measured  binding  parameters  in  a  consistent  experimental  design  
for  all  the  components.  Our  intercomparable  measurements  will  provide  important  
information  required  for  a  system-­wide  understanding.    
Co-­receptor  control  
The   importance   of   co-­receptors   in   controlling   VEGF   activity   has   been  
demonstrated  extensively  14.  In  the  absence  of  NRP-­1  or  HSPGs,  VEGF  is  unable  
to  signal  properly  and  vascular  development  is  impaired  52,  58,  80.  However,  there  
are  still  many  unknowns  about  the  specific  mechanisms  that  co-­receptors  use  to  
modulate  VEGF  activity.  Specifically,  how  co-­receptors  act  together  to  orchestrate  
the  finely   tuned  angiogenic  signal   induced  by  VEGF  remains  to  be  defined.  We  
aimed   to   delineate   novel   co-­receptor  mechanisms   for   the   regulation   of   VEGF-­
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VEGFR   interactions.   To   achieve   this,  we   first   studied   the   interactions   between  
VEGF   and   receptors   with   co-­receptors,   NRP-­1   and   HS   and   then   we   added  
additional  components  to  measure  their  influence  in  the  system.    
Neuropilin-­1  as  a  VEGF  co-­receptor  
VEGF  binding  to  NRP-­1  is  required  during  angiogenesis,  since  endothelial  
cells  expressing  a  mutant  NRP-­1  are  unable  to  bind  VEGF,  and  fail  to  migrate  and  
activate  angiogenesis  in  response  to  VEGF  186.  The  exact  mechanism  of  NRP-­1  
action   remains   unknown.   Therefore,   we   decided   to   characterize   the   complex  
interactions  between  NRP-­1,  receptors  and  VEGF.  We  found  that  VEGF165  bound  
NRP-­1  with   lower   affinities   than   to   VEGFR-­1   and   VEGFR-­2,   and   observed   no  
VEGF121  binding  to  NRP-­1.  Homodimerization  and  oligomerization  of  NRP-­1  might  
play   important   roles   in   forming   high   affinity   binding   sites   for   VEGF   186   on   cell  
surfaces.  However,  we  did  not  observe  any  differences  in  VEGF  binding  kinetics  
between  the  pre-­dimerized  form  of  NRP-­1  and  the  monomeric  protein.  It  is  possible  
that  the  immobilization  of  the  monomer  to  the  chip  surfaces  renders  each  molecule  
in  close  proximity  to  each  other,  allowing  for  a  “pre-­dimerized”  effect  on  binding  
kinetics  to  the  monomeric  protein.  Further  analysis  on  the  function  of  dimerization  
and  oligomerization  of  NRP-­1  and  how  it  influences  VEGF  binding  will  be  important  
to  fully  understand  the  mechanism  of  action.    
High  NRP-­1  expression  is  an  indicator  of  a  poor  response  to  the  ant-­VEGF  
therapy,   bevacizumab   187,   emphasizing   the   importance   of   understanding   how  
NRP-­1   regulates   VEGF   during   pathological   angiogenesis.   Some   studies   have  
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shown   that   expression   of   NRP-­1   in   tumor   cells   leads   to   enhanced   tumor  
angiogenesis  125,  188.  However,  a  different  study  showed  that  expression  of  NRP-­1  
on  non-­endothelial  cells  can  suppress  angiogenesis  146.  Contradicting  results  are  
likely  due  to  differences  in  experimental  design;;  however,  it  is  important  to  consider  
the  influence  of  additional  components  of  the  system,  such  as  HSPGs.    
HSPGs  as  VEGF  co-­receptors    
The   involvement  of  HS   in   the  VEGF  system  was  first  demonstrated  by  a  
report  showing   that  when  cell   surface  HS  chains  are  digested  with  heparinase,  
VEGF   binding   to   vascular   endothelial   cells   is   inhibited,   and   that   this   effect   is  
rescued   by   the   addition   of   heparin   80.   Since   then,   the   study   of   HSPGs   role   in  
angiogenesis   has   grown   exponentially.   VEGF   binds   directly   to   HS   chains   and  
HSPGs  can  serve  as  a  platform  to  establish  GF  gradients  for  endothelial  cells  to  
migrate   and   allow   for   blood   vessel   branching   189.   Additionally,   HS   can   interact  
directly  with  receptors  and  modulate  signaling  81.  However,  little  is  know  about  the  
nature   of   these   interactions   and   how   they   specifically   regulate   receptor-­ligand  
interactions.   We   observed   that   while   VEGFR-­2   does   not   bind   heparin   directly  
heparin  does  enhance  VEGF165  binding  to  VEGFR-­2.  This  could  be  achieved  by  a  
process   in   which   VEGF   in   the   presence   of   heparin   has   a   reduced   rate   of  
dissociation   from  VEGFR-­2   compared   to   that   observed  with   VEGF   alone.   The  
results   presented   in   this   study   support   a   model   where   VEGF165   facilitates   the  
association   of   heparin/HS   with   VEGFR-­2   to   generate   a   high   affinity   ternary  
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complex.  On  the  other  hand,  VEGFR-­1  directly  interacted  with  heparin  but  this  did  
not  influence  VEGF  binding  to  the  receptor.    
Co-­receptor  synergy  
Since  HSPGs  and  NRP  were  identified  as  VEGF  co-­receptors,  most  models  
of   their   function   have   consider   that   they   aid   in   complex   formation   by   directly  
associating  with  either  the  receptor  or  ligand  to  enhance  receptor-­ligand  binding,  
or  that  they  act  by  forming  a  stable  ternary  complex  with  the  receptor  and  ligand.  
However,  it  seems  that  these  classic  models  might  not  effectively  capture  the  full  
complexity  of  the  VEGF  system.  Recently,  new  data  have  surfaced  indicating  that  
the  role  of  co-­receptors  within  the  VEGF  system  is  dependent  on  cellular  context  
145,  146.  The  observation  that  NRP-­1   interacts  directly  with  heparin  suggests   that  
these   co-­receptors   might   act   together   to   modulate   VEGF165-­VEGFR-­2.   We  
envision  a  complex  system  whereby  HSPGs  on  the  cell  surface  might  function  as  
a  common  modulator  of  VEGF  binding  to  VEGFR-­2  and  NRP-­1.    
Thus,   the  goal  of   the  present  study  was   to   identify  potential  mechanistic  
elements   for  how  co-­receptors   influence  VEGF  activity.   In   this   regard,   the  data  
presented   here   demonstrate   that   interactions   between   VEGF   receptors   and  
heparin/HS   have   distinct   structural   requirements   depending   on   the   receptor   in  
question,   and   that   interactions   between   various   binding   partners   dramatically  
influence   binding   to   heparin/HS.   The   differential   functions   of   the   signaling  
receptors,  VEGFR-­1  and  VEGFR-­2,  in  the  VEGF  system  suggest  that  HS  may  play  
a   sophisticated   role   in   modulating   the   angiogenic   response   by   selectively  
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stabilizing   particular   ligand-­receptor   complexes   based   on   the   specific   cellular  
context.    
We  conducted  a  series  of  binding  studies  using  defined  components  that  
revealed  multiple  possible  mechanisms  by  which  heparin/HS  might  influence  the  
ability   of   VEGF   to   form   complexes   with   its   receptors.   In   our   proposed   model,  
VEGFR-­2  and  soluble  monomeric  NRP-­1  do  not  interact  with  heparin  under  these  
conditions,  and  VEGF  binds  only  with   low  affinity   (Illustration  4.1A).  Monomeric  
NRP-­1   can   enhance   VEGFR-­2   binding   to   heparin,   but   to   a   lower   extent   than  
VEGF165.   VEGF   can   also   enhance   NRP-­1   binding   to   heparin,   but   the   highest  
binding   to   heparin   is   achieved   only   in   the   presence   of   all   three   components,  
VEGF165,   VEGFR-­2   and   NRP-­1   monomer   (Illustration   4.1A).   This   model   is  
consistent  with  previous  studies  that  have  shown  that  maximal  binding  of  VEGF  to  
VEGFR-­2  on  cells  requires  cell  surface  HS  and  that  HSPGs  and  VEGFR-­2  appear  
to  associate  on  cell  surfaces  80,  190.  Thus,  even  though  VEGFR-­2  and  HS  do  not  
appear  to  form  a  stable  binary  complex  in  isolation,  these  molecules  in  conjunction  
with   NRP-­1   appear   to   synergistically   form   a   high   affinity   “active”   complex.  
Interestingly,   our   data   indicate   mechanisms   where   heparin/HS   can   modulate  
VEGF  binding  to  VEGFR-­2.  Specifically,  the  observation  that  monomeric  NRP-­1  
can  synergize  with  VEGFR-­2-­VEGF165  complexes  to  enhance  binding  to  heparin,  
suggest  a  system  where  all  components  are  required  to  produce  a  very  high  affinity  
complex   (Illustration   4.1).   Furthermore,   we   have   demonstrated   that   these  
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synergistic  binding  events  translate  into  alterations  in  endothelial  cell  responses  to  
VEGF165.    
Influence  of  HS  Structure  in  VEGF  regulation  
The   HS   structural   requirements   to   bind   VEGF   have   been   described  
previously   191,  but   the   interactions  between  HS  and   receptors  and  co-­receptors  
have   not   been   characterized.   Here,   we   describe   in   detail   the   binding   between  
HSPGs   and   VEGFR-­1   and   NRP-­1.   We   found   that   the   interactions   between  
heparin/HS  and  the  VEGFRs  are  specific   to  each  receptor   type  suggesting  that  
heparin/HS   influences   VEGF   at   multiple   levels.   Moreover,   our   findings  
demonstrating  that  there  are  distinct  heparin/HS  structural  requirements  for  direct  
binding  of  heparin/HS  to  VEGFR-­1  and  NRP-­1  as  well  as  for  the  synergistic  binding  
of   VEGF-­NRP-­1   and   VEGF-­VEGFR-­2   indicate   that   modifications   in   HS   fine  
structure  might  be  used  to  guide  VEGF  activity  within  a  physiological  context.  Our  
cell  culture  model  has  begun  to  address  how  these  complex  interactions  directly  
regulate  the  biological  output  of  endothelial  cells  in  response  to  VEGF.    
Changes  in  HS  sulfation  patterns  are  mediated  both  through  alterations  in  
biosynthesis  and  by  a  family  of  extracellular  enzymes,  the  HS  sulfatases,  which  
remove   or   modify   specific   sulfate   groups   in   heparan   sulfate   chains   192.   For  
example,  HSulf-­2,  an  endoglucosamine  C-­6  sulfatase,  has  been  shown  to  release  
VEGF   from   its   association   with   heparin,   as   well   as   to   play   critical   roles   in  
modulating  other  growth  factor  systems  193.  In  this  study  we  used  chlorate  to  inhibit  
the  cellular  production  of  sulfated  glycosaminoglycans,  as  a  means  to  evaluate  the  
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role   of   sulfated   HS   in   this   system.   Thus,   our   data   demonstrating   that   VEGF’s  
response   and   NRP-­1’s   ability   to   influence   VEGF   activity   were   eliminated   in  
chlorate-­treated   cells.   This   effect   could   be   partially   rescued   by   the   addition   of  
heparin,  strongly  support  a  model  whereby  full  VEGF  activity  is  dependent  on  the  
presence  of  HS  in  endothelial  cells.  Thus,  it  is  possible  that  extracellular  sulfatases  
are  also   involved   in   regulating  other  aspects  of  VEGF  function  by  changing   the  
binding   properties   between   HSPGs   and   cell   surface   receptors.   A   number   of  
studies  have  indicated  that  HSPGs  play  critical  roles  in  modulating  growth  factor  
activity,  yet  the  specific  mechanisms  remain  somewhat  obscure.  More  structure-­
specific  studies  are  required  to  fully  understand  the  implications  that  changes  in  
HS  sulfation  have  on  VEGF  function.  The  data  presented  here  indicate  that  HSPGs  
provide  high-­order  control  of  VEGF  by  participating  in  multiple  interactions  with  the  
various   components   of   the   system.   These   data   further   suggest   that   targeted  
modulation  of  HSPGs  might  eventually  be  an  effective  means  to  selectively  control  
VEGF  in  a  context  specific  manner.        
Fibronectin,  Integrins  and  the  ECM  in  the  VEGF  system  
The   ECM   is   a   complex   and   dynamic   structure   that   provides   cellular  
architecture   as  well   as   cues   for   cells   required   for   proper   tissue   function.  Many  
components   have   been   demonstrated   to   be   involved   in   the   regulation   of  
angiogenesis  and  VEGF,  including  Fn,  integrins  and  HSPGs.  Our  laboratory  has  
demonstrated  that  VEGF  directly  interacts  with  Fn  and  that  this  interaction  is  HS-­
dependent   86.  Heparin   can   induce  a  conformational   change  on  Fn   leading   to  a  
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more  extended  conformation  that  exposes  cryptic  VEGF  binding  sites  87.  Here,  we  
provide  additional  evidence  of  this  interaction,  and  demonstrate  that  VEGFR-­1  and  
NRP-­1   also   interact   with   Fn   in   the   open   conformation.   Additionally,   we  
demonstrate   that   VEGFR-­2-­VEGF165   complexes   can   bind   Fn   after   it   has   been  
modified  by  heparin  demonstrating  that  these  two  binding  events  are  not  mutually  
exclusive.   The   heparin-­induced   conformational   change   of   Fn   did   not   affect   its  
ability  to  bind  α5β1  integrin,  suggesting  that  Fn  can  act  as  a  link  for  the  interaction  
of   ligand-­bound   VEGF   receptors   and   integrins,   and   that   this   interaction   might  
modulate  adhesion  and/or  endocytosis  of  receptor  complexes  in  a  specific  manner.  
We   have   begun   to   study   the   complex   interactions   between   VEGF-­receptor  
complexes  and  Fn/integrin  complexes  that  could  be  important  in  the  regulation  of  
VEGF-­induced  angiogenic  signaling.    
Additionally,  NRP-­1  has  been  shown   to  co-­immunopurify  and  co-­localize  
with  integrins  and  it  was  further  shown  that  NRP-­1  can  interact  with  α5β1  integrin  
and   may   contribute   to   VEGF   regulation   in   endothelial   cells   194.   Here,   we  
demonstrate  that  NRP-­1  binds  fibronectin  directly  suggesting  that  this  interaction  
represents  the  link  between  integrins  and  NRP-­1  in  cells.  NRP-­1  is  also  involved  
in   endothelial   cell  migration   and   adhesion,   since   genetic   targeting   of  NRP-­1   in  
endothelial  cells  leads  to  reduced  cell  adhesion  to  Fn  matrices  186.  This  function  is  
VEGF-­independent  because  a  mutant  NRP-­1  unable  to  bind  VEGF  was  still  able  




In   the   present   study,   we   have   characterized   regulatory   molecular  
interactions   relevant   to  VEGF  activity.  We  used  a  different  approach   to  study  a  
highly  complex  system  in  the  hopes  of  better  understanding  how  all  components  
work   together   to   achieve   appropriate   regulation   of   angiogenesis.   By  
deconstructing   this   system   and   isolating   the   components,   we   can   build   a  
foundation  from  the  ground  up  and  add  levels  of  complexity  one  at  a  time.  This  
approach  has   the  advantage  of  providing   information  about   the  behavior  of   the  
system   in   specific   cellular   contexts   (i.e.   when   HS-­modifying   enzymes   are  
overexpressed,  or  in  the  absence  of  co-­receptors).    
The   kinetic   data   obtained   in   this   study   could   be   used   to   develop  
mathematical  models  to  predict  cellular  outcomes  under  an  array  of  conditions  that  
would   not   be   easily   sampled   using   experimental   systems.   Additionally,   the   co-­
receptor  mechanisms  proposed  could  also  apply  to  other  biological  systems.  For  
example,  NRP-­1  functions  as  a  semaphorin  receptor  in  axonal  guidance  where  it  
might  also  be  regulated  by  HSPGs.    Thus,  our  observations  could  also  be  applied  
to   understand   how   semaphorin   activity   might   be   modulated   during   tissue  
development  and   repair.  Other  heparin-­binding  growth   factors   could  be  directly  
regulated   by   structural   changes   in   HS,   and   non-­heparin   binding   ligands   and  
receptors  could  be  regulated  by  HS  through  interactions  that  are  independent  of  
direct  HS-­ligand  binding.    
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Taken  together,  the  findings  presented  here  further  demonstrate  the  highly  
complex   systems   that   have   evolved   in   nature   for   the   regulation   of   biological  
processes  in  the  body.  The  study  of  such  complex  networks  presents  a  significant  
challenge   in   the   field.   Novel   ways   to   study   these   regulatory   mechanisms   are  
required  in  order  to  eventually  understand  these  systems  to  the  degree  that  they  
can  be  rationally  manipulated  for  clinical  benefit.    
FUTURE  DIRECTIONS  
During   angiogenesis,   different   biological   responses   are   activated   in  
endothelial   cells   including   proliferation,   migration,   and   invasion,   which   are   all  
required  for  blood  vessel  branching.  It  will  be  important  to  test  our  findings  beyond  
receptor  activation  to  detect  differences  in  biological  output.  It   is  possible  that  in  
the  presence  of  NRP-­1,  migration  is  activated  preferentially  over  proliferation.  By  
using  our  cell  culture  system  and  soluble  proteins,  we  can  measure  cell  migration,  
invasion,  proliferation  and  tube  formation  on  a  matrigel  matrix.   It   is   important   to  
note  that  cell  culture  systems  add  a  number  of  additional  variables  that  in  many  
cases   cannot   be   controlled,   posing   significant   limitations   in   the   delineation   of  
specific  mechanisms  of  regulation  in  the  system.    
The   discrepancies   observed   between   the   kinetics   we   obtained   in   our  
system  and  those  reported  in  the  literature  raises  interesting  questions  about  the  
pre-­dimerized  system  and  how   it   relates   to   receptor  association  on   the  plasma  
membrane.  One  way  we  could  test  the  system  is  to  use  monomeric  receptors  at  
different  densities  and  compare  the  kinetics  observed  under  those  conditions  with  
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our  chimeric  receptor  results.  Additionally,  expression  of  receptor  mutants  that  are  
unable   to   dimerize   could   also   provide   interesting   information   regarding   how  
dimerization  ties  in  with  ligand  binding  and  biological  activity.    
We  have  begun  to  delineate  new  mechanisms  by  which  HSPGs  and  NRP-­
1  regulate  VEGF  activity.  Here  we  have  studied   the   two  most  prominent  VEGF  
isoforms  during  angiogenesis  signaling.  It  will  be  informative  to  study  the  regulation  
of  other  VEGF  isoforms  that  bind  NRP-­1  and  HS  and  their  biological  importance.  
Additionally,  our  findings  on  the  specific  structural  requirements  of  HS  for  binding  
VEGFR-­1  and  NRP-­1  suggest  possible  mechanisms  cells  use  to  fine-­tune  VEGF  
responses.  It  will  be  relevant  to  test  how  HS  chains  with  specific  structural  features  
synergize  with  NRP-­1  and  regulate  VEGF  response  in  endothelial  cells.  Moreover,  
overexpression   and   knockdown   of   various   HS-­modifying   enzymes   will   provide  
information   on   how   VEGF   signaling   is   regulated   in   different   cellular   contexts  
through  HS  biosynthesis.    
As  a  long-­term  extension  of  this  work,  we  envision  it  providing  a  basis  for  
the   development   of   a   VEGF   super   binder   to   enhance   angiogenesis   to   re-­
vascularize  ischemic  tissues.  One  group  has  proposed  using  NRP-­1  Fc  chimera  
as   a   pro-­angiogenic   therapy,   since   they   observed   that   it   induced   cell   tubular  
morphogenesis  in  a  fibroblast/endothelial  co-­culture  model  196.  We  imagine  these  
molecules   to   have   features   pertaining   to   HS   and   NRP-­1   that   bind   VEGFR-­2  
preferentially   over   VEGFR-­1,   regardless   of   the   cellular   microenvironment.  
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Additionally,  it  is  possible  that  different  combinations  of  NRP-­1  and  HS  could  also  
serve  as  to  bind  and  sequester  to  inhibit  angiogenesis  in  to  treat  diseases.    
It  is  clear  that  the  original  receptor-­ligand  model  for  growth  factor  activation  
that   envisions   the   ligand   functioning   as   a   binary   switch   that   turns   on   receptor  
signaling  is  far  too  simple  to  capture  the  true  level  of  complexity  involved  in  growth  
factor-­mediated  cell  regulation.    Our  work  here  reveals  a  striking  level  of  complexity  
within  a  single  growth  factor  system  (VEGF)  whereby  multiple  receptors,  ligands  
and  co-­receptors  appear  to  act  in  concert  to  bring  about  robust  and  highly  flexible  
control.  While   this   is  not  surprising   in  hindsight,   the  work  here  helps   to  shine  a  
bright  light  on  the  need  to  apply  a  rigorous  quantitative  approach  to  decipher  this  
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